<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>

<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30153654</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-4589</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Aging</Title>
                <ISOAbbreviation>Aging (Albany NY)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MiR-146b inhibits autophagy in prostate cancer by targeting the PTEN/Akt/mTOR signaling pathway.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/aging.101534</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer (PCa) is considered as a common visceral cancer in males and the sixth major cause of cancer-related deaths in males worldwide. Significant diagnostic and therapeutic advances have been made in the past decades. However, an improved understanding of their molecular mechanism is still needed. In the present research, we first detected the expression of miR-146b by quantitative real-time PCR (qRT-PCR) and found that miR-146b expression was increased in PCa. Subsequently, we found that miR-146b play an important role in the viability and proliferation capacity of PCa cells functionally. To explore the mechanism, we performed western blot to examine the autophagy-related markers, and found that miR‑146b may promote autophagy in PCa cells via activation of PTEN/AKT/mTOR signaling pathway. Furthermore, we performed the dual luciferase reporter assay to clarify the relationship between miR-146b and PTEN. In conclusion, this study demonstrated that miR-146b inhibited autophagy in PCa by targeting the PTEN/Akt/mTOR signaling pathway, and it could be a potential candidate for application in the treatment of PCa.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Song</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Zhiying</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Computer Science and Engineering, Northeastern University, Shenyang 110004, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Lina</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Zhenyong</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Aging (Albany NY)</MedlineTA>
            <NlmUniqueID>101508617</NlmUniqueID>
            <ISSNLinking>1945-4589</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AKT/m-TOR signaling pathway</Keyword>
            <Keyword MajorTopicYN="N">PTEN</Keyword>
            <Keyword MajorTopicYN="N">autophagy</Keyword>
            <Keyword MajorTopicYN="N">microRNA-146b</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30153654</ArticleId>
            <ArticleId IdType="pii">101534</ArticleId>
            <ArticleId IdType="doi">10.18632/aging.101534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30153435</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3792</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of urology</Title>
                <ISOAbbreviation>J. Urol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0022-5347(18)43782-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2018.08.044</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The NCCN guidelines recently endorsed a subclassification of intermediate-risk prostate cancer (IR-PCa) into favourable (FIR) and unfavourable (UIR) subgroups. However, this subclassification was developed in a treatment-heterogeneous cohort, hence the natural history of androgen deprivation treatment (ADT)-naïve FIR- and UIR-PCa remains unknown.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Three academic centres pooled data from IR-PCa patients treated with radical monotherapy (dose-escalated external beam radiotherapy [DE-EBRT], brachytherapy [BT], or radical prostatectomy [RP]), without combined ADT. Cumulative incidence with competing risk analysis was used to estimate biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2550 intermediate risk men (1063 FIR and 1487 UIR) were included, of which 1149 had RP, 1143 had DE-EBRT, and 258 had BT. The median follow-up for the different treatments ranged from 60.4-107.4 months. The 10-year cumulative incidence of DM for FIR vs UIR were 0.2% (95%CI 0.2-0.2) vs. 11.6% (95%CI 7.7-15.5) for RP (p&lt;0.001), 2.8% (95%CI 0.8-4.8) vs. 13.5% (95%CI 9.6-17.4) for DE-EBRT (p&lt;0.001), and 3.5% (95%CI 0-7.4) vs. 10.2% (95%CI 4.3-16.1) for BT (p=0.063). The 10-year rates for PCSM for FIR vs UIR were 0% (95%CI 0-0) vs. 3.7% (95%CI 1.7-5.7) for RP (p=0.016), 0.5% (95%CI 0.5-0.5) vs. 5.6% (95%CI 3.6-7.6) for DE-EBRT (p=0.015), and 0% (95%CI 0-0) vs. 2.5% (95%CI 0.5-4.5) for BT (p=0.028).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This multicenter international effort independently validates the prognostic value of the IR-PCa subclassification in ADT-naïve patients across all radical treatment modalities. It is unlikely that treatment intensification will meaningfully improve oncologic outcomes for FIR men.</AbstractText>
                <CopyrightInformation>Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Berlin</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. Electronic address: alejandro.berlin@rmp.uhn.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moraes</LastName>
                    <ForeName>F Y</ForeName>
                    <Initials>FY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanmamed</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Glicksman</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koven</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Espin-Garcia</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leite</LastName>
                    <ForeName>E T T</ForeName>
                    <Initials>ETT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Sirio-Libanes, São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>J L F</ForeName>
                    <Initials>JLF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Sirio-Libanes, São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gadia</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Sirio-Libanes, São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nesbitt</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Catton</LastName>
                    <ForeName>C N</ForeName>
                    <Initials>CN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaffenberger</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salami</LastName>
                    <ForeName>S S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgan</LastName>
                    <ForeName>T M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hearn</LastName>
                    <ForeName>J W D</ForeName>
                    <Initials>JWD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>W C</ForeName>
                    <Initials>WC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehra</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chung</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleshner</LastName>
                    <ForeName>N E</ForeName>
                    <Initials>NE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zumsteg</LastName>
                    <ForeName>Z S</ForeName>
                    <Initials>ZS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dess</LastName>
                    <ForeName>R T</ForeName>
                    <Initials>RT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>F Y</ForeName>
                    <Initials>FY</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCSF Department of Urology, San Francisco, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finelli</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spratt</LastName>
                    <ForeName>D E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Urol</MedlineTA>
            <NlmUniqueID>0376374</NlmUniqueID>
            <ISSNLinking>0022-5347</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">prognostic classifications</Keyword>
            <Keyword MajorTopicYN="N">risk grouping</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30153435</ArticleId>
            <ArticleId IdType="pii">S0022-5347(18)43782-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.juro.2018.08.044</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30153334</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2473-4209</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medical physics</Title>
                <ISOAbbreviation>Med Phys</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate lesion delineation from multiparametric magnetic resonance imaging based on locality alignment discriminant analysis.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mp.13155</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Multiparametric MRI (mpMRI) has shown promise in the detection and localization of prostate cancer foci. Although techniques have been previously introduced to delineate lesions from mpMRI, these techniques were evaluated in data sets with T2 maps available. The generation of T2 map is not included in the clinical prostate mpMRI consensus guidelines; the acquisition of which requires repeated T2-weighted (T2W) scans and would significantly lengthen the scan time currently required for the clinically recommended acquisition protocol, which includes T2W, diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) imaging. The goal of this study is to develop and evaluate an algorithm that provides pixel-accurate lesion delineation from images acquired based on the clinical protocol.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">25 pixel-based features were extracted from the T2-weighted (T2W), apparent diffusion coefficient (ADC) and dynamic contrast-enhanced (DCE) images. The pixel-wise classifi-cation was performed on the reduced space generated by locality alignment discriminant analysis (LADA), a version of linear discriminant analysis (LDA) localized to patches in the feature space. Post-processing procedures, including removal of isolated points identified and filling of holes inside detected regions, were performed to improve delineation accuracy. The segmentation result was evaluated against the lesions manually delineated by four expert observers according to the Prostate Imaging-Reporting and Data System (PI-RADS) detection guideline.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The LADA-based classifier (60 ± 11%) achieved a higher sensitivity than the LDAbased classifier (51 ± 10%), thereby demonstrating, for the first time, that higher classification performance was attained on the reduced space generated by LADA than by LDA. Further sensitivity improvement (75 ± 14%) was obtained after post-processing, approaching the sensitivities attained by previous mpMRI lesion delineation studies in which non-clinical T2 maps were available.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The proposed algorithm delineated lesions accurately and efficiently from images acquired following the clinical protocol. The development of this framework may potentially accelerate the clinical uses of mpMRI in prostate cancer diagnosis and treatment planning. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Mingquan</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Electronic Engineering, City University of Hong Kong, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Weifu</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Electronic Engineering, City University of Hong Kong, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Mathematics, Sun Yat-sen University, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mingbo</LastName>
                    <ForeName>Zhao</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Information Science and Technology, Donghua University, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gibson</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Engineering, University of Western Ontario, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Medical Image Computing, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bastian-Jordan</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cool</LastName>
                    <ForeName>Derek W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kassam</LastName>
                    <ForeName>Zahra</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Lawson Health Research Institute, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Huageng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chow</LastName>
                    <ForeName>Tommy W S</ForeName>
                    <Initials>TWS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Electronic Engineering, City University of Hong Kong, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ward</LastName>
                    <ForeName>Aaron D</ForeName>
                    <Initials>AD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lawson Health Research Institute, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiu</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Electronic Engineering, City University of Hong Kong, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Phys</MedlineTA>
            <NlmUniqueID>0425746</NlmUniqueID>
            <ISSNLinking>0094-2405</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer lesion delineation</Keyword>
            <Keyword MajorTopicYN="N">Locality alignment discriminant analysis (LADA)</Keyword>
            <Keyword MajorTopicYN="N">Multiparametric MRI (mpMRI)</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30153334</ArticleId>
            <ArticleId IdType="doi">10.1002/mp.13155</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30152718</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1937-335X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Tissue engineering. Part A</Title>
                <ISOAbbreviation>Tissue Eng Part A</ISOAbbreviation>
            </Journal>
            <ArticleTitle>dual growth factor incorporated heparin-pluronic hydrogel/gelatin-poly-tyramine hydrogel.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1089/ten.TEA.2017.0469</ELocationID>
            <Abstract>
                <AbstractText>The number of cases of erectile dysfunction (ED) caused after radical prostatectomy (RP) prostate cancer (PCa) treatment is increasing steadily. Although various studies have been conducted for treatment of post-RP ED, there is still a need for more effective methods. A dual growth factor incorporated heparin-pluronic/gelatin-poly(ethylene glycol)-tyramine (HP/GPT) hydrogel, which consists of a bFGF-loaded HP hydrogel and NGF-loaded GPT hydrogel, can control dose and rate of growth factor release. In this study, we demonstrated that dual growth factor incorporated HP/GPT hydrogel could further improve erectile function in a rat model of bilateral cavernous nerve injury (BCNI). We showed that erectile function was decreased after BCNI, but it was further improved by treatment with a dual growth factor incorporated HP/GPT hydrogel compared to groups treated with single growth factor in a rat model of cavernous nerve injury. Also, we observed an increase in cGMP levels in the dual growth factor group when compared to the groups treated with single growth factor. This effect was associated with greater up-regulation of nNOS and eNOS expression in the penile tissue of the group treated with dual growth factor incorporated HP/GPT than in the other experimental groups. Apoptosis in the penile tissue treated with the dual growth factor incorporated HP/GPT hydrogel was lower than those treated singly with either bFGF or NGF incorporated GPT hydrogel. Both a-SMA and CD31 expression increased in the group treated with dual growth factor incorporated HP/GPT hydrogel when compared to in the others experimental groups. Altogether, our results proved that the sequential and continuous release of growth factors from dual growth factor incorporated HP/GPT hydrogel prevented fibrosis and nerve damage induced by BCNI in the corpus cavernosum, and promoted the recovery of erectile function. Dual growth factor incorporated HP/GPT hydrogel may be a potent clinical application for the treatment of post-RP ED.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Ae Ryang</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary's Hospital,The Catholic University of Korea,, Urology , The Catholic University of Korea 505 Banpo-dong, Seocho-gu, 137-040 Seoul, Korea , Seoul, Korea, Republic of ; exactly@nate.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Yong Hyun</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul, Korea, Republic of ; lestat04@empas.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Seung Hwan</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary's Hospital,The Catholic University of Korea,, Urology, Seoul, Korea, Republic of ; shwan52@naver.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ga Eun</ForeName>
                    <Initials>GE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary's Hospital,The Catholic University of Korea, Urology , Seoul, Korea, Republic of ; silscm@nate.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Mee Young</ForeName>
                    <Initials>MY</Initials>
                    <AffiliationInfo>
                        <Affiliation>seoul, Korea (the Republic of) ; iris1774@hanmail.net.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Son</LastName>
                    <ForeName>Joo Young</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Su-won, Korea (the Republic of) ; jyson85@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ha</LastName>
                    <ForeName>U-Syn</ForeName>
                    <Initials>US</Initials>
                    <AffiliationInfo>
                        <Affiliation>seoul, Korea (the Republic of) ; ushamd@catholic.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hong</LastName>
                    <ForeName>Sung Hoo</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Department of Urology, seoul, Korea, Republic of ; toomey@catholic.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sae Woong</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary's Hospital, The Catholic University, Urology, Seoul, Korea, Republic of ; ksw1227@catholic.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Ki Dong</ForeName>
                    <Initials>KD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ajou university, Department of Molecular Science &amp; Technology , Youngtong, Paldal, Suwon , Suwon, Korea, Republic of , 442-749 ; kdp@ajou.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ji Youl</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Catholic University, Seoul St. Mary's Hospital, Dept. of Urology, Seoul, Korea, Republic of ; uroljy@catholic.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Tissue Eng Part A</MedlineTA>
            <NlmUniqueID>101466659</NlmUniqueID>
            <ISSNLinking>1937-3341</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30152718</ArticleId>
            <ArticleId IdType="doi">10.1089/ten.TEA.2017.0469</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30152125</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2473-4209</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medical physics</Title>
                <ISOAbbreviation>Med Phys</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inverse optimization of low-cost kilovoltage x-ray arc therapy plans.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mp.13153</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The objective of this work was to investigate the benefits of using inverse optimization treatment planning for kilovoltage arc therapy (KVAT) and to assess the dosimetric limitations of KVAT.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Monte Carlo (MC) calculated, inversely optimized KVAT plans of spherical, idealized breast, lung and prostate lesions were calculated using the EGSnrc/BEAMnrc and DOSXYZnrc MC codes. The dose delivered with the KVAT system, which generates 200 - 225 kV photon beamlets, was calculated and inversely optimized using an optimization framework developed at McGill University. KVAT dose distributions were compared with inversely optimized and MC generated megavoltage (MV) volumetric modulated arc therapy (VMAT) plans as a reference. Prescription doses delivered to 95% of the planning target volume (PTV) were 38.5 (10 fractions), 60 (30 fractions) and 73.8 (41 fractions) Gy for the breast, lung and prostate patients, respectively. Dose distributions, dose volume histograms and PTV homogeneity indices were used to evaluate KVAT and VMAT plans based on RTOG protocols.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All organ-at-risk (OAR) doses were within prescribed dose limits for KVAT and VMAT plans. Generally, KVAT plans delivered higher doses to OARs. For example, due to the lower energy of KVAT, 50% of the rib volume received 12.9 Gy from KVAT while only receiving 2.5 Gy from VMAT. OAR doses were especially high for the KVAT prostate plan due to the presence of large volumes of bony anatomy, which illustrates a limitation of the KVAT system. The KVAT treatment times per fraction for the breast, lung and prostate patients were 2.8, 2.6 and 5.5 minutes, respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The inversely optimized KVAT plans presented in this work have demonstrated the ability of our novel low-cost, kilovoltage x-ray therapy system to safely treat deep-seated spherical lesions in breast and lung patients while meeting RTOG dose constraints on OARs. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Breitkreutz</LastName>
                    <ForeName>D Y</ForeName>
                    <Initials>DY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physics and Astronomy, University of Victoria PO Box 1700 ST CSC,, Victoria, BC, V8W 2Y2, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Renaud</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Medical Physics Unit, McGill University1001, boul. Décarie, Montréal, QC, H4A 3J1, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seuntjens</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Medical Physics Unit, McGill University1001, boul. Décarie, Montréal, QC, H4A 3J1, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weil</LastName>
                    <ForeName>M D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sirius Medicine LLC PO Box 414,, Half Moon Bay, CA, 94019, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zavgorodni</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physics and Astronomy, University of Victoria PO Box 1700 ST CSC,, Victoria, BC, V8W 2Y2, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Vancouver Island Centre - BC Cancer Agency, 2410 Lee Ave, Victoria, BC, V8R 6V5, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bazalova-Carter</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physics and Astronomy, University of Victoria PO Box 1700 ST CSC,, Victoria, BC, V8W 2Y2, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Vancouver Island Centre - BC Cancer Agency, 2410 Lee Ave, Victoria, BC, V8R 6V5, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Phys</MedlineTA>
            <NlmUniqueID>0425746</NlmUniqueID>
            <ISSNLinking>0094-2405</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Monte Carlo</Keyword>
            <Keyword MajorTopicYN="N">inverse optimization</Keyword>
            <Keyword MajorTopicYN="N">kilovoltage x-rays</Keyword>
            <Keyword MajorTopicYN="N">lung irradiation</Keyword>
            <Keyword MajorTopicYN="N">partial breast irradiations</Keyword>
            <Keyword MajorTopicYN="N">prostate irradiation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30152125</ArticleId>
            <ArticleId IdType="doi">10.1002/mp.13153</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30152050</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1754-9485</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical imaging and radiation oncology</Title>
                <ISOAbbreviation>J Med Imaging Radiat Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparative study between <sup>68</sup> Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1754-9485.12791</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The management of prostate cancer has undergone significant advances since the introduction of <sup>68</sup> Ga-prostate-specific membrane antigen (<sup>68</sup> Ga-PSMA) positron emission tomography (PET) scans. Data on the use of <sup>68</sup> Ga-PSMA PET scans in the setting of biochemical recurrence is widely available. Data on the use of <sup>68</sup> Ga-PSMA PET as an initial staging modality, however, is limited. The aim of this retrospective study was to compare the staging of patients with newly diagnosed prostate cancer between <sup>68</sup> Ga-PSMA PET and current conventional imaging modalities. The potential impact of any change in stage will be analysed.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Details of all patients who underwent <sup>68</sup> Ga-PSMA PET in South Australia between March 2016 and March 2017 were obtained. One hundred and thirty-one patients with newly diagnosed prostate cancer who had <sup>68</sup> Ga-PSMA PET prior to consideration of definitive treatment were included in this study. The stage pre-<sup>68</sup> Ga-PSMA PET (based on conventional imaging) and post-<sup>68</sup> Ga-PSMA PET was recorded. The stage was classified as A - localised disease, B - presence of regional lymphadenopathy, C - oligometastatic disease (up to three metastases) and D - widespread metastases. Management plans were recorded.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study showed that the use of <sup>68</sup> Ga-PSMA PET resulted in a change of stage in 37 (28%) patients with an upstage in 17 (13%) patients and a downstage in 20 (15%) patients (P &lt; 0.001). <sup>68</sup> Ga-PSMA PET excluded oligometastatic disease in 11 (8%) patients who had suspicious oligometastatic disease based on a single conventional imaging modality. These <sup>68</sup> Ga-PSMA PET findings impacted on management in at least 24 (18%) patients.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of <sup>68</sup> Ga-PSMA PET scans in initial staging can have a significant impact on staging and management when compared to current conventional imaging modalities.</AbstractText>
                <CopyrightInformation>© 2018 The Royal Australian and New Zealand College of Radiologists.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Hui Sze</ForeName>
                    <Initials>HS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4969-1503</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Genesis Care, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leung</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1834-9131</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Genesis Care, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartholomeusz</LastName>
                    <ForeName>Dylan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sutherland</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Terrace Urology, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le</LastName>
                    <ForeName>Hien</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nottage</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dr Jones and Partners Medical Imaging, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iankov</LastName>
                    <ForeName>Ivan</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Joe H</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>J Med Imaging Radiat Oncol</MedlineTA>
            <NlmUniqueID>101469340</NlmUniqueID>
            <ISSNLinking>1754-9477</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
PSMA
</Keyword>
            <Keyword MajorTopicYN="N">PROSTATIC neoplasm</Keyword>
            <Keyword MajorTopicYN="N">positron emission tomography</Keyword>
            <Keyword MajorTopicYN="N">prostate-specific membrane antigen</Keyword>
            <Keyword MajorTopicYN="N">staging</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30152050</ArticleId>
            <ArticleId IdType="doi">10.1111/1754-9485.12791</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30151999</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-7634</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer medicine</Title>
                <ISOAbbreviation>Cancer Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1735</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated how differences in the method of the first-line androgen deprivation therapy (ADT) affected the time to castration-resistant prostate cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The Japan Study Group of Prostate Cancer compiled a nationwide community-based database on prostate cancer patients who underwent ADT. That database included 13 774 patients who were started on ADT by surgical or medical castration alone (monotherapy group, 5395 cases) or ADT in combination with a nonsteroidal anti-androgen (combined androgen blockade (CAB) group, 8379 cases). We used logistic regression analysis with background factors as independent factors to calculate propensity scores in regard to selection of CAB. Next, for 8826 cases of propensity score-matched patients, we compared the survival rates in the two groups.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The CAB group showed a significantly better progression-free survival (PFS) rate (65.6% vs 59.6% at 5 years; median time to progression, 11.6 vs 7.1 years; hazard ratio in the CAB group: 0.78, with a 95% confidence interval of 0.72 to 0.84; P &lt; 0.001). In subgroup analysis based on the background factors, the PFS rate was generally better in the CAB group in all risk subgroups except for those having significant risk factors.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Propensity score matching analysis revealed the prolongation of PFS by CAB in prostate cancer patients without significant risk factors. It would possible to decide the type of the first-line ADT according to the prostate cancer risk.</AbstractText>
                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Onozawa</LastName>
                    <ForeName>Mizuki</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9700-0274</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, School of Medicine, International University of Health and Welfare, Chiba, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akaza</LastName>
                    <ForeName>Hideyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinotsu</LastName>
                    <ForeName>Shiro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oya</LastName>
                    <ForeName>Mototsugu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, School of Medicine, Keio University, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogawa</LastName>
                    <ForeName>Osamu</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitamura</LastName>
                    <ForeName>Tadaichi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shinsui Clinic, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Kazuhiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naito</LastName>
                    <ForeName>Seiji</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Harasanshin Hospital, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Namiki</LastName>
                    <ForeName>Mikio</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Hasegawa Hospital, Toyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishimura</LastName>
                    <ForeName>Kazuo</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirao</LastName>
                    <ForeName>Yoshihiko</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Osaka Gyoumeikan Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsukamoto</LastName>
                    <ForeName>Taiji</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Sapporo Medical University, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Med</MedlineTA>
            <NlmUniqueID>101595310</NlmUniqueID>
            <ISSNLinking>2045-7634</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">castration-resistant</Keyword>
            <Keyword MajorTopicYN="N">disease-free survival</Keyword>
            <Keyword MajorTopicYN="N">hormone-sensitive</Keyword>
            <Keyword MajorTopicYN="N">nonsteroidal anti-androgens</Keyword>
            <Keyword MajorTopicYN="N">propensity score</Keyword>
            <Keyword MajorTopicYN="N">prostatic neoplasms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151999</ArticleId>
            <ArticleId IdType="doi">10.1002/cam4.1735</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30151743</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1619-7089</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of nuclear medicine and molecular imaging</Title>
                <ISOAbbreviation>Eur. J. Nucl. Med. Mol. Imaging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing <sup>225</sup>Ac-PSMA-617 RLT.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-018-4135-8</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The main side effect of prostate-specific membrane antigen targeting alpha therapy (PSMA TAT) is dry mouth syndrome. Inflammation of the salivary glands and consequent reduced salivary function have been reported in patients after radioiodine therapy. The beneficial effects of sialendoscopy on radiation-induced inflammation in tissue are well known. Thus sialendoscopy with dilatation, saline irrigation and steroid injections (prednisolone) was performed before and after <sup>225</sup>Ac-PSMA-617 TAT to reduce inflammatory effects in the salivary glands and to improve or prevent xerostomia.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Eleven men with metastatic castration-resistant prostate cancer (mean age 68.5 years, range 58-80 years) underwent sialendoscopy, dilatation, saline irrigation and steroid injection of both submandibular and both parotid glands before or after every cycle of <sup>225</sup>Ac-PSMA-617 TAT. Sialendoscopy and steroid injection were performed by a senior ENT physician. Quality of life was evaluated using two health-related quality of life (HRQOL) questionnaires, the Xerostomia Questionnaire (XQ) and the Xerostomia Inventory (XI) before and 3 months after the intervention.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In all 11 patients both parotid and both submandibular glands were affected by radiation sialadenitis and sialendoscopy was performed. The patients experienced no complications after sialendoscopy, and showed a significant improvement in HRQOL as measured using the XQ and XI. After sialendoscopy the XQ score decreased significantly from 77.7 ± 13.6 to 42.7 ± 14.8 (p = 0.003) and the XI score decreased from 44.5 ± 6.9 to 25.8 ± 12.8 (p = 0.003). Due to the limited number of patients we only report tendencies.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sialendoscopy with dilatation, saline irrigation and steroid injection had beneficial effects on salivary gland function and HRQOL in patients undergoing <sup>225</sup>Ac-PSMA-617 RLT. However, even with sialadenoscopic support after multiple cycles of TAT, salivary gland function was reduced and xerostomia was present. Therefore, not only inflammation but also the direct effect of radiation is a putative cause of dry mouth. Further research is necessary to determine the main side effects of PSMA TAT.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rathke</LastName>
                    <ForeName>Hendrik</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5148-6974</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany. hendrik.rathke@med.uni-heidelberg.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kratochwil</LastName>
                    <ForeName>Clemens</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hohenberger</LastName>
                    <ForeName>Ralph</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS), Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giesel</LastName>
                    <ForeName>Frederik Lars</ForeName>
                    <Initials>FL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bruchertseifer</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Karlsruhe, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flechsig</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgenstern</LastName>
                    <ForeName>Alfred</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Karlsruhe, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hein</LastName>
                    <ForeName>Matti</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, SLK Klinikum Am Gesundbrunnen, Heilbronn, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plinkert</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS), Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haberkorn</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bulut</LastName>
                    <ForeName>Olcay Cem</ForeName>
                    <Initials>OC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS), Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, SLK Klinikum Am Gesundbrunnen, Heilbronn, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA>
            <NlmUniqueID>101140988</NlmUniqueID>
            <ISSNLinking>1619-7070</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ac-225</Keyword>
            <Keyword MajorTopicYN="N">PSMA-617</Keyword>
            <Keyword MajorTopicYN="N">PSMA-RLT</Keyword>
            <Keyword MajorTopicYN="N">TAT</Keyword>
            <Keyword MajorTopicYN="N">Xerostomia</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151743</ArticleId>
            <ArticleId IdType="doi">10.1007/s00259-018-4135-8</ArticleId>
            <ArticleId IdType="pii">10.1007/s00259-018-4135-8</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30151629</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1613-2254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical ultrasonics (2001)</Title>
                <ISOAbbreviation>J Med Ultrason (2001)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10396-018-0897-7</ELocationID>
            <Abstract>
                <AbstractText>Abiraterone is an agent effective for castration-resistant prostate cancer, but there have been no reports of cardiotoxic effects inducing cardiomyopathy, to our knowledge. We present a case of an 86-year-old man with castration-resistant prostate cancer treated with abiraterone. He had received an androgen receptor antagonist (bicalutamide) and a gonadotropin-releasing hormone antagonist (degarelix) for 3 years. These agents were changed to enzalutamide due to elevation of plasma prostate-specific antigen level of 129 ng/mL. One year later, the oral androgen receptor inhibitor (enzalutamide) caused drug-induced lung injury and was changed to abiraterone. Transthoracic echocardiography (TTE) revealed normal left ventricular systolic function, and left ventricular ejection fraction (LVEF) was 67%. Four weeks after administration of abiraterone, he complained of dyspnea on effort and bilateral leg edema, and he was diagnosed with heart failure. TTE showed hypokinesis of the diffuse LV, and LVEF decreased to 45%. The various causes of heart failure were excluded. Since a cardiotoxic effect of abiraterone was suspected, administration of abiraterone was discontinued. Two weeks after cessation of abiraterone, LVEF ameliorated to 57%, and then 5 months after cessation of abiraterone, LVEF further improved to 65%. To our knowledge, this is the first report of definite cancer therapeutics-related cardiac dysfunction due to a hormonal agent such as abiraterone diagnosed according to the American Society of Echocardiography and European Association of Cardiovascular Imaging criteria.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsugu</LastName>
                    <ForeName>Toshimitsu</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3399-8757</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Federation of National Public Service Personnel Mutual Aid Association Tachikawa Hospital, 4-2-22, Nishiki, Tachikawa, Tokyo, 190-8531, Japan. tsugu.z7@keio.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagatomo</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, National Defense Medical College Hospital, Tokorozawa, 359-8513, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakajima</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Federation of National Public Service Personnel Mutual Aid Association Tachikawa Hospital, 4-2-22, Nishiki, Tachikawa, Tokyo, 190-8531, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kageyama</LastName>
                    <ForeName>Toshimi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Federation of National Public Service Personnel Mutual Aid Association Tachikawa Hospital, 4-2-22, Nishiki, Tachikawa, Tokyo, 190-8531, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akise</LastName>
                    <ForeName>Yushi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Federation of National Public Service Personnel Mutual Aid Association Tachikawa Hospital, Tachikawa, 190-8531, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Endo</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itabashi</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murata</LastName>
                    <ForeName>Mitsushige</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Preventive Medicine, School of Medicine, Keio University, Tokyo, 160-8582, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitamura</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Federation of National Public Service Personnel Mutual Aid Association Tachikawa Hospital, 4-2-22, Nishiki, Tachikawa, Tokyo, 190-8531, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Med Ultrason (2001)</MedlineTA>
            <NlmUniqueID>101128385</NlmUniqueID>
            <ISSNLinking>1346-4523</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cardiac toxicity</Keyword>
            <Keyword MajorTopicYN="N">Cardio-oncology</Keyword>
            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">Echocardiography</Keyword>
            <Keyword MajorTopicYN="N">Hormonal therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151629</ArticleId>
            <ArticleId IdType="doi">10.1007/s10396-018-0897-7</ArticleId>
            <ArticleId IdType="pii">10.1007/s10396-018-0897-7</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30151600</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-8726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of urology</Title>
                <ISOAbbreviation>World J Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle><sup>68</sup>Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-018-2460-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND"><sup>68</sup>Ga-PSMA Positron Emission Tomography/Computerized Tomography (PET/CT) has shown promising results for the detection of recurrent prostate cancer (RPCa). However, the diagnostic value of this method is yet to be validated. The aim of this study was to determine the influence of clinical and biochemical variables on the detection rate of <sup>68</sup>Ga-PSMA PET/CT in patients with RPCa.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This is a prospective study of 121 patients who underwent <sup>68</sup>Ga-PSMA-PET/CT and conventional imaging (CI) for RPCa. Detection rates were analyzed and correlated with various clinical and biochemical variables such as Gleason score GS), androgen deprivation therapy (ADT), trigger PSA (tPSA), PSA doubling-time (PSAdt) and PSA velocity (PSAv).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS"><sup>68</sup>Ga-PSMA-PET/CT showed at least one focus of pathological <sup>68</sup>Ga-PSMA uptake in 92/121 (76%) of patients. Nodal metastases (in 47% of patients) were the most common site of recurrent disease followed by bones (36%) and prostate (32%). Out of 121 patients, 57 (47%) had only positive findings on PSMA scan verified by biopsy or follow-up. The majority of these lesion were located in the lymph nodes (31/57, 54,5%), which were below the detection limit of CT. Univariate analysis showed higher detection rate of PET/CT with increasing tPSA, PSAv and short PSAdt. Best cutoff for tPSA, PSAv and PSAdt was 0.5 ng/ml, 2.25 ng/ml/year and 8.65 months, respectively. The detection rate of PSMA-PET/CT was higher in patients with high grade tumors (GS &gt; 7, 23.7% vs 76.3%) and in patients who were on ADT during of PSMA scan (76.3% vs 96%). In multiple logistic regression analysis, PSAdt and concurrent ADT were identified as predictors of positive <sup>68</sup>Ga-PSMA-PET/CT.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"><sup>68</sup>Ga-PSMA-PET/CT is useful for re-staging patients with RPCa and has improved performance compared with CI for disease detection. Detection rates are improved in patients on ADT and with short PSAdt.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akdemir</LastName>
                    <ForeName>Elif Neslihan</ForeName>
                    <Initials>EN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuncel</LastName>
                    <ForeName>Murat</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2352-3587</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. muratmtx@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akyol</LastName>
                    <ForeName>Fadıl</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Medical Faculty, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bilen</LastName>
                    <ForeName>Cenk Yucel</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Medical Faculty, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baydar</LastName>
                    <ForeName>Dilek Ertoy</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medical Faculty, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karabulut</LastName>
                    <ForeName>Erdem</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Medical Faculty, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozen</LastName>
                    <ForeName>Haluk</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Medical Faculty, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caglar</LastName>
                    <ForeName>Meltem</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>World J Urol</MedlineTA>
            <NlmUniqueID>8307716</NlmUniqueID>
            <ISSNLinking>0724-4983</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">68Ga-PSMA</Keyword>
            <Keyword MajorTopicYN="N">PET-CT</Keyword>
            <Keyword MajorTopicYN="N">PSA</Keyword>
            <Keyword MajorTopicYN="N">PSA doubling time</Keyword>
            <Keyword MajorTopicYN="N">PSA velocity</Keyword>
            <Keyword MajorTopicYN="N">Recurrent prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151600</ArticleId>
            <ArticleId IdType="doi">10.1007/s00345-018-2460-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s00345-018-2460-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30151598</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-8726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of urology</Title>
                <ISOAbbreviation>World J Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate cancer navigation: initial experience and association with time to care.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-018-2452-y</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate factors associated with use of patient navigation in a prostate cancer population and identify whether navigation is associated with prolonged time to care. Cancer patient navigation has been shown to improve access to cancer screening, diagnosis, and treatment, but little is known about patient navigation in prostate cancer care.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">All men diagnosed with localized prostate cancer between 2009 and 2015 were abstracted from the MaineHealth multi-specialty tumor registry. Regression analyses controlling for patient-, disease-, and system-level factors evaluated characteristics associated with navigation utilization. The association between navigation utilization, barriers to care, and longer time to treatment was assessed with Cox proportional hazards regression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the patient population (n = 1587), 85% of men were navigated. Navigation use was associated with earlier year of diagnosis, treatment by a high-volume urologist, and lower risk disease (p &lt; 0.05). Treatment delay was associated with low-risk disease (vs: intermediate OR 0.62, 95% CI 0.46-0.85 and high OR 0.16, 95% CI 0.1-0.25) and receipt of navigation services (OR 1.65, 95% CI 1.12-2.45) but not distance to care, insurance, or treatment choice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed that patients with low-risk prostate cancer were more likely to utilize navigation, but traditional barriers to care were not associated with utilization. Navigation was associated with longer time to treatment, which likely reflects clinically appropriate delays associated with greater shared decision making. Time to treatment may not be the ideal metric for evaluating navigation in prostate cancer; shared decision making, patient satisfaction, and psychosocial outcomes may be more appropriate.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Serrell</LastName>
                    <ForeName>Emily C</ForeName>
                    <Initials>EC</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2531-5784</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hansen</LastName>
                    <ForeName>Moritz</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Outcomes Research and Evaluation, Maine Medical Center, 509 Forest Avenue, Suite 200, Portland, ME, 04101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mills</LastName>
                    <ForeName>Greg</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Outcomes Research and Evaluation, Maine Medical Center, 509 Forest Avenue, Suite 200, Portland, ME, 04101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perry</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Maine Medical Center Cancer Institute, Scarborough, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robbins</LastName>
                    <ForeName>Tracy</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Maine Medical Center Cancer Institute, Scarborough, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feinberg</LastName>
                    <ForeName>Melanie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Maine Medical Center Cancer Institute, Scarborough, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Remick</LastName>
                    <ForeName>Scot C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Maine Medical Center Cancer Institute, Scarborough, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beaule</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayn</LastName>
                    <ForeName>Matt</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kinkead</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Paul K J</ForeName>
                    <Initials>PKJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Outcomes Research and Evaluation, Maine Medical Center, 509 Forest Avenue, Suite 200, Portland, ME, 04101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sammon</LastName>
                    <ForeName>Jesse D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, MA, USA. jsammon79@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Maine Medical Center, Portland, ME, USA. jsammon79@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Outcomes Research and Evaluation, Maine Medical Center, 509 Forest Avenue, Suite 200, Portland, ME, 04101, USA. jsammon79@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>World J Urol</MedlineTA>
            <NlmUniqueID>8307716</NlmUniqueID>
            <ISSNLinking>0724-4983</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Patient navigation</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Quality improvement</Keyword>
            <Keyword MajorTopicYN="N">Shared decision making</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151598</ArticleId>
            <ArticleId IdType="doi">10.1007/s00345-018-2452-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s00345-018-2452-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30151298</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2093-6966</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pharmacopuncture</Title>
                <ISOAbbreviation>J Pharmacopuncture</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Case Series of Snake Venom Pharmacopuncture for Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Observational Study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>280-286</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3831/KPI.2017.20.034</ELocationID>
            <Abstract>
                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">This case series aims to report the efficacy and the safety of using snake venom pharmacopuncture (SVP) for chemotherapy-induced peripheral neuropathy (CIPN).</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Three heterogeneous cancer (1 endometrium, 1 cervix, and 1 prostate cancer) patients were referred to the East-West Cancer Center (EWCC), Dunsan Korean Medicine Hospital of Daejeon University, from August 02, 2017, to September 15, 2017, for treatment with SVP, and they were treated with SVP 4 times, 6 times, and 8 times, respectively. During the treatment period, the efficacy of SVP therapy was assessed by using the Numerical Rating Scale (NRS) and the Common Terminology Criteria for Adverse Events (CTCAE), and the stability was evaluated by using blood tests. Following each session, all patients were examined closely for any allergenic responses or adverse effects.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">All patients showed noticeable improvements of their NRS and CTCAE scores. Except for bleeding and bruising at the SVP injection site, no major side effects were noted. One of the patients reported mild chilling and a sore throat after receiving the second treatment; those symptoms went away after a few hours. No hematologic toxicity, hepatotoxicity, or nephrotoxicity was found on the blood test.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The results of this research suggest positive potential benefits of using SVP for treating patients with CIPN. Also, the excellent safety results of SVP seen in this research should lead to larger clinical trials aimed at developing SVP into a potential intervention for managing patients with the symptoms of CIPN.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Si Yeon</ForeName>
                    <Initials>SY</Initials>
                    <AffiliationInfo>
                        <Affiliation>East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University, Daejeon, The Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Kyeore</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University, Daejeon, The Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Kwhang Ho</ForeName>
                    <Initials>KH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dalraechon Korean Medicine Clinic, Yangyang-gun, Gangwon-do, The Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>Hwa-Seung</ForeName>
                    <Initials>HS</Initials>
                    <AffiliationInfo>
                        <Affiliation>East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University, Daejeon, The Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>J Pharmacopuncture</MedlineTA>
            <NlmUniqueID>101572812</NlmUniqueID>
            <ISSNLinking>2093-6966</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Sadverse effects</Keyword>
            <Keyword MajorTopicYN="N">peripheral nervous system diseases</Keyword>
            <Keyword MajorTopicYN="N">pharmacoacupuncture treatment</Keyword>
            <Keyword MajorTopicYN="N">snake venoms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30151298</ArticleId>
            <ArticleId IdType="doi">10.3831/KPI.2017.20.034</ArticleId>
            <ArticleId IdType="pii">kpi-20-280</ArticleId>
            <ArticleId IdType="pmc">PMC6104720</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30150937</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1663-9812</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in pharmacology</Title>
                <ISOAbbreviation>Front Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>889</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2018.00889</ELocationID>
            <Abstract>
                <AbstractText>Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by cells and involved in intercellular communication through transfer of proteins and genetic material. EMV release is also associated with various pathologies, including cancer, where increased EMV release is amongst other associated with chemo-resistance and active transfer of pro-oncogenic factors. Recent studies show that EMV-inhibiting agents can sensitize cancer cells to chemotherapeutic agents and reduce cancer growth <i>in vivo</i>. Cannabidiol (CBD), a phytocannabinoid derived from <i>Cannabis sativa</i>, has anti-inflammatory and anti-oxidant properties, and displays anti-proliferative activity. Here we report a novel role for CBD as a potent inhibitor of EMV release from three cancer cell lines: prostate cancer (PC3), hepatocellular carcinoma (HEPG2) and breast adenocarcinoma (MDA-MB-231). CBD significantly reduced exosome release in all three cancer cell lines, and also significantly, albeit more variably, inhibited microvesicle release. The EMV modulating effects of CBD were found to be dose dependent (1 and 5 μM) and cancer cell type specific. Moreover, we provide evidence that this may be associated with changes in mitochondrial function, including modulation of STAT3 and prohibitin expression, and that CBD can be used to sensitize cancer cells to chemotherapy. We suggest that the known anti-cancer effects of CBD may partly be due to the regulatory effects on EMV biogenesis, and thus CBD poses as a novel and safe modulator of EMV-mediated pathological events.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kosgodage</LastName>
                    <ForeName>Uchini S</ForeName>
                    <Initials>US</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cellular and Molecular Immunology Research Centre, School of Human Sciences, London Metropolitan University, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mould</LastName>
                    <ForeName>Rhys</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henley</LastName>
                    <ForeName>Aine B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nunn</LastName>
                    <ForeName>Alistair V</ForeName>
                    <Initials>AV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guy</LastName>
                    <ForeName>Geoffrey W</ForeName>
                    <Initials>GW</Initials>
                    <AffiliationInfo>
                        <Affiliation>GW Research, Sovereign House Vision Park, Cambridge, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomas</LastName>
                    <ForeName>E L</ForeName>
                    <Initials>EL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inal</LastName>
                    <ForeName>Jameel M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bell</LastName>
                    <ForeName>Jimmy D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lange</LastName>
                    <ForeName>Sigrun</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tissue Architecture and Regeneration Research Group, Department of Biomedical Sciences, University of Westminster, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University College London School of Pharmacy, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Pharmacol</MedlineTA>
            <NlmUniqueID>101548923</NlmUniqueID>
            <ISSNLinking>1663-9812</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">cannabidiol (CBD)</Keyword>
            <Keyword MajorTopicYN="N">combinatory treatment</Keyword>
            <Keyword MajorTopicYN="N">exosomes</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">microvesicles (MVs)</Keyword>
            <Keyword MajorTopicYN="N">mitochondria</Keyword>
            <Keyword MajorTopicYN="N">peptidylarginine deiminase (PAD)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30150937</ArticleId>
            <ArticleId IdType="doi">10.3389/fphar.2018.00889</ArticleId>
            <ArticleId IdType="pmc">PMC6099119</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30150582</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2072-6643</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrients</Title>
                <ISOAbbreviation>Nutrients</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nontoxic Glucomoringin-Isothiocyanate (GMG-ITC) Rich Soluble Extract Induces Apoptosis and Inhibits Proliferation of Human Prostate Adenocarcinoma Cells (PC-3).</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E1174</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/nu10091174</ELocationID>
            <Abstract>
                <AbstractText>The incidence of prostate cancer malignancy along with other cancer types is increasing worldwide, resulting in high mortality rate due to lack of effective medications. <i>Moringa oleifera</i> has been used for the treatment of communicable and non-communicable ailments across tropical countries, yet, little has been documented regarding its effect on prostate cancer. We evaluated the acute toxicity and apoptosis inducing effect of glucomoringin-isothiocyanate rich soluble extracts (GMG-ITC-RSE) from <i>M. oleifera</i> in vivo and in vitro, respectively. Glucomoringin was isolated, identified, and characterized using fundamental analytical chemistry tools where Sprague-Dawley (SD) rats, murine fibroblast (3T3), and human prostate adenocarcinoma cells (PC-3) were used for acute toxicity and bioassays experiments. GMG-ITC-RSE did not instigate adverse toxic reactions to the animals even at high doses (2000 mg/kg body weight) and affected none of the vital organs in the rats. The extract exhibited high levels of safety in 3T3 cells, where more than 90% of the cells appeared viable when treated with the extract in a time-dependent manner even at high dose (250 µg/mL). GMG-ITC-RSE significantly triggered morphological aberrations distinctive to apoptosis observed under microscope. These findings obviously revealed the putative safety of GMG-ITC-RSE in vivo and in vitro, in addition to its anti-proliferative effect on PC-3 cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jaafaru</LastName>
                    <ForeName>Mohammed Sani</ForeName>
                    <Initials>MS</Initials>
                    <Identifier Source="ORCID">0000-0002-6635-4931</Identifier>
                    <AffiliationInfo>
                        <Affiliation>UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. biojafar@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Kaduna State University, 2336 Kaduna, Nigeria. biojafar@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abd Karim</LastName>
                    <ForeName>Nurul Ashikin</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. ck_zimase89@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohamed Eliaser</LastName>
                    <ForeName>Enas</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. en_mo2008@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Faculty of Science, El-Mergib University, El Khums, Libya. en_mo2008@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maitalata Waziri</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">0000-0003-4843-584X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Kaduna State University, 2336 Kaduna, Nigeria. petermwaziri@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahmed</LastName>
                    <ForeName>Hamidu</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000-0002-5274-447X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Biomolecular Medicine, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. boderel@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mustapha Barau</LastName>
                    <ForeName>Mohammed</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Forensic Science, Nigeria Police Academy, Wudil, 3474 Kano, Nigeria. mustahpabar@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Liliya</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Mitomasa Sdn. Bhd., 13-1, Jalan L J 3, Taman Industri Lembah Jaya, 68000 Ampang, Selangor, Malaysia. liliya@live.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abdull Razis</LastName>
                    <ForeName>Ahmad Faizal</ForeName>
                    <Initials>AF</Initials>
                    <Identifier Source="ORCID">0000-0001-9205-3764</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Biomolecular Medicine, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. madfaizal@upm.edu.my.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Food Safety and Food Integrity, Institute of Tropical Agriculture and Food Security, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. madfaizal@upm.edu.my.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Food Science, Faculty of Food Science and Technology, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. madfaizal@upm.edu.my.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Nutrients</MedlineTA>
            <NlmUniqueID>101521595</NlmUniqueID>
            <ISSNLinking>2072-6643</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PC-3</Keyword>
            <Keyword MajorTopicYN="N">acute toxicity</Keyword>
            <Keyword MajorTopicYN="N">anti-proliferation</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">cytotoxicity</Keyword>
            <Keyword MajorTopicYN="N">glucomoringin-isothiocyanate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30150582</ArticleId>
            <ArticleId IdType="pii">nu10091174</ArticleId>
            <ArticleId IdType="doi">10.3390/nu10091174</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30149628</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
                <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E289</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers10090289</ELocationID>
            <Abstract>
                <AbstractText>The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. Previous studies have shown that miR-205 negatively regulates prostate cancer cell proliferation, metastasis, and drug resistance. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of a viable nanoparticle platform to deliver miR-205 is highly sought. A novel magnetic nanoparticle (MNP)-based nanoplatform composed of an iron oxide core with poly(ethyleneimine)-poly(ethylene glycol) layer(s) was developed. An optimized nanoplatform composition was confirmed by examining the binding profiles of MNPs with miR-205 using agarose gel and fluorescence methods. The novel formulation was applied to prostate cancer cells for evaluating cellular uptake, miR-205 delivery, and anticancer, antimetastasis, and chemosensitization potentials against docetaxel treatment. The improved uptake and efficacy of formulations were studied with confocal imaging, flow cytometry, proliferation, clonogenicity, Western blot, q-RT-PCR, and chemosensitization assays. Our findings demonstrated that the miR-205 nanoplatform induces significant apoptosis and enhancing chemotherapeutic effects in prostate cancer cells. Overall, these study results provide a strong proof-of-concept for a novel nonviral-based nanoparticle protocol for effective microRNA delivery to prostate cancer cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nagesh</LastName>
                    <ForeName>Prashanth K B</ForeName>
                    <Initials>PKB</Initials>
                    <Identifier Source="ORCID">0000-0003-3518-405X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. pbhusett@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chowdhury</LastName>
                    <ForeName>Pallabita</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. pchowdhu@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hatami</LastName>
                    <ForeName>Elham</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">0000-0001-6776-4003</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. ehatami@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boya</LastName>
                    <ForeName>Vijaya K N</ForeName>
                    <Initials>VKN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. drvijayboya@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kashyap</LastName>
                    <ForeName>Vivek K</ForeName>
                    <Initials>VK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. vkashya1@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khan</LastName>
                    <ForeName>Sheema</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. skhan14@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hafeez</LastName>
                    <ForeName>Bilal B</ForeName>
                    <Initials>BB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. BHAFEEZ@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chauhan</LastName>
                    <ForeName>Subhash C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. SCHAUHA1@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaggi</LastName>
                    <ForeName>Meena</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. mjaggi@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yallapu</LastName>
                    <ForeName>Murali M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA. myallapu@uthsc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">chemosensitivity and EMT</Keyword>
            <Keyword MajorTopicYN="N">docetaxel</Keyword>
            <Keyword MajorTopicYN="N">miR-205</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30149628</ArticleId>
            <ArticleId IdType="pii">cancers10090289</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers10090289</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30149080</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0003</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of biological macromolecules</Title>
                <ISOAbbreviation>Int. J. Biol. Macromol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exploring the interaction of anti-androgendrug-bicalutamide with human alpha-2-macroglobulin: A biophysical investigation.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0141-8130(18)32760-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijbiomac.2018.08.117</ELocationID>
            <Abstract>
                <AbstractText>Bicalutamide (BCT), a drug used in the treatment of prostate cancer, antagonises the actions of androgens, at the receptor level, thereby inhibiting the growth of prostate tumours. Alpha-2-macroglobulin (α<sub>2</sub>M), a pan-proteinase inhibitor, inhibits proteinase, regardless of specificity and catalytic mechanism. α<sub>2</sub>M is deficient inpatients of advanced prostate cancer with bone metastases. Our studies explored the interaction of BCT with α<sub>2</sub>M and analysed the BCT induced structural alteration to the α<sub>2</sub>M. The result suggests that BCT decreases the antiproteolytic potential and causes structural and functional change in human α<sub>2</sub>M.UV-visible absorption spectroscopy confirms the formation of α<sub>2</sub>M-BCT complex. Fluorescence analysis shows significant quenching in fluorescence intensity of α<sub>2</sub>M upon binding with BCT. Synchronous fluorescence result suggests the interaction of BCT with α<sub>2</sub>Mchanged the microenvironment around tyrosine residues. Secondary structure of α<sub>2</sub>M also undergoes a slight change upon complexation with the drug as evident by shift in negative ellipticity in far UV CD spectroscopy. FTIR results confirm the alteration in secondary structure of α<sub>2</sub>M upon drug interaction. Molecular docking studies show that BCT bind to a monomer of α<sub>2</sub>M primarily through hydrophobic force. Thermodynamics parameters were also determined by isothermal titration calorimetry found that the binding was exothermic in nature.</AbstractText>
                <CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zia</LastName>
                    <ForeName>Mohammad Khalid</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siddiqui</LastName>
                    <ForeName>Tooba</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>Syed Saqib</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahsan</LastName>
                    <ForeName>Haseeb</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Dentistry, JamiaMilliaIslamia, New Delhi, 110025, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khan</LastName>
                    <ForeName>Fahim Halim</ForeName>
                    <Initials>FH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India. Electronic address: fahimhkhan@rediffmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int J Biol Macromol</MedlineTA>
            <NlmUniqueID>7909578</NlmUniqueID>
            <ISSNLinking>0141-8130</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alpha-2-acroglobulin</Keyword>
            <Keyword MajorTopicYN="N">Anticancer drug</Keyword>
            <Keyword MajorTopicYN="N">Antiproteinase</Keyword>
            <Keyword MajorTopicYN="N">Bicalutamide</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30149080</ArticleId>
            <ArticleId IdType="pii">S0141-8130(18)32760-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2018.08.117</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30148753</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-6586</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in urology</Title>
                <ISOAbbreviation>Curr Opin Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A risk-stratified approach to the management of high-grade T1 bladder cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOU.0000000000000548</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">A bladder-preserving approach for high-grade nonmuscle invasive bladder cancer that has invaded the lamina propria (T1HG) may result in increased recurrence, progression, and even death from bladder cancer in some patients. Initial radical cystectomy does have increased cancer-specific survival (CSS), but represents significant overtreatment for many patients. An evidence-based, risk-stratified approach is required to select patients for immediate radical cystectomy in order to improve CSS.</AbstractText>
                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">A restaging transurethral resection aids in optimal staging and treatment of T1HG. Intravesical Bacillus Calmette-Guerin induction followed by 3 years of maintenance is the standard adjuvant management. However, when very high-risk (hydronephrosis, abnormal bimanual examination, variant histology, lymphovascular invasion, or residual disease on re-resection, and Bacillus Calmette-Guerin failure or early recurrence) or multiple high-risk factors (concomitant CIS, size &gt;3 cm, multifocality, unfavorable tumor location, extensive lamina propria invasion, and elderly) are present, the risk of progression often outweighs the risk associated with radical cystectomy. In these cases, an immediate radical cystectomy likely provides an improved opportunity for cure compared to a bladder-preserving strategy.</AbstractText>
                <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">In order to increase the CSS of patients diagnosed with T1HG bladder cancer, an aggressive approach may benefit those with increased risk of progression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mannas</LastName>
                    <ForeName>Miles P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Taeweon</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nykopp</LastName>
                    <ForeName>Timo K</ForeName>
                    <Initials>TK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costa</LastName>
                    <ForeName>Jose Batista da</ForeName>
                    <Initials>JBD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Peter C</ForeName>
                    <Initials>PC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Opin Urol</MedlineTA>
            <NlmUniqueID>9200621</NlmUniqueID>
            <ISSNLinking>0963-0643</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30148753</ArticleId>
            <ArticleId IdType="doi">10.1097/MOU.0000000000000548</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30148452</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1952-4005</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European cytokine network</Title>
                <ISOAbbreviation>Eur. Cytokine Netw.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites.</ArticleTitle>
            <Pagination>
                <MedlinePgn>59-72</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1684/ecn.2018.0409</ELocationID>
            <Abstract>
                <AbstractText>Interleukin-6 (IL-6) expression and secretion, induced by inflammatory processes, stimulate the acute phase response cascade. The overexpression of IL-6 contributes to a variety of inflammatory diseases, e.g. rheumatoid arthritis, Castleman's disease, multiple myeloma, and prostate cancer. Screening for high amounts of IL-6 in the patients' blood serum can be crucial for an adequate treatment. In this study, five novel murine monoclonal antibodies (mAbs) reactive to human IL-6 were generated. The mAbs were characterized for potential diagnostic purposes and recombinant antibodies were derived thereof. Initial epitope mapping using a combination of blocking experiments and Hyper-IL-6, a fusion protein consisting of IL-6 and the soluble IL-6 receptor revealed distinct but overlapping binding sites. At least one of the mAbs was found to interact with the region of IL-6/ IL-R complex formation. Three mAbs were applied successfully in intracellular staining by flow cytometry, whereas one of the mAbs showed comparable binding as a reference reagent. Furthermore, the mAbs were tested for applications in various immunological assays such as ELISA, Western blot and surface plasmon resonance spectroscopy (SPR), using IL-6 from commercial sources as well as in-house produced protein (IL-6_IME). The limit of detection was determined by sandwich ELISA (0.5 ng/mL, SD ±0.005). Our results also demonstrated that the recombinant IL-6 produced was functional and correctly folded. These findings support the use of the generated mAb clones as promising candidates for application in various immunological assays for diagnostic and scientific purposes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chouman</LastName>
                    <ForeName>Karinna</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korioth-Schmitz</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sack</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Biotechnology, RWTH Aachen University, Aachen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmitz</LastName>
                    <ForeName>Jörn Engelbert</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Federela Office of Bundeswehr Personnel Management, Cologne; Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pham</LastName>
                    <ForeName>Anh Tuan</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fischer</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Biotechnology, RWTH Aachen University, Aachen, Germany, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street Suite 300, Indianapolis, IN 46202, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barth</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klockenbring</LastName>
                    <ForeName>Torsten</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fendel</LastName>
                    <ForeName>Rolf</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany, Institute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, Tübingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Eur Cytokine Netw</MedlineTA>
            <NlmUniqueID>9100879</NlmUniqueID>
            <ISSNLinking>1148-5493</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antibody characterization</Keyword>
            <Keyword MajorTopicYN="N">interleukin-6</Keyword>
            <Keyword MajorTopicYN="N">intracellular detection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30148452</ArticleId>
            <ArticleId IdType="pii">ecn.2018.0409</ArticleId>
            <ArticleId IdType="doi">10.1684/ecn.2018.0409</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30148254</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2510-3636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of hybrid imaging</Title>
                <ISOAbbreviation>Eur J Hybrid Imaging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pre-treatment <sup>18</sup>F-choline PET/CT is prognostic for biochemical recurrence, development of bone metastasis, and cancer specific mortality following radical local therapy of high-risk prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>16</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s41824-018-0034-2</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">The aim of this study was to determine whether lymph node metastasis on pre-treatment <sup>18</sup>F-choline PET/CT is an independent prognostic factor for biochemical recurrence (BCR), skeletal metastasis, and cancer specific mortality (CSM), after radical local treatment (radical prostatectomy and/or radiotherapy) in men with high-risk prostate cancer. Medical records were reviewed for men with newly diagnosed high-risk prostate cancer who had pre-treatment <sup>18</sup>F-choline positron emission tomography fused with computed tomography (PET/CT) scan for primary metastasis staging.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Of 174 eligible men, 124 met the criteria for inclusion. The PET/CT scan was negative for metastasis in 97 (78%) men, inconclusive in 15 (12%), and positive in 12 (10%). The men with a positive PET/CT scan had significantly shorter time to BCR (<i>p</i> = 0.02), time to skeletal metastasis (<i>p</i> = 0.002), and time to prostate cancer specific death (<i>p</i> &lt; 0.001). On multivariable Cox regression analysis, including also tumour stage, Gleason score, and PSA, a non-negative PET/CT scan was the only significant covariate for time to BCR (HR 2.6, 95% CI 1.3-5.5) and time to skeletal metastasis (HR 2.7, 95% CI 1.3-5.9).</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">In men with a newly diagnosed high-risk prostate cancer and a negative or inconclusive bone scan, <sup>18</sup>F-choline uptake on PET/CT suggestive metastasis was associated with recurrence, progression to distant metastasis, and prostate cancer death. This strongly indicates that the choline uptakes represented metastasis and not false positive findings.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kjölhede</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000-0001-6441-4729</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Göteborg, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Almquist</LastName>
                    <ForeName>Helén</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Center for Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden.</Affiliation>
                        <Identifier Source="GRID">grid.411843.b</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lyttkens</LastName>
                    <ForeName>Kerstin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>2Center for Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden.</Affiliation>
                        <Identifier Source="GRID">grid.411843.b</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bratt</LastName>
                    <ForeName>Ola</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Göteborg, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Hybrid Imaging</MedlineTA>
            <NlmUniqueID>101724113</NlmUniqueID>
            <ISSNLinking>2510-3636</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Choline</Keyword>
            <Keyword MajorTopicYN="N">PET/CT</Keyword>
            <Keyword MajorTopicYN="N">Prognosis</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
        <CoiStatement>HK, specialist in urology and PhD in urologic cancer. OB, specialist in urology, professor in urologic cancer. HA, specialist in nuclear medicine, PhD. KL, specialist in radiology, PhD.The Regional Ethical Review Board in Lund approved the study protocol (LU552/2007) without written informed consent, according to Swedish law at the time.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30148254</ArticleId>
            <ArticleId IdType="doi">10.1186/s41824-018-0034-2</ArticleId>
            <ArticleId IdType="pii">34</ArticleId>
            <ArticleId IdType="pmc">PMC6097795</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30147335</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1178-6930</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>OncoTargets and therapy</Title>
                <ISOAbbreviation>Onco Targets Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4837-4844</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/OTT.S169101</ELocationID>
            <Abstract>
                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Prostate cancer (PCa) is one of the most common malignancies in men. However, a lack of understanding of the mechanism underlying PCa metastasis has strongly limited the effectiveness of therapy for this disease. Thus, investigating the mechanism of PCa may help improve the prognosis of PCa patients. The goal of this study was to investigate the role of microRNA-194 (miR-194) in PCa.</AbstractText>
                <AbstractText Label="Materials and methods" NlmCategory="UNASSIGNED">The expression of miR-194 and cadherin 2 (CDH2) at the transcriptional level was measured by quantitative real-time polymerase chain reaction (qRT-PCR). The MTT assay cell apoptosis assay and Western blotting were used to determine the role of miR-194 and CDH2 in the PC3 human PCa cell line. The dual luciferase reporter assay system was performed to clarify the relationship between miR-194 and CDH2. qRT-PCR results showed that miR-194 was downregulated and CDH2 was upregulated in PC3 cells.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Transfection with miR-194 mimics decreased cell viability and increased the rate of apoptosis compared with the control group of PC3 cells. Bioinformatics and the luciferase reporter assay indicated that CDH2 was a target of miR-194, and Western blot analysis suggested that CDH2 was negatively regulated by miR-194. Further studies revealed that the downregulation of CDH2 suppressed cell viability and promoted the apoptosis of PC3 cells and that miR-194 directly targeted CDH2 in PC3 cells. Finally, the in vivo experiments showed that miR-194 mimics suppressed tumor growth and induced apoptosis in a greater proportion of cells by decreasing the expression of CDH2 compared with the control group.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The results of this study showed that miR-194 targeted CDH2 to regulate PCa cell survival in vitro and suppress tumor growth in vivo. These findings suggest that miR-194 may be a useful therapeutic target in PCa.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Song</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China, zhangzy@sj-hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Zhiying</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of computer science and engineering, Northeastern University, Shenyang 110004, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China, zhangzy@sj-hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Lina</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China, zhangzy@sj-hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China, zhangzy@sj-hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Zhenyong</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China, zhangzy@sj-hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Onco Targets Ther</MedlineTA>
            <NlmUniqueID>101514322</NlmUniqueID>
            <ISSNLinking>1178-6930</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CDH2</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">cell viability</Keyword>
            <Keyword MajorTopicYN="N">microRNA-194</Keyword>
            <Keyword MajorTopicYN="N">prostatic cancer</Keyword>
        </KeywordList>
        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30147335</ArticleId>
            <ArticleId IdType="doi">10.2147/OTT.S169101</ArticleId>
            <ArticleId IdType="pii">ott-11-4837</ArticleId>
            <ArticleId IdType="pmc">PMC6098416</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30147102</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1998-4774</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>55</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <MedlineDate>2018 Jan-Mar</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Indian journal of cancer</Title>
                <ISOAbbreviation>Indian J Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.</ArticleTitle>
            <Pagination>
                <MedlinePgn>94-97</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/ijc.IJC_346_17</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Many agents have shown survival advantage in metastatic castrate-resistant prostate cancer (mCRPC). Despite this improvement, survival is poor, especially in subgroup of elderly patients who are not fit for cytotoxic chemotherapy.</AbstractText>
                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">This is a single-institutional data review of mCRPC treated between December 2012 and May 2016 with oral cyclophosphamide (50-100 mg/day) ± oral prednisolone. mCRPCs failed or not fit for docetaxel and/or abiraterone were included in this study. Monthly prostate-specific antigen (PSA) was monitored, and toxicity of cyclophosphamide was recorded. PSA response was defined as ≥50% reduction from precyclophosphamide value. The median follow-up was calculated from the day of starting cyclophosphamide and the last date of follow-up or death, whichever is later.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Eighteen patients were included with a median age of 74.5 years (range: 59-83). The site of metastasis was bone in 15, bone and distant lymph nodes in 2, and rectum in 1 patient. The median duration of androgen deprivation was 21 months (range: 3-42.9 months). The median cyclophosphamide exposure was 2 months (range: 0.9-13.5 months) after a median follow-up of 5.8 months. Overall PSA response rate was 44%. The median PSA progression-free survival with cyclophosphamide was 4.7 months (range: 0.9-13.5 months). Five patients had durable PSA response of 9.9, 10.1, 10.5, 12.1, and 13.5 months, respectively. No Grade 3 or 4 toxicity was observed with cyclophosphamide.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Oral metronomic cyclophosphamide was found to be an effective and well-tolerated therapy in mCRPC after failure or not fit for docetaxel and/or abiraterone. In few patients, cyclophosphamide induced durable PSA response. This finding needs further evaluation in a prospective manner.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dabkara</LastName>
                    <ForeName>Deepak</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ganguly</LastName>
                    <ForeName>Sandip</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biswas</LastName>
                    <ForeName>Bivas</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghosh</LastName>
                    <ForeName>Joydeep</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Indian J Cancer</MedlineTA>
            <NlmUniqueID>0112040</NlmUniqueID>
            <ISSNLinking>0019-509X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cyclophosphamide</Keyword>
            <Keyword MajorTopicYN="N">metastatic</Keyword>
            <Keyword MajorTopicYN="N">prostate</Keyword>
            <Keyword MajorTopicYN="N">steroids</Keyword>
        </KeywordList>
        <CoiStatement>There are no conflicts of interest</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30147102</ArticleId>
            <ArticleId IdType="pii">IndianJournalofCancer_2018_55_1_94_239587</ArticleId>
            <ArticleId IdType="doi">10.4103/ijc.IJC_346_17</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30146230</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-0682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jul</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical genitourinary cancer</Title>
                <ISOAbbreviation>Clin Genitourin Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1558-7673(18)30203-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clgc.2018.07.016</ELocationID>
            <Abstract>
                <AbstractText>Patients receiving androgen deprivation therapy are associated with increasing loss of bone mineral density (BMD) and higher risk of skeletal-related events. We reviewed and analyzed the influence of diphosphonates on BMD change. A systemic literature research was conducted in PubMed and related bibliographies. The focus of data extraction was BMD percentage change of lumbar spine, total hip, and femoral neck after 12 months. Standardized mean difference (SMD) was pooled with the random-effects model, and metaregression and subgroup analysis were performed to explore heterogeneity. Nine articles (n = 920) were included and finally analyzed after screening 118 articles. We found significant improvement in BMD percentage changes of the lumbar spine, total hip, and femoral neck at 1 year (respectively, SMD = 6.379, 95% confidence interval [CI] = 3.740-9.018, P &lt; .001, I<sup>2</sup> = 98.8%, P &lt; .001; SMD = 4.870, 95% CI, 2.256-7.485, P &lt; .001, I<sup>2</sup> = 98.9%, P &lt; .001; SMD = 3.634, 95% CI, 1.989-5.279, P &lt; .001, I<sup>2</sup> = 97.3%, P &lt; .001). In individual variable metaregression analysis, application zoledronic acid or not showed a statistically significant influence on BMD percentage change of total hip (P = .018). In subgroup analyses, both zoledronic acid and alendronate showed a significant improvement in BMD percentage changes. Diphosphonates significantly increased BMD percentage changes of the lumbar spine, total hip, and femoral neck in men receiving androgen deprivation therapy for prostate cancer. Patients with androgen deprivation therapy should be evaluated BMD loss, and timely therapy with diphosphonates may be an appropriate strategy to prevent osteoporosis.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Congcong</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Wenjun</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xuanzhang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Ruifang</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. Electronic address: xxzhang828@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Genitourin Cancer</MedlineTA>
            <NlmUniqueID>101260955</NlmUniqueID>
            <ISSNLinking>1558-7673</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BMD</Keyword>
            <Keyword MajorTopicYN="N">Bisphosphonate</Keyword>
            <Keyword MajorTopicYN="N">Meta</Keyword>
            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">Prostatic neoplasms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30146230</ArticleId>
            <ArticleId IdType="pii">S1558-7673(18)30203-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clgc.2018.07.016</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30145777</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-8726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of urology</Title>
                <ISOAbbreviation>World J Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-018-2459-4</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate image-guided Transperineal Elastic-Registration biopsy (TPER-B) in the risk-stratification of low-intermediate risk prostate cancer detected by Transrectal-ultrasound biopsy (TRUS-B) when estimates of cancer grade and volume discorded with multiparametric Magnetic Resonance Imaging (MRI).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">All patients referred for active surveillance or organ-conservative management were collegially reviewed for consistency between TRUS-B results and MRI. Image-guided TPER-B of the index target (IT) defined as the largest Prostate Imaging-Reporting Data System-v2 ≥ 3 abnormality was organized for discordant cases. Pathology reported Gleason grade, maximum cancer core length (MCCL) and total CCL (TCCL).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 237 prostate cancer patients (1-4/2018), 30 were required TPER-B for risk-stratification. Eight cores were obtained [Median and IQR: 8 (6-9)] including six (IQR: 4-6) in the IT. TPER-B of the IT yielded longer MCCL [Mean and (95%CI): 6.9 (5.0-8.8) vs. 2.6 mm (1.9-3.3), p &lt; 0.0001] and TCCL [19.7 (11.6-27.8) vs. 3.6 mm (2.6-4.5), p = 0.0002] than TRUS-B of the gland. On TPER-B cores, longer MCCL [Mean and (95%CI): 8.7 mm (6.7-10.7) vs. 4.1 mm (0.6-7.6), p = 0.002] were measured in Gleason score-7 cancers. TPER-B cores upgraded 13/30 (43.3%) patients. 14/30 (46.7%) met University College London-definition 1 and 18/30 (60.0%) definition 2, which correlate with clinically significant cancers &gt; 0.5 mL and &gt; 0.2 mL, respectively. 7/16 (43.8%) patients under active surveillance were re-allocated toward prostatectomy (n = 5) or radiation therapy (n = 2). In 14 patients not yet assigned, TPER-B risk-stratification spurred the selection (13/14, 92.9%) of treatments with curative intent.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Image-guided TPER-B of the index target provided more cancer material for pathology. Subsequent re-evaluation of cancer volume and grade switched a majority of patients towards higher-risk groups and treatments with curative intent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Covin</LastName>
                    <ForeName>Bertrand</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roumiguié</LastName>
                    <ForeName>Mathieu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quintyn-Ranty</LastName>
                    <ForeName>Marie-Laure</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graff</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khalifa</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aziza</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ploussard</LastName>
                    <ForeName>Guillaume</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Portalez</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Institut Universitaire du Cancer, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malavaud</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2793-9459</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Universitaire du Cancer, Toulouse, France. bernard.malavaud@me.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>World J Urol</MedlineTA>
            <NlmUniqueID>8307716</NlmUniqueID>
            <ISSNLinking>0724-4983</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biopsy</Keyword>
            <Keyword MajorTopicYN="N">Diagnostic imaging</Keyword>
            <Keyword MajorTopicYN="N">Endoscopy</Keyword>
            <Keyword MajorTopicYN="N">Prostatic Neoplasms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30145777</ArticleId>
            <ArticleId IdType="doi">10.1007/s00345-018-2459-4</ArticleId>
            <ArticleId IdType="pii">10.1007/s00345-018-2459-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30145092</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1769-6658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title>
                <ISOAbbreviation>Cancer Radiother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Hypofractionnated radiotherapy for elderly patients with prostate cancer].</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1278-3218(18)30279-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2018.07.124</ELocationID>
            <Abstract>
                <AbstractText>Radiation therapy technique and schedules could be adapted to patient's age because of a natural history of prostate cancer perceived as different, taking into account the comorbidities of patients but also a particular tolerance of elderly subjects. Thus, in localized prostate cancer, evaluation of associated diseases is essential before considering a treatment that will be of interest only if the life expectancy is greater than 10 years. When a curative approach is decided, radiotherapy holds a place of choice. Due to the recent results of randomized studies evaluating moderate hypofractionnated radiotherapy, showing a carcinological equivalence compared to a standard fractionation, this reduction in the duration of treatment appears particularly indicated in this elderly population. This approach permits to maintain the quality of life of patients, potentially with lower costs for society. The purpose of this article is to present the results of randomized trials of moderate hypofractionnation and discuss their application in the population of elderly patients with localized prostate cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sargos</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France. Electronic address: p.sargos@bordeaux.unicancer.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Créhange</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, centre Georges-François-Leclerc, 1, avenue du Professeur-Marion, 21000 Dijon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hennequin</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Latorzeff</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, clinique Pasteur, 1, rue de la Petite-Vitesse, 31300 Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Crevoisier</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35042 Rennes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roubaud</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département d'oncologie médicale, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Supiot</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Radiothérapie du cancer de la prostate localisé chez le sujet âgé : l’hypofractionnement modéré est-il le traitement de référence ?</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Cancer Radiother</MedlineTA>
            <NlmUniqueID>9711272</NlmUniqueID>
            <ISSNLinking>1278-3218</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer de la prostate</Keyword>
            <Keyword MajorTopicYN="N">Elderly patients</Keyword>
            <Keyword MajorTopicYN="N">Geriatric assessment</Keyword>
            <Keyword MajorTopicYN="N">Hypofractionnated radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">Oncogériatrie</Keyword>
            <Keyword MajorTopicYN="N">Prostate</Keyword>
            <Keyword MajorTopicYN="N">Radiothérapie hypofractionnée</Keyword>
            <Keyword MajorTopicYN="N">Sujet âgé</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30145092</ArticleId>
            <ArticleId IdType="pii">S1278-3218(18)30279-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.canrad.2018.07.124</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30143894</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-7339</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
                <ISOAbbreviation>Support Care Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-018-4410-z</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In older cancer patients, treatment decision-making is often complex. A comprehensive geriatric assessment (CGA) is an established tool used in geriatric medicine to identify unmet need requiring intervention. This study aimed to assess whether using a CGA in older male cancer patients with incurable but manageable disease provides information that would alter a cancer clinician's intended management plan. Acceptability and feasibility were secondary aims.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Elderly men with incurable but manageable malignancies (advanced prostate cancer and multiple myeloma) who had previously received at least one line of treatment were recruited from hospital outpatient clinics. A CGA was undertaken. Additional parameters measuring pain, fatigue and disease-specific concerns were also recorded, at the recommendation of patient involvement groups. Results were made available to clinicians. Patient and clinician acceptability and changes in subsequent management were recorded.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-eight patients completed the study. The median ages were 70.8 years and 74 years for myeloma and prostate respectively. Most identified concerns are related to disease-specific concerns (93%), pain (91%), frailty (57%) and nutrition (52%). Results altered the clinician's oncological management plan in nine cases only. Patients found the format and content of CGA acceptable.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Many unmet needs were identified in this population of elderly men with manageable but non curable cancer which led to supportive care referrals and interventions. The CGA, however, did not result in significant changes in clinical oncology treatment plans for the majority of patients. The application of the CGA and other assessments was viewed positively by participants and can feasibly be undertaken in the outpatient oncology setting.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Handforth</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5171-4917</Identifier>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK. C.Handforth@sheffield.ac.uk.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield, S10 2SJ, UK. C.Handforth@sheffield.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burkinshaw</LastName>
                    <ForeName>Roger</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freeman</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Janet E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield, S10 2SJ, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Snowden</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Rd, Sheffield, S10 2JF, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coleman</LastName>
                    <ForeName>Robert E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield, S10 2SJ, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenfield</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road, Sheffield, S10 2SJ, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Support Care Cancer</MedlineTA>
            <NlmUniqueID>9302957</NlmUniqueID>
            <ISSNLinking>0941-4355</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Advanced prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Comprehensive geriatric assessment</Keyword>
            <Keyword MajorTopicYN="N">Multiple myeloma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30143894</ArticleId>
            <ArticleId IdType="doi">10.1007/s00520-018-4410-z</ArticleId>
            <ArticleId IdType="pii">10.1007/s00520-018-4410-z</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30143400</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-1449</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brachytherapy</Title>
                <ISOAbbreviation>Brachytherapy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1538-4721(18)30457-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brachy.2018.07.001</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited. We report long-term clinical outcomes data for patients with cT3a/b disease receiving LDR-BT.</AbstractText>
                <AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">Ninety-nine men (median age: 69.4 years) with cT3a/bN0M0 high-risk prostate adenocarcinoma received definitive LDR-BT or LDR-BT boost after external beam radiation therapy (EBRT) at a single institution between 1998 and 2007. About 86% of patients received androgen deprivation therapy. Freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), and overall survival (OS) was calculated using the Kaplan-Meier method with the Phoenix definition used as definition of failure. Cox regression analysis was used to compare outcomes between clinical stage, initial PSA, Gleason Score, and percent core positive rate.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">With a median followup of 7 years, 7-year rate of FFBF, PCSS, and OS for the entire cohort was 65.2% (±5.6%), 90.1% (±3.6%), and 77.9% (±4.7%), respectively. LDR-BT boost patients achieved a 7-year FFBF rate of 73.5 (±6.5%). No significant difference in outcomes was present between T3a or T3b disease, Gleason score, iPSA stratification and percent core positive rates.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LDR-BT, primarily as a boost in conjunction with ADT and EBRT, is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer resulting in excellent biochemical control and survival outcomes. LDR-BT boost implantation of patients should be strongly considered for cT3 patients given the merits of trimodality care.</AbstractText>
                <CopyrightInformation>Copyright © 2018 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Manuj</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD. Electronic address: manuj.agarwal@umm.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chhabra</LastName>
                    <ForeName>Arpit M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amin</LastName>
                    <ForeName>Neha</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braccioforte</LastName>
                    <ForeName>Michelle H</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Foundation of Chicago, Westmont, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Molitoris</LastName>
                    <ForeName>Jason K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moran</LastName>
                    <ForeName>Brian J</ForeName>
                    <Initials>BJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Foundation of Chicago, Westmont, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Brachytherapy</MedlineTA>
            <NlmUniqueID>101137600</NlmUniqueID>
            <ISSNLinking>1538-4721</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Brachytherapy</Keyword>
            <Keyword MajorTopicYN="N">Extracapsular</Keyword>
            <Keyword MajorTopicYN="N">LDR</Keyword>
            <Keyword MajorTopicYN="N">Low-dose-rate</Keyword>
            <Keyword MajorTopicYN="N">Seminal vesicle</Keyword>
            <Keyword MajorTopicYN="N">T3, prostate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30143400</ArticleId>
            <ArticleId IdType="pii">S1538-4721(18)30457-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brachy.2018.07.001</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30142541</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1950-6007</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>107</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title>
                <ISOAbbreviation>Biomed. Pharmacother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>793-805</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0753-3322(18)33177-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2018.08.061</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To examine the functions of growth factor midkine (MK) and a flavonoid quercetin on survival, apoptosis and migration of prostate cancer (PCa) stem cells (CSCs).</AbstractText>
                <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">CD44<sup>+</sup>/CD133<sup>+</sup> and CD44<sup>+</sup> stem cells were isolated from PC3 and LNCaP cells, respectively by magnetic-activated cell sorting system. 3D cell culture was used to evaluate the ability of quercetin, MK siRNA, and the combination of both to inhibit spheroid formation, apoptosis and cell cycle arrest. Image-based cytometer, RT-qPCR, Western blotting and transwell migration assays were performed.</AbstractText>
                <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">Quercetin treatment for 24-72 h inhibited PC3 and CD44+/CD133+ stem cell proliferation in a time- and dose-dependent manner. Knockdown of endogenous MK expression significantly suppressed proliferation of CD44<sup>+</sup>/CD133<sup>+</sup> and CD44<sup>+</sup> cells as well as their parent cells. Co-administration of MK siRNA and quercetin reduced the cell survival, induced apoptosis and caused G1 phase cell cycle arrest more effectively than the individual therapy. Knockdown of MK significantly enhanced the inhibitory effect of quercetin on CD44<sup>+</sup>/CD133<sup>+</sup> migration and spheroid formation. In addition, the combined therapy inhibited the phosphorylation of PI3K, AKT and ERK1/2, and reduced the protein expression of p38, ABCG2 and NF-κB.</AbstractText>
                <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">Quercetin alone exhibited significant cytotoxic effects on CD44<sup>+</sup>/CD133<sup>+</sup>. MK plays an important role in the proliferation of CD44<sup>+</sup>/CD133<sup>+</sup> and CD44<sup>+</sup> cells in particular, and quercetin and MK-silencing therapy may be an important strategy in targeting CSCs that play a role in relapse, migration and drug resistance.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Erdogan</LastName>
                    <ForeName>Suat</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biology, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey. Electronic address: suaterdogan@trakya.edu.tr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turkekul</LastName>
                    <ForeName>Kader</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biology, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dibirdik</LastName>
                    <ForeName>Ilker</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biochemistry, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doganlar</LastName>
                    <ForeName>Oguzhan</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biology, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doganlar</LastName>
                    <ForeName>Zeynep B</ForeName>
                    <Initials>ZB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biology, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bilir</LastName>
                    <ForeName>Ayhan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Histology and Embryology, School of Medicine, Istanbul Aydin University, Istanbul, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oktem</LastName>
                    <ForeName>Gulperi</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Histology and Embryology, School of Medicine, Ege University, Izmir, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Biomed Pharmacother</MedlineTA>
            <NlmUniqueID>8213295</NlmUniqueID>
            <ISSNLinking>0753-3322</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">LNCaP</Keyword>
            <Keyword MajorTopicYN="N">Midkine</Keyword>
            <Keyword MajorTopicYN="N">Migration</Keyword>
            <Keyword MajorTopicYN="N">PC3</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer stem cells</Keyword>
            <Keyword MajorTopicYN="N">Quercetin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30142541</ArticleId>
            <ArticleId IdType="pii">S0753-3322(18)33177-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.08.061</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30142421</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-1186</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacological research</Title>
                <ISOAbbreviation>Pharmacol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1043-6618(18)30709-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phrs.2018.08.016</ELocationID>
            <Abstract>
                <AbstractText>Δ<sup>4</sup>-abiraterone (Δ4A) is an active metabolite of abiraterone (ABI), which is approved in the treatment of metastatic castration resistant prostate cancer (mCRPC). The contribution of Δ4A to the clinical antitumor activity of ABI remains unknown. The aim of this study was to explore the relationship between plasma Δ4A concentration and survival in 36 mCRPC patients treated with abiraterone acetate (1000 mg/day) plus prednisone (10 mg/day). Plasma trough ABI and Δ4A concentrations were monthly assayed using liquid chromatography during the first 3 months of treatment. ABI and Δ4A C<sub>min</sub> were defined as the mean of trough concentrations measured for each patient. Predictive factors regarding progression-free survival (PFS) and overall survival (OS) were explored using univariate Cox model. Mean plasma ABI and Δ4A C<sub>min</sub> were 12.6 ± 6.8 ng/mL and 1.6 ± 1.3 ng/mL, respectively. The mean metabolic ratio Δ4A/ABI was of 0.18 ± 0.25. In regard with in vitro pharmacodynamic data, effective plasma concentrations for ABI and Δ4A were reached in 30 patients (83.3%) and only 2 patients (5.6%), respectively. Higher Δ4A C<sub>min</sub> was associated with shorter OS (Hazard ratio, HR 1.54; CI95% 1.06-2.22; p = 0.022) but not with PFS. The HR associated with the metabolic Δ4A/ABI ratio for PFS and OS were 7.80 (CI 95% 1.63-37.38; p = 0.010) and 12.52 (CI 95% 1.95-80.47, p = 0.0078), respectively. The present study shows Δ4A is unlikely to have meaningful contribution to pharmacodynamic activity of ABI in mCPRC, rather that higher plasma Δ4A concentration is associated with worse clinical outcomes. A high Δ4A/ABI metabolic ratio could help to identify mCRPC patients with poorer survival.</AbstractText>
                <CopyrightInformation>Copyright © 2018. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Blanchet</LastName>
                    <ForeName>Benoit</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France; CARPEM, Paris, France; UMR8638 CNRS, Pharmacy UFR, University of Paris Descartes, PRES sorbonne Paris Cité, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carton</LastName>
                    <ForeName>Edith</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France; University of Paris Descartes, CARPEM, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alyamani</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Golmard</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biopathology Department, Institut Curie, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huillard</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France; University of Paris Descartes, CARPEM, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomas-Scheomann</LastName>
                    <ForeName>Audrey</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UMR8638 CNRS, Pharmacy UFR, University of Paris Descartes, PRES sorbonne Paris Cité, France; Department of Clinical Pharmacy, Hôpital Cochin, AP-HP, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidal</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France; CARPEM, Paris, France; UMR8638 CNRS, Pharmacy UFR, University of Paris Descartes, PRES sorbonne Paris Cité, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldwasser</LastName>
                    <ForeName>François</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France; University of Paris Descartes, CARPEM, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharifi</LastName>
                    <ForeName>Nima</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alexandre</LastName>
                    <ForeName>Jérôme</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France; University of Paris Descartes, CARPEM, Paris, France; Cochin Institute, INSERM U1016, Paris, France. Electronic address: jerome.alexandre@aphp.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Pharmacol Res</MedlineTA>
            <NlmUniqueID>8907422</NlmUniqueID>
            <ISSNLinking>1043-6618</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Delta-4 abiraterone metabolite</Keyword>
            <Keyword MajorTopicYN="N">abiraterone</Keyword>
            <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30142421</ArticleId>
            <ArticleId IdType="pii">S1043-6618(18)30709-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.phrs.2018.08.016</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30142405</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-9995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Urology</Title>
                <ISOAbbreviation>Urology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The 17-gene Genomic Prostate Score Assay Predicts Outcome after Radical Prostatectomy Independent of PTEN Status.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0090-4295(18)30764-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urology.2018.07.018</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the ability of loss of phosphatase and tensin homolog (PTEN) and Genomic Prostate Score assay (GPS) in predicting the biochemical-recurrence (BCR) and clinical-recurrence (CR) after radical prostatectomy (RP) for clinically localized prostate cancer (PCa).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">377 patients with and without CR were retrospectively selected by stratified cohort sampling design from RP database. PTEN status (by IHC and FISH) and GPS results were determined for RP specimens. BCR was defined as PSA ≥0.2 ng/mL or initiation of salvage therapy for a rising PSA. CR was defined as local recurrence/distant metastases.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline mean age, PSA, and GPS score for the cohort were 61.1 years, 8 ng/dl, and 32.8. PTEN loss was noted in 38% patients by FISH and 25% by IHC. The concordance between FISH and IHC for PTEN loss was 66% (Kappa coefficient 0.278; p&lt;0.001). On univariable analysis, loss of PTEN by FISH or IHC was associated with BCR and CR (p&lt;0.05). However, after adjusting for GPS results, PTEN loss was not a significant predictor for CR or BCR (p&gt;0.1). The GPS result remained strongly associated with CR and BCR after adjusting for PTEN status (p&lt;0.001). PTEN status and GPS results only weakly correlated. GPS was widely distributed regardless of PTEN status indicating the biological heterogeneity of prostate cancer even in PTEN-deficient cases.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GPS is a significant predictor of aggressive prostate cancer, independent of PTEN status. After adjustment for GPS results, PTEN was not independently associated with recurrence for PCa.</AbstractText>
                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Magi-Galluzzi</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isharwal</LastName>
                    <ForeName>Sudhir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Falzarano</LastName>
                    <ForeName>Sara M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsiatis</LastName>
                    <ForeName>Athanasios</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dee</LastName>
                    <ForeName>Ann</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maddala</LastName>
                    <ForeName>Tara</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knezevic</LastName>
                    <ForeName>Dejan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Febbo</LastName>
                    <ForeName>Phillip G</ForeName>
                    <Initials>PG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawrence</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Inc., Redwood City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klein</LastName>
                    <ForeName>Eric A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Glickman Urology and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: kleine@ccf.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urology</MedlineTA>
            <NlmUniqueID>0366151</NlmUniqueID>
            <ISSNLinking>0090-4295</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Genomic Prostate Score</Keyword>
            <Keyword MajorTopicYN="N">Phosphatase and Tensin homolog (PTEN)</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">biochemical recurrence</Keyword>
            <Keyword MajorTopicYN="N">clinical recurrence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30142405</ArticleId>
            <ArticleId IdType="pii">S0090-4295(18)30764-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.urology.2018.07.018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30142318</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3792</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of urology</Title>
                <ISOAbbreviation>J. Urol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0022-5347(18)43729-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2018.08.043</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">3TmpMRI with PI-RADSv2 scoring is a common tool in prostate cancer (PCa) diagnosis and informs the likelihood of a cancerous lesion. We sought to investigate whether PI-RADSv2 also predicts adverse pathologic (AP) features mainly in patients with biopsy Gleason score (GS) 3+4.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed 326 consecutive men with preoperative template and/or MR-US fusion biopsy GS 6-7 from a prospectively maintained database of those undergoing robotic radical prostatectomy (RALP). The primary analysis was done on patients with biopsy GS 3+4 assessing the primary outcome of AP using univariate and multivariate logistic regression and secondary outcome of biochemical-recurrence free survival using Kaplan-Meier methods. Similar analysis was done on patients with biopsy GS 6-7.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In GS 3+4, stratified by PI-RADSv2 were 0-2 (27%), 3 (15%), 4 (36%) and 5 (23%). On univariate analysis, a PI-RADSv2 category 5 was predictive of AP vs. categories of 0-2 (OR 10.7, 95%CI 3.7-31; p=&lt;0.001). On multivariate analysis PI-RADSv2 category 5 was associated with AP (OR 11.4, 95%CI 3.7-35; p=&lt;0.0001) when adjusting for preoperative MR targeted-biopsy. In men with targeted biopsy GS 3+4 PCa, a PI-RADSv2 category 5 was associated with AP (OR 14.7, 95%CI 1.5-146.9, p=0.02). Men with biopsy Gleason 3+4 had a 2-year BRFS for PI-RADSv2 4 (92%), 5 (58%), respectively.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A PI-RADSv2 category 5 lesion in patients with biopsy GS 3+4 lesion was predictive of AP and BRFS. These findings suggest that pre-operative 3TmpMRI may serve as a prognostic marker of treatment outcomes independently of biopsy GS or biopsy type.</AbstractText>
                <CopyrightInformation>Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Faiena</LastName>
                    <ForeName>Izak</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salmasi</LastName>
                    <ForeName>Amirali</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mendhiratta</LastName>
                    <ForeName>Neil</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Markovic</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahuja</LastName>
                    <ForeName>Preeti</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elashoff</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raman</LastName>
                    <ForeName>Steven S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles; Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reiter</LastName>
                    <ForeName>Robert E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles. Electronic address: RReiter@mednet.ucla.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Urol</MedlineTA>
            <NlmUniqueID>0376374</NlmUniqueID>
            <ISSNLinking>0022-5347</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30142318</ArticleId>
            <ArticleId IdType="pii">S0022-5347(18)43729-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.juro.2018.08.043</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30141351</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8301</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Future oncology (London, England)</Title>
                <ISOAbbreviation>Future Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2018-0090</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To understand why thalidomide and lenalidomide exhibit different responses in metastatic prostate cancer (mPCa) treatment.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the perturbation signatures of thalidomide, lenalidomide, flutamide treated mPCa cell line from Library of Integrated Network-based Cellular Signatures database and transcriptome of docetaxel-treated mPCa patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Flutamide and docetaxel downregulated 'Steroid Biosynthesis', 'Cell cycle' and PCa specific transcription factor networks. Thalidomide inhibited 'Cell cycle' and 'E2F network', possibly accounting for its synergistic effects with docetaxel. Conversely, lenalidomide promoted 'Cell cycle' and 'Cholesterol biosynthesis'.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hence, we propose that lenalidomide upregulates cholesterol synthesis followed by enhanced rate of cell cycle, thereby nurturing a hyperproliferative tumor microenvironment. In summary, this study offers a possible explanation for the differential outcomes in the treatment of mPCa with thalidomide and lenalidomide.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sundaresan</LastName>
                    <ForeName>Lakshmikirupa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>AU-KBC Research Center, Anna University, Chennai, India.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Anna University, Chennai, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Pavitra</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>AU-KBC Research Center, Anna University, Chennai, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chatterjee</LastName>
                    <ForeName>Suvro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>AU-KBC Research Center, Anna University, Chennai, India.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Anna University, Chennai, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Future Oncol</MedlineTA>
            <NlmUniqueID>101256629</NlmUniqueID>
            <ISSNLinking>1479-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">LINCS data</Keyword>
            <Keyword MajorTopicYN="N">cell cycle</Keyword>
            <Keyword MajorTopicYN="N">cholesterol biosynthesis</Keyword>
            <Keyword MajorTopicYN="N">combinational therapy</Keyword>
            <Keyword MajorTopicYN="N">docetaxel</Keyword>
            <Keyword MajorTopicYN="N">flutamide</Keyword>
            <Keyword MajorTopicYN="N">lenalidomide</Keyword>
            <Keyword MajorTopicYN="N">metastatic prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">thalidomide</Keyword>
            <Keyword MajorTopicYN="N">transcriptome</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30141351</ArticleId>
            <ArticleId IdType="doi">10.2217/fon-2018-0090</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30141348</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8301</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Future oncology (London, England)</Title>
                <ISOAbbreviation>Future Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2018-0158</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Di Nunno</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cimadamore</LastName>
                    <ForeName>Alessia</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santoni</LastName>
                    <ForeName>Matteo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Macerata Hospital, Macerata, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarpelli</LastName>
                    <ForeName>Marina</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fiorentino</LastName>
                    <ForeName>Michelangelo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology Department, S. Orsola-Malpighi Hospital, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciccarese</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iacovelli</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology &amp; Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopez-Beltran</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Cordoba University Medical School, Cordoba, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Massari</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montironi</LastName>
                    <ForeName>Rodolfo</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Future Oncol</MedlineTA>
            <NlmUniqueID>101256629</NlmUniqueID>
            <ISSNLinking>1479-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MET inhibitor</Keyword>
            <Keyword MajorTopicYN="N">bone metastasis</Keyword>
            <Keyword MajorTopicYN="N">cabozantinib</Keyword>
            <Keyword MajorTopicYN="N">castration-resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">metastatic RCC</Keyword>
            <Keyword MajorTopicYN="N">multityrosine kinases inhibitor</Keyword>
            <Keyword MajorTopicYN="N">osteoblastic activation</Keyword>
            <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
            <Keyword MajorTopicYN="N">target therapy</Keyword>
            <Keyword MajorTopicYN="N"> angiogenesis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30141348</ArticleId>
            <ArticleId IdType="doi">10.2217/fon-2018-0158</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30141307</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2476-762X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Asian Pacific journal of cancer prevention : APJCP</Title>
                <ISOAbbreviation>Asian Pac. J. Cancer Prev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>miR-1266-5p and miR-185-5p Promote Cell Apoptosis in Human Prostate Cancer Cell Lines</ArticleTitle>
            <Pagination>
                <MedlinePgn>2305-2311</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Objective: Small non-coding RNA molecules are dysregulated in prostate cancer (PCa). In our previous study,
downregulation of miR-1266 and miR-185 was demonstrated in PCa tissues and cell lines. The aim of the present
study was to investigate whether miR-1266 and miR-185 are involved in the regulation of B-cell lymphoma (BCL) 2
and BCL2L1, respectively, and whether transfection of PCa cell lines with miR-1266 and miR-185 mimics can alter
tumorigenic phenotypes. Methods: In order to investigate the regulation of BCL2 and BCL2L1 mRNA levels by
miR-1266 and miR-185, respectively, a luciferase reporter assay was used. Real-time PCR was also used to analyze
changes in the levels of BCL2 and BCL2L1 mRNAs in PCa cell lines following transfection with synthetic miR-1266
and miR-185. Cell apoptosis was determined by Annexin V protein expression analysis via flow cytometry. In addition
to the MTT assay, a cell proliferation assay was performed. Result: A luciferase assay confirmed that the BCL2 and
BCL2L1 genes may be targeted by miR-1266 and miR-185, respectively, through binding to their 3′UTR regions.
Transfection of PC3 and DU145 cells with miR-1266 and miR-185 induced apoptosis and reduced proliferation, which
also revealed an inverse correlation with BCL2 and BCL2L1 gene expression in the treated cells. Conclusion: Our
data suggests that miR-1266 and miR-185 may be novel candidates for further research in PCa treatment through the
anti-apoptotic pathway.</AbstractText>
                <CopyrightInformation>Creative Commons Attribution License</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ostadrahimi</LastName>
                    <ForeName>Shiva</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, Department of Experimental Cancer Medicine, Karolinska Institutet Huddinge, 141 86 Stockholm, Sweden. Email: fard-esfahani@pasteur.ac.ir , dr.reza.mahdian@gmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abedi Valugerdi</LastName>
                    <ForeName>Manuchehr</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Moustapha</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haddad</LastName>
                    <ForeName>Ghazal</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fayaz</LastName>
                    <ForeName>Shima</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parvizhamidi</LastName>
                    <ForeName>Monireh</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahdian</LastName>
                    <ForeName>Reza</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fard Esfahani</LastName>
                    <ForeName>Pezhman</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Thailand</Country>
            <MedlineTA>Asian Pac J Cancer Prev</MedlineTA>
            <NlmUniqueID>101130625</NlmUniqueID>
            <ISSNLinking>1513-7368</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">miR-1266-5p</Keyword>
            <Keyword MajorTopicYN="Y">miR-185-5p</Keyword>
            <Keyword MajorTopicYN="Y">prostate cancer</Keyword>
            <Keyword MajorTopicYN="Y">BCL2</Keyword>
            <Keyword MajorTopicYN="Y">BCL2L1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30141307</ArticleId>
            <ArticleId IdType="doi">10.22034/APJCP.2018.19.8.2305</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30141201</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0045</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Prostate</Title>
                <ISOAbbreviation>Prostate</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/pros.23710</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Castration resistant prostate cancer (CRPC) represents the most aggressive status of this neoplastic disease, also characterized by the absence of biomarkers predictive of clinical outcome. New drugs as abiraterone or enzalutamide, affecting androgen receptor pathway at different levels, inhibit the proliferative advantage of prostate cancer cells with important long term benefits. Despite the advantages of this second-generation androgen deprivation therapy (ADT), resistance mechanisms, primitive or acquired, often develop. The existence of androgen receptor (AR) splice variants (AR-Vs), in particular AR-V7 expression detected in circulating tumor cells (CTCs), represents an example of acquired resistance, as evidenced in preclinical and clinical studies. Recent studies also have suggested the role of AR-V7 as a prognostic biomarker in mCRPC. In this field, hot topics are the methodology used to isolate CTC and the assay for AR-V7 measurement. Our study aims to develop a standardized operating procedure (SOP) to evaluate AR-V7 in CRPC.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">The application of a realized cell based Reference Sample as Standardized Quality Control tool for CTC-AR-V7 assay has been shown. Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer.</AbstractText>
                <AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">The standardized procedure has high sensitivity and specificity and enables the detection and quantification of the spliced variant with respect to the full length AR (AR-FL) mRNA in CTC DNA purified from the blood of patients with CRPC. This procedure has been further validated in a consecutive series of patients with mCRPC, confirming its role as prognostic biomarker.</AbstractText>
                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tommasi</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2157-2978</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pilato</LastName>
                    <ForeName>Brunella</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carella</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lasorella</LastName>
                    <ForeName>Antonia</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bird srl, R&amp;D Facility, Rezzato, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Danza</LastName>
                    <ForeName>Katia</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vallini</LastName>
                    <ForeName>Ivan</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bird srl, R&amp;D Facility, Rezzato, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Summa</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naglieri</LastName>
                    <ForeName>Emanuele</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Prostate</MedlineTA>
            <NlmUniqueID>8101368</NlmUniqueID>
            <ISSNLinking>0270-4137</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AR-V7 splicing variant</Keyword>
            <Keyword MajorTopicYN="N">androgen receptor</Keyword>
            <Keyword MajorTopicYN="N">castration resistant</Keyword>
            <Keyword MajorTopicYN="N">metastatic prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30141201</ArticleId>
            <ArticleId IdType="doi">10.1002/pros.23710</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30140660</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2287-8882</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Prostate international</Title>
                <ISOAbbreviation>Prostate Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.</ArticleTitle>
            <Pagination>
                <MedlinePgn>104-109</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prnil.2017.10.002</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">We aimed to identify the candidate prostate cancer patients suitable for neoadjuvant androgen-deprivation therapy (ADT) with radical prostatectomy (RP).</AbstractText>
                <AbstractText Label="Materials and methods" NlmCategory="UNASSIGNED">This study included 711 Japanese patients with clinically localized prostate cancer who were treated with RP between 2000 and 2013. Patients were treated with or without neoadjuvant ADT before RP. The prognostic significance of neoadjuvant ADT on biochemical recurrence (BCR) was analyzed according to various clinicopathological characteristics.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">BCR occurred in 186 (26.2%) of 711 patients. The group treated with neoadjuvant ADT showed higher levels of prostate-specific antigen at diagnosis and advanced clinical T-stage, but suppressed pathological T-stage. Neoadjuvant ADT was not associated with the risk of BCR. In subgroup analysis, neoadjuvant ADT was significantly associated with increased BCR in patients aged &gt;65 years [hazard ratio (95% confidence interval), 2.04 (1.13-3.43), <i>P</i> = 0.020]. Among the 53 patients with available serum testosterone levels, neoadjuvant ADT was associated with the risk of BCR according to serum testosterone levels.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">This study demonstrated that neoadjuvant ADT showed potential deleterious effects in older patients and patients with lower serum testosterone levels, while a possible improved prognosis in patients with high serum testosterone levels treated with neoadjuvant ADT was suggested, warranting further exploration.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akitake</LastName>
                    <ForeName>Naoko</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiota</LastName>
                    <ForeName>Masaki</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Obata</LastName>
                    <ForeName>Hirofumi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takeuchi</LastName>
                    <ForeName>Ario</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kashiwagi</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imada</LastName>
                    <ForeName>Kenjiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiyoshima</LastName>
                    <ForeName>Keijiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inokuchi</LastName>
                    <ForeName>Junichi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tatsugami</LastName>
                    <ForeName>Katsunori</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eto</LastName>
                    <ForeName>Masatoshi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Prostate Int</MedlineTA>
            <NlmUniqueID>101605566</NlmUniqueID>
            <ISSNLinking>2287-8882</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2016 Jun;19(2):191-6</RefSource>
                <PMID Version="1">26857022</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1991 Feb 6;265(5):618-21</RefSource>
                <PMID Version="1">1824790</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2015 Dec;35(12):6925-32</RefSource>
                <PMID Version="1">26637918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Urol. 2014 Jun;21(6):578-83</RefSource>
                <PMID Version="1">24405474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2007 Jan;99(1):5-7</RefSource>
                <PMID Version="1">17227487</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2008 Jul-Aug;28(4C):2487-92</RefSource>
                <PMID Version="1">18751439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019</RefSource>
                <PMID Version="1">17054269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1999 May 5;281(17):1591-7</RefSource>
                <PMID Version="1">10235151</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2015 Jul;86(1):10-5</RefSource>
                <PMID Version="1">26048432</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Urol. 2014 Jun;11(6):342-51</RefSource>
                <PMID Version="1">24818848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2002 Jul;168(1):9-12</RefSource>
                <PMID Version="1">12050481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2008 Sep;180(3):904-9; discussion 909-10</RefSource>
                <PMID Version="1">18635221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2006 Jun;7(6):472-9</RefSource>
                <PMID Version="1">16750497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2007 May;51(5):1175-84</RefSource>
                <PMID Version="1">17240528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2007 Jul 1;110(1):81-6</RefSource>
                <PMID Version="1">17516446</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2002 Oct;90(6):561-6</RefSource>
                <PMID Version="1">12230618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr J. 2001 Oct;48(5):573-8</RefSource>
                <PMID Version="1">11789562</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2002 Feb;87(2):589-98</RefSource>
                <PMID Version="1">11836290</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</RefSource>
                <PMID Version="1">25559415</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2009 Mar;181(3):956-62</RefSource>
                <PMID Version="1">19167731</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2010 Jun;75(6):1396-404</RefSource>
                <PMID Version="1">19969335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2003 Sep;170(3):791-4</RefSource>
                <PMID Version="1">12913699</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2002 Jan;167(1):112-6</RefSource>
                <PMID Version="1">11743286</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 1993 Dec 15;72(12 Suppl):3788-92</RefSource>
                <PMID Version="1">7504577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1998 Sep 16;280(11):969-74</RefSource>
                <PMID Version="1">9749478</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Age</Keyword>
            <Keyword MajorTopicYN="N">Neoadjuvant androgen-deprivation therapy</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Radical prostatectomy</Keyword>
            <Keyword MajorTopicYN="N">Testosterone</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30140660</ArticleId>
            <ArticleId IdType="doi">10.1016/j.prnil.2017.10.002</ArticleId>
            <ArticleId IdType="pii">S2287-8882(17)30115-0</ArticleId>
            <ArticleId IdType="pmc">PMC6104286</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30140656</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2287-8882</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Prostate international</Title>
                <ISOAbbreviation>Prostate Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review.</ArticleTitle>
            <Pagination>
                <MedlinePgn>75-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prnil.2018.03.005</ELocationID>
            <Abstract>
                <AbstractText>Radiation therapy (RT) is a curative treatment option for localized prostate cancer. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule (IDN) is an emerging treatment option that involves the prophylactic irradiation of the whole prostate while increasing RT doses to the visible prostatic tumor. Because of the lack of large multicentre trials, a systematic review was performed in an attempt to get an overview on the feasibility and efficacy of focal dose escalation to the IDN. A bibliographic search for articles in English, which were listed in MEDLINE from 2000 to 2016 to identify publications on RT with focal directed boost to the IDN, was performed. The review was completed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Twenty-two articles describing 1,378 patients treated with RT using focal boost were identified and fulfilled the selection criteria. Intensity-modulated radiation therapy (IMRT) was used in 720 patients (52.3%), volumetric modulated arc therapy was used in 45 patients (3.3%), stereotactic body radiation therapy (SBRT) in 113 patients (8.2%), and low-dose rate and high-dose rate brachytherapy (BT) were used in 305 patients (22.1%) and 195 patients (14.1%), respectively. Use of androgen deprivation therapy varied substantially among series. Biochemical disease-free survival at 5 years was reported for a cohort of 812 (58.9%) patients. The combined median biochemical disease-free survival for this group of patients was 85% (range: 78.8-100%; 95% confidence interval: 77.1-82.7%). The average occurrence of grade III or worse gastrointestinal and genitourinary late toxicity was, respectively, 2.5% and 3.1% for intensity-modulated RT boost, 10% and 6% for stereotactic body RT, 6% and 2% for low-dose rate BT, and 4% and 4.3% for high-dose rate BT. This review shows encouraging results for focal dose escalation to the IDN with acceptable short- to medium-term side effects and biochemical disease control rates. However, owing to the heterogeneity of patient population and the short follow-up, the results should be interpreted with caution. Considering that the clinical endpoint in the studies was biochemical recurrence, the use and duration of androgen deprivation therapy administration should be carefully considered before driving definitive conclusions. Randomized trials with long-term follow-up are needed before this technique can be generally recommended.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Feutren</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiotherapy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Current Position Department of Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herrera</LastName>
                    <ForeName>Fernanda G</ForeName>
                    <Initials>FG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiotherapy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Prostate Int</MedlineTA>
            <NlmUniqueID>101605566</NlmUniqueID>
            <ISSNLinking>2287-8882</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Urol. 2016 Apr;13(4):226-35</RefSource>
                <PMID Version="1">26902337</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brachytherapy. 2016 May-Jun;15(3):266-73</RefSource>
                <PMID Version="1">27009848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1196-207</RefSource>
                <PMID Version="1">15234056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2017 Feb 1;109(2):1-8</RefSource>
                <PMID Version="1">28376214</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2010 Dec;106(11):1607-11</RefSource>
                <PMID Version="1">20553262</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Cancer. 2016 May;59:142-151</RefSource>
                <PMID Version="1">27035363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2016 Apr;119(1):91-6</RefSource>
                <PMID Version="1">26900090</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):960-964</RefSource>
                <PMID Version="1">27302511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2012 Jul;110(1):50-5</RefSource>
                <PMID Version="1">22077660</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2013 Jan;63(1):101-7</RefSource>
                <PMID Version="1">22980443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Cancer. 2013 Apr;49(6):1374-403</RefSource>
                <PMID Version="1">23485231</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2009 Nov;74(5):1094-9</RefSource>
                <PMID Version="1">19773038</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2012 Sep 1;72(12):1295-305</RefSource>
                <PMID Version="1">22213075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2009 May;15(5):559-65</RefSource>
                <PMID Version="1">19363497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Urol. 2014 Apr;32(2):329-33</RefSource>
                <PMID Version="1">22885658</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9</RefSource>
                <PMID Version="1">22330997</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Panminerva Med. 2016 Mar;58(1):16-22</RefSource>
                <PMID Version="1">25923839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2005 Feb 20;23(6):1192-9</RefSource>
                <PMID Version="1">15718316</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101</RefSource>
                <PMID Version="1">10192361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285</RefSource>
                <PMID Version="1">28262473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virchows Arch. 2014 May;464(5):589-94</RefSource>
                <PMID Version="1">24619626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1093-104</RefSource>
                <PMID Version="1">12829147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38</RefSource>
                <PMID Version="1">11872289</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2011 Jun;59(6):962-77</RefSource>
                <PMID Version="1">21367519</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2013 Mar 13;8:58</RefSource>
                <PMID Version="1">23497695</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2013 Jul 22;8:183</RefSource>
                <PMID Version="1">23875672</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA Oncol. 2015 Jul;1(4):505-27</RefSource>
                <PMID Version="1">26181261</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e423-9</RefSource>
                <PMID Version="1">21477947</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brachytherapy. 2017 Jan - Feb;16(1):201-206</RefSource>
                <PMID Version="1">27919653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1085-96</RefSource>
                <PMID Version="1">10863082</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2016 Jun;119(3):398-404</RefSource>
                <PMID Version="1">27162160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2012 Jun;13(6):622-32</RefSource>
                <PMID Version="1">22512844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2011 May;99(2):187-92</RefSource>
                <PMID Version="1">21600669</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2012 May;103(2):217-22</RefSource>
                <PMID Version="1">22341794</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):236-46</RefSource>
                <PMID Version="1">18722274</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93</RefSource>
                <PMID Version="1">22331003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2012 Sep;62(3):469-71</RefSource>
                <PMID Version="1">22521091</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):29-34</RefSource>
                <PMID Version="1">20961696</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2006 Dec;176(6 Pt 1):2432-7</RefSource>
                <PMID Version="1">17085122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-977</RefSource>
                <PMID Version="1">26054865</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Oncol. 2016 Feb 16;6:24</RefSource>
                <PMID Version="1">26909338</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2011 Sep;71(12):1309-16</RefSource>
                <PMID Version="1">21308714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Oncol (R Coll Radiol). 2016 Mar;28(3):165-70</RefSource>
                <PMID Version="1">26482453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9</RefSource>
                <PMID Version="1">17707266</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):317-324</RefSource>
                <PMID Version="1">29229326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2012 Jul;110(1):28-35</RefSource>
                <PMID Version="1">22093966</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2005 Jun;75(3):325-33</RefSource>
                <PMID Version="1">15967524</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brachytherapy. 2012 Jul-Aug;11(4):292-8</RefSource>
                <PMID Version="1">22464911</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jul 12;487(7406):239-43</RefSource>
                <PMID Version="1">22722839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Oncol. 2014 Oct 28;4:301</RefSource>
                <PMID Version="1">25389521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97</RefSource>
                <PMID Version="1">18374232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2012 Aug 15;118(16):4053-62</RefSource>
                <PMID Version="1">22281794</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2007 Sep 18;2:36</RefSource>
                <PMID Version="1">17877821</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):130-6</RefSource>
                <PMID Version="1">22330987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8</RefSource>
                <PMID Version="1">24113055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2013 Nov;109(2):217-21</RefSource>
                <PMID Version="1">24060175</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brachytherapy. 2007 Apr-Jun;6(2):149-56</RefSource>
                <PMID Version="1">17434109</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Int. 2016 Dec;4(4):130-135</RefSource>
                <PMID Version="1">27995111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295</RefSource>
                <PMID Version="1">28433432</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):50-7</RefSource>
                <PMID Version="1">19910135</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>OMICS J Radiol. 2014 Dec;3(4):null</RefSource>
                <PMID Version="1">25717423</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2017 Nov;120 Suppl 3:35-42</RefSource>
                <PMID Version="1">28749017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105</RefSource>
                <PMID Version="1">12128107</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):921-9</RefSource>
                <PMID Version="1">10386651</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2009 Oct 22;361(17):1704-6</RefSource>
                <PMID Version="1">19846858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):595-9</RefSource>
                <PMID Version="1">12062602</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):291-303</RefSource>
                <PMID Version="1">16618584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2005 Sep 14;294(10):1233-9</RefSource>
                <PMID Version="1">16160131</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer J. 2000 Jul-Aug;6(4):249-55</RefSource>
                <PMID Version="1">11038145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):799-807</RefSource>
                <PMID Version="1">18407430</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2012 Jan 1;18(1):308-16</RefSource>
                <PMID Version="1">22048240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18</RefSource>
                <PMID Version="1">19616743</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):656-63</RefSource>
                <PMID Version="1">19250768</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2009 Nov;93(2):213-9</RefSource>
                <PMID Version="1">19717197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Oncol. 2012 Apr;35(2):158-62</RefSource>
                <PMID Version="1">21336090</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2013 Apr 09;8:84</RefSource>
                <PMID Version="1">23570391</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brachytherapy. 2007 Jan-Mar;6(1):16-25</RefSource>
                <PMID Version="1">17284381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2012 Jan 30;7:14</RefSource>
                <PMID Version="1">22289620</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Oncol. 2012 Jun 09;7:82</RefSource>
                <PMID Version="1">22681643</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2018 May;121 Suppl 3:28-32</RefSource>
                <PMID Version="1">29360286</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Boost</Keyword>
            <Keyword MajorTopicYN="N">Brachytherapy</Keyword>
            <Keyword MajorTopicYN="N">Dominant intraprostatic lesion</Keyword>
            <Keyword MajorTopicYN="N">Hypofractionated radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">Localized prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Review</Keyword>
            <Keyword MajorTopicYN="N">Stereotactic body radiation therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30140656</ArticleId>
            <ArticleId IdType="doi">10.1016/j.prnil.2018.03.005</ArticleId>
            <ArticleId IdType="pii">S2287-8882(17)30162-9</ArticleId>
            <ArticleId IdType="pmc">PMC6104294</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30139889</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-5675</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of nuclear medicine technology</Title>
                <ISOAbbreviation>J Nucl Med Technol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual Tracer PET/CT (<sup>68</sup>Ga-PSMA and <sup>18</sup>F-FDG): Potential Clinical Utility in Therapeutic Decision-Making and Treatment Monitoring.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">jnmt.118.215582</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.2967/jnmt.118.215582</ELocationID>
            <Abstract>
                <AbstractText>Transformed small cell carcinoma of prostate represents a distinct tumor biology from the adenocarcinoma counterpart and penile metastasis from prostate cancer is a rare entity. Unique features of this transformation include unresponsiveness to hormonal therapy and presence of visceral metastases, which can demonstrate hypermetabolism on <sup>18</sup>F-FDG PET/CT. The importance of dual tracer PET/CT using <sup>68</sup>Ga-PSMA and <sup>18</sup>F-FDG is illustrated in metastatic prostatic adenocarcinoma (Gleason's score 4+3=7) with previous history of bilateral orchidectomy, chemotherapy and radiotherapy, who presented with abdominal pain and backache, dysuria and increasing serum PSA. The value of sequential dual tracer PET/CT to assess disease status, theranostics and monitoring response to multimodality therapies is illustrated.</AbstractText>
                <CopyrightInformation>Copyright © 2018 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Parghane</LastName>
                    <ForeName>Rahul Vithalrao</ForeName>
                    <Initials>RV</Initials>
                    <AffiliationInfo>
                        <Affiliation>RADIATION MEDICINE CENTRE (BARC), Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basu</LastName>
                    <ForeName>Sandip</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>RADIATION MEDICINE CENTRE (BARC), Tata Memorial Hospital Annexe, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Nucl Med Technol</MedlineTA>
            <NlmUniqueID>0430303</NlmUniqueID>
            <ISSNLinking>0091-4916</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">177Lu-PSMA therapy</Keyword>
            <Keyword MajorTopicYN="N">18F-FDG PET/CT</Keyword>
            <Keyword MajorTopicYN="N">68Ga-PSMA PET/CT</Keyword>
            <Keyword MajorTopicYN="N">Oncology: GU</Keyword>
            <Keyword MajorTopicYN="N">PET/CT</Keyword>
            <Keyword MajorTopicYN="N">Penile metastases</Keyword>
            <Keyword MajorTopicYN="N">Small cell carcinoma of prostate</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139889</ArticleId>
            <ArticleId IdType="pii">jnmt.118.215582</ArticleId>
            <ArticleId IdType="doi">10.2967/jnmt.118.215582</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30139879</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">clincanres.0768.2018</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-18-0768</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Primary staging of prostate cancer (PC) relies on modalities, which are limited. We evaluate simultaneous [<sup>68</sup>Ga]Ga-PSMA-11positron emission tomography (PSMA-PET)/magnetic resonance imaging (MRI) as a new diagnostic method for primary TNM-staging compared to histology and its impact on therapeutic decisions.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We investigated 122 patients with PSMA-PET/MRI prior to planned radical prostatectomy (RP). Primary endpoint was the accuracy of PSMA-PET/MRI in tumor staging as compared to staging-relevant histology. Additionally, a multidisciplinary team reassessed the initial therapeutic approach to evaluate its impact on the therapeutic management.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">PSMA-PET/MRI correctly identified PC in 119 of 122 patients (97.5%). 81 patients were treated with RP and pelvic lymphadenectomy. The accuracy for T-staging was 82.5% (95%CI 73-90; P&lt;0.001), for T2-stage: 85% (95%CI 71-94; P&lt;0.001), T3a-stage: 79% (95%CI 43-85; P&lt;0.001), T3b-stage: 94% (95%CI 73-100; P&lt;0.001) and 93% (95%CI 84-98) for N1-stage (P&lt;0.001). PSMA-PET/MRI changed the therapeutic strategy in 28.7% of the patients with either the onset of systemic therapy/radiotherapy (n=16) or active surveillance (n=19).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PSMA-PET/MRI can provide an accurate staging of newly diagnosed PC. Additionally, treatment strategies were changed in almost a third of the patients due to the information of this hybrid imaging technique.</AbstractText>
                <CopyrightInformation>Copyright ©2018, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grubmüller</LastName>
                    <ForeName>Bernhard</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baltzer</LastName>
                    <ForeName>Pascal A</ForeName>
                    <Initials>PA</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-3755-5398</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartenbach</LastName>
                    <ForeName>Sabrina</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, HistoConsultingHartenbach.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Andrea</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Helbich</LastName>
                    <ForeName>Thomas Hans</ForeName>
                    <Initials>TH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haug</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-8308-6174</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Nuclear Medicine, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldner</LastName>
                    <ForeName>Gregor</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiooncology, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wadsak</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4479-8053</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfaff</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitterhauser</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3173-5272</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balber</LastName>
                    <ForeName>Theresa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berroterán-Infante</LastName>
                    <ForeName>Neydher</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-9247-6457</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grahovac</LastName>
                    <ForeName>Marko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Babich</LastName>
                    <ForeName>John W</ForeName>
                    <Initials>JW</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1616-3416</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Radiology, Weill Cornell Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seitz</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-8424-9492</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kramer</LastName>
                    <ForeName>Gero</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Susani</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, medical university of Viena.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazal</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kenner</LastName>
                    <ForeName>Lukas</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shariat</LastName>
                    <ForeName>Shahrokh Francois</ForeName>
                    <Initials>SF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hacker</LastName>
                    <ForeName>Marcus</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartenbach</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Imaging and Image guided Therapy, Medical University of Vienna markus.hartenbach@me.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139879</ArticleId>
            <ArticleId IdType="pii">1078-0432.CCR-18-0768</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-0768</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30139716</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-0682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jul</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical genitourinary cancer</Title>
                <ISOAbbreviation>Clin Genitourin Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1558-7673(18)30470-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clgc.2018.07.014</ELocationID>
            <Abstract>
                <AbstractText>Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Iacovelli</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: roberto.iacovelli@aovr.veneto.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciccarese</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mosillo</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tortora</LastName>
                    <ForeName>Giampaolo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Genitourin Cancer</MedlineTA>
            <NlmUniqueID>101260955</NlmUniqueID>
            <ISSNLinking>1558-7673</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Abiraterone</Keyword>
            <Keyword MajorTopicYN="N">CSPC</Keyword>
            <Keyword MajorTopicYN="N">Docetaxel</Keyword>
            <Keyword MajorTopicYN="N">HSPC</Keyword>
            <Keyword MajorTopicYN="N">Prognosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139716</ArticleId>
            <ArticleId IdType="pii">S1558-7673(18)30470-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clgc.2018.07.014</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30139594</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2253-8070</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Revista espanola de medicina nuclear e imagen molecular</Title>
                <ISOAbbreviation>Rev Esp Med Nucl Imagen Mol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Importance of <sup>68</sup>Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S2253-654X(18)30150-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remn.2018.07.005</ELocationID>
            <Abstract>
                <AbstractText>Radiotherapy is a treatment with curative intent, both in patients with primary diagnosis of prostate cancer (PCa) and in patients presenting with biochemical recurrence after radical prostatectomy (RP). Moreover, the use of stereotactic body radiotherapy as a metastasis directed therapy in patients with oligometastatic PCa has significantly increased in the recent years. Conventional imaging techniques, including transrectal ultrasound, computed tomography (CT), morphologic magnetic resonance and bone scintigraphy have traditionally played a minor role in all those clinical scenarios due to its low diagnostic accuracy. The recent development of the positron emission tomography (PET) radiotracer <sup>68</sup>Ga-PSMA binding to the prostate specific membrane antigen (PSMA), a transmembrane glycoprotein overexpressed in PCa cells, has shown promising results. Detection rates for PCa lesions are higher than CT and higher than the best technique available, the PET/CT with choline. Its superiority has been demonstrated even at very low PSA levels (&lt;1 ng/ml). This increase in diagnostic accuracy represents a potential impact on patient management, especially in radiotherapy. Even if this imaging technique is already available for routine clinical practice in some European countries, in Spain, unfortunately, there is very limited access. In this review, we analyze the main studies that investigate the usefulness of <sup>68</sup>Ga-PSMA PET/CT in patients with PCa and its potential impact on radiotherapy treatments. In addition, we compared the <sup>68</sup>Ga-PSMA PET/CT, with the multiparametric magnetic resonance imaging and the PET/CT with choline, in the different clinical scenarios.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Couñago</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea de Madrid, Madrid, España. Electronic address: felipe.counago@quironsalud.es.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Artigas</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Medicina Nuclear y Terapias Metabólicas, Jules Bordet Institute, Bruselas, Bélgica.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sancho</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gómez-Iturriaga</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario Cruces, Biocruces Health Research Institute, Barakaldo, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gómez-Caamaño</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Complexo Hospitalario Universitario Santiago de Compostela, La Coruña, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maldonado</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Medicina Nuclear, Hospital Universitario Quirónsalud, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caballero</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario de Fuenlabrada, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>López-Campos</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Recio</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Radiología, Hospital Universitario Quirónsalud, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Del Cerro</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea de Madrid, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henríquez</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Oncología Radioterápica, Hospital Universitario de Sant Joan, Institute d'Investigació Sanitària Pere Virgili (IISPV), Reus, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>PET/TC con <sup>68</sup>Ga-PSMA, importancia en la práctica hospitalaria. Visión del oncólogo radioterápico.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Spain</Country>
            <MedlineTA>Rev Esp Med Nucl Imagen Mol</MedlineTA>
            <NlmUniqueID>101585329</NlmUniqueID>
            <ISSNLinking>2253-654X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Choline-PET</Keyword>
            <Keyword MajorTopicYN="N">Cáncer de próstata</Keyword>
            <Keyword MajorTopicYN="N">Multiparametric MRI</Keyword>
            <Keyword MajorTopicYN="N">PET-PSMA</Keyword>
            <Keyword MajorTopicYN="N">PET-colina</Keyword>
            <Keyword MajorTopicYN="N">PSMA-PET</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">RM multiparamétrica</Keyword>
            <Keyword MajorTopicYN="N">Radioterapia</Keyword>
            <Keyword MajorTopicYN="N">Radiotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139594</ArticleId>
            <ArticleId IdType="pii">S2253-654X(18)30150-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.remn.2018.07.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30139347</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2458</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC public health</Title>
                <ISOAbbreviation>BMC Public Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1060</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-018-5976-6</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patient reports of health related quality of life can provide important information about the long-term impact of prostate cancer. Because patient symptoms and function can differ by age of the survivor, the aim of our study was to examine patient-reported quality of life and prostate symptoms by age at diagnosis among a registry of Dutch prostate cancer survivors.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A population of 617 individuals from the Patient Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship (PROFILES) database was surveyed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and prostate symptom (EORTC QLQ-PR25) scales. Age at diagnosis was the main independent variable, with three age categories: 60 years and younger, 61-70 years, and 71 years and older. Dependent variables were the EORTC-QLQ-C30 and EORTC QLQ-PR25 scales, divided into positive and negative outcomes. Positive measures of health-related quality of life included global health, physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. Negative outcomes included fatigue, nausea, pain, dyspnea, insomnia, appetite, constipation, and diarrhea. We also assessed sexual activity, and urinary, bowel and hormonal symptoms. Descriptive analyses included frequencies with chi-square tests and medians with Kruskal-Wallis tests. Multivariable adjusted analyses were conducted by median regression modeling.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the numerous scales showing some unadjusted association with age group, only two scales demonstrated significant differences between prostate cancer patients age 71+ compared to the youngest group (age &lt; 61) after multivariable adjustment. On average, the oldest patients experienced an 8.3-point lower median physical functioning score (β = - 8.3; 95% CI = - 13.9, - 2.8; p = 0.003) and a 16.7-point lower median sexual activity score (β = - 16.7; 95% CI = - 24.7, - 8.6; p &lt; 0.001) while controlling for BMI, marital status, time since diagnosis, comorbidities (heart condition), Gleason score, and treatment (prostatectomy).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results suggest that patient age at diagnosis should be considered among factors that contribute to health-related quality of life outcomes for prostate cancer survivors.</AbstractText>
                <AbstractText Label="IMPLICATIONS FOR CANCER SURVIVORS" NlmCategory="CONCLUSIONS">A possible reevaluation of screening recommendations may be appropriate to acknowledge age as a factor contributing to health-related quality of life outcomes for prostate cancer survivors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kurian</LastName>
                    <ForeName>Christine J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leader</LastName>
                    <ForeName>Amy E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thong</LastName>
                    <ForeName>Melissa S Y</ForeName>
                    <Initials>MSY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Psychology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keith</LastName>
                    <ForeName>Scott W</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeigler-Johnson</LastName>
                    <ForeName>Charnita M</ForeName>
                    <Initials>CM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2641-7755</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. Charnita.Zeigler-Johnson@jefferson.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Public Health</MedlineTA>
            <NlmUniqueID>100968562</NlmUniqueID>
            <ISSNLinking>1471-2458</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Age at diagnosis</Keyword>
            <Keyword MajorTopicYN="N">HRQL</Keyword>
            <Keyword MajorTopicYN="N">Health-related quality of life</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139347</ArticleId>
            <ArticleId IdType="doi">10.1186/s12889-018-5976-6</ArticleId>
            <ArticleId IdType="pii">10.1186/s12889-018-5976-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30139231</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2476-762X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Asian Pacific journal of cancer prevention : APJCP</Title>
                <ISOAbbreviation>Asian Pac. J. Cancer Prev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Germline Mutations and Polymorphisms of Androgen Receptor in Prostate Cancer Patients: Frequency and Results of in Silico Analysis</ArticleTitle>
            <Pagination>
                <MedlinePgn>2241-2245</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Background: Germline and somatic polymorphisms and mutations of the Androgen Receptor (AR) gene are known to
be associated with the incidence of prostate cancer (PCa) in different populations. In this study we assessed germline AR
polymorphisms and mutations in PCa patients with prediction of pathogenicity of the identified mutations by in silico
analysis. Methods: Diagnosis of PCa was based on histopathology of prostate tissue (Gleason Score criteria) and serum
prostate-specific antigen (PSA) levels. Genomic DNA was extracted from peripheral blood of 38 patients. All exons and
exon-intron boundaries of AR were amplified using polymerase chain reactions (PCR) followed by Sanger sequencing.
In silico analysis was performed using Polyphen-2 and Mutation Taster®. Results: Two polymorphisms, CAG repeat
sequence (13-34 repeats in length) and p.Pro214Glu (MAF: 0.0789) located in exon 1 were identified. A missense
mutation (c.47C&gt;A/p.Pro146Glu) and in-frame deletion of a CAG sequence leading to loss of Arginine at codon 85
(c.252_254delCAG/p.Arg85-) were identified in a 70 year old patient with a Gleason Score and PSA level of 2 and
2.4ng/dL, respectively. His PSA level decreased to &lt; 0.5 ng/dL after 9 months of androgen deprivation therapy. Identified
mutations were predicted to be non-disease causing by Polyphen-2 and Mutation Taster®. Conclusion: Our data
demonstrated that the frequency of germline mutations of AR was low in PCa patients in Indonesia (5.26%: 2/38 alleles),
so that they are not likely to be major etiological factors. The in silico analysis of identified AR mutations in this study
corroborated the clinopathology features of the patient.</AbstractText>
                <CopyrightInformation>Creative Commons Attribution License</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sribudiani</LastName>
                    <ForeName>Yunia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Science, Division of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Genetics Working Group, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. Email: y.sribudiani@unpad.ac.id</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marwan</LastName>
                    <ForeName>Deineke W</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aulanni’am</LastName>
                    <ForeName>Aulanni’am</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Widodo</LastName>
                    <ForeName>Muhammad A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Purnomo</LastName>
                    <ForeName>Basuki B</ForeName>
                    <Initials>BB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Panigoro</LastName>
                    <ForeName>Ramdan</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Utomo</LastName>
                    <ForeName>Ahmad B</ForeName>
                    <Initials>AB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Thailand</Country>
            <MedlineTA>Asian Pac J Cancer Prev</MedlineTA>
            <NlmUniqueID>101130625</NlmUniqueID>
            <ISSNLinking>1513-7368</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Androgen receptor</Keyword>
            <Keyword MajorTopicYN="Y">germline</Keyword>
            <Keyword MajorTopicYN="Y">mutation</Keyword>
            <Keyword MajorTopicYN="Y">polymorphism</Keyword>
            <Keyword MajorTopicYN="Y">prostate cancer (PCa)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30139231</ArticleId>
            <ArticleId IdType="doi">10.22034/APJCP.2018.19.8.2241</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30138121</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-6586</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in urology</Title>
                <ISOAbbreviation>Curr Opin Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate cancer multifocality, the index lesion, and the microenvironment.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOU.0000000000000537</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Most of focal therapies has addressed index lesion as the targeted tumour focus to treat localized prostate cancer (PCa), a multifocal disease. The interaction between tumour foci and host cells creates a tumour microenvironment (TME) which affects tumour growth, cellular proliferation, and PCa progression. This review aims to better understand the biology of cancer foci and their interaction with the prostatic microenvironment after focal therapy.</AbstractText>
                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Index lesions are representative of PCa grade in low-risk patients, but the other foci of tumour, the satellite lesions, gain relevance in higher risk patients. Multiparametric MRI, guided biopsies and new biomarkers in combination are important to address PCa multifocality and to adequately select patients to focal therapy. Stromal, immune, and tumoural components are integrated in tumourigenesis and modified after the inflammation induced by focal therapy.</AbstractText>
                <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">TME and inflammation play an important role in PCa progression, but further researches are necessary to understand how once protective components of prostate microenvironment become protumour elements and how inflammation induced by focal therapy can affect them. Learning how to modulate TME is an exploratory molecular field that can lead us to better manage PCa in both prevention and treatment scenarios.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tourinho-Barbosa</LastName>
                    <ForeName>Rafael R</ForeName>
                    <Initials>RR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Faculdade de Medicina do ABC (ABC Medical School), São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de la Rosette</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Istanbul Medipol University, Istanbul, Turkey.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanchez-Salas</LastName>
                    <ForeName>Rafael</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Opin Urol</MedlineTA>
            <NlmUniqueID>9200621</NlmUniqueID>
            <ISSNLinking>0963-0643</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30138121</ArticleId>
            <ArticleId IdType="doi">10.1097/MOU.0000000000000537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30138021</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1930-7810</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>37</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Health psychology : official journal of the Division of Health Psychology, American Psychological Association</Title>
                <ISOAbbreviation>Health Psychol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pilot randomized trial of a couple-based physical activity videoconference intervention for sedentary cancer survivors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>861-865</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1037/hea0000608</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Including partners in interventions to increase physical activity (PA) could promote better adherence and longer-term effects. In preparation for a future large-scale randomized controlled trial (RCT), this randomized pilot trial tested the acceptability of a novel couple-based PA intervention for breast and prostate cancer survivors and the feasibility of conducting an RCT testing the intervention.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">Twenty cancer survivors (70% female; mean age = 63.0 years, SD = 8.9) and their partners (35% female; mean age = 62.8 years, SD = 7.7) were randomized to either the intervention or waitlist control. Couples in the intervention received four videoconference sessions including training in communication and support skills and behavior change techniques. Measures of PA and partner support for exercise were collected from survivors and partners before randomization and postintervention. Survivors also completed a physical well-being measure, and intervention participants completed a treatment acceptability measure.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Recruitment was challenging; approximately 18% of eligible survivors and their partners agreed to participate. Ninety-two percent of randomized participants completed postintervention surveys, and 78% of dyads randomized to the intervention arm completed all 4 sessions. Mean acceptability ratings were moderate to high. Mean difference scores suggested that participants in the intervention arm tended to report greater improvements in PA, partner support, and physical well-being than those in the control arm.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These preliminary findings suggest that the couple-based PA intervention was acceptable to survivors and their partners and that a large-scale RCT is likely to be feasible with modified recruitment strategies. Recommendations for improving recruitment and conducting a larger study are presented. (PsycINFO Database Record</AbstractText>
                <CopyrightInformation>(c) 2018 APA, all rights reserved).</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Porter</LastName>
                    <ForeName>Laura S</ForeName>
                    <Initials>LS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Control and Population Sciences, Duke Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Xiaomei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Control and Population Sciences, Duke Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lyna</LastName>
                    <ForeName>Pauline</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Control and Population Sciences, Duke Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kraus</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olsen</LastName>
                    <ForeName>Maren</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Bioinformatics.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patterson</LastName>
                    <ForeName>Emily</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry and Behavioral Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puleo</LastName>
                    <ForeName>Blair</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry and Behavioral Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pollak</LastName>
                    <ForeName>Kathryn I</ForeName>
                    <Initials>KI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Control and Population Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>Duke Cancer Institute</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Health Psychol</MedlineTA>
            <NlmUniqueID>8211523</NlmUniqueID>
            <ISSNLinking>0278-6133</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30138021</ArticleId>
            <ArticleId IdType="pii">2018-41555-004</ArticleId>
            <ArticleId IdType="doi">10.1037/hea0000608</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30136199</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-8726</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of urology</Title>
                <ISOAbbreviation>World J Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00345-018-2457-6</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We evaluated whether an increased body-mass index (BMI) and decreased physical activity increase the risk of locally advanced or high-risk prostate cancer (PCa) at radical prostatectomy (RP), and treatment failure after surgery.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data were collected from the PROCURE Biobank, a prospective cohort of patients with localized PCa undergoing RP in four academic centers in Québec between 2006 and 2013. Treatment failure was defined as biochemical recurrence and/or initiation of secondary, non-adjuvant therapy, and analyzed using the Kaplan-Meier method, log-rank tests, and Cox proportional-hazards models. Uni- and multivariate (ordered) logistic regression was used for time-independent variables.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">1813 patients were included. Median follow-up time was 69 months. Patients who reported a lower BMI were generally older, of Asian descent, and physically more active (p &lt; 0.05). Younger, black, and overweight/obese patients reported less physical activity (p &lt; 0.05). In multivariate analyses, a higher BMI increased the risk for locally advanced, high-risk PCa (defined as a pT3, N1 and/or Gleason 8-10 tumor; odds ratio 1.33, p &lt; 0.001), but increased physical activity did not predict high-risk disease (odds ratio 0.84, p = 0.39). Patients with a higher BMI also had a larger prostate at surgery (odds ratio 1.13, p = 0.03). BMI and physical activity were not associated with positive surgical margins or time to treatment failure (p &gt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BMI was an independent predictor for locally advanced, high-risk disease in this cohort of PCa patients undergoing RP, but was unrelated to treatment failure. Physical activity was not related to locally advanced, high-risk PCa or treatment failure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wissing</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada. michel.wissing@mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, McGill University, 5100 Boulevard de Maisonneuve West, Room 720F, Montreal, QC, H4A 3T2, Canada. michel.wissing@mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chevalier</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Program, McGill University Health Centre - Research Institute, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McKercher</LastName>
                    <ForeName>Ginette</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Program, McGill University Health Centre - Research Institute, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>PROCURE, Mont-Royal, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laprise</LastName>
                    <ForeName>Claudie</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, McGill University, 5100 Boulevard de Maisonneuve West, Room 720F, Montreal, QC, H4A 3T2, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aprikian</LastName>
                    <ForeName>Saro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Program, McGill University Health Centre - Research Institute, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>PROCURE, Mont-Royal, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Flaherty</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarlata</LastName>
                    <ForeName>Eleonora</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Program, McGill University Health Centre - Research Institute, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Université de Montréal, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carmel</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lacombe</LastName>
                    <ForeName>Louis</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Laval University, Laval, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brimo</LastName>
                    <ForeName>Fadi</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, McGill University, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Latour</LastName>
                    <ForeName>Mathieu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Cell Biology, Université de Montreal, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ekindi-Ndongo</LastName>
                    <ForeName>Nadia</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Université de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Têtu</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Laval University, Laval, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aprikian</LastName>
                    <ForeName>Armen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, McGill University Health Centre, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, McGill University, 5100 Boulevard de Maisonneuve West, Room 720F, Montreal, QC, H4A 3T2, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Program, McGill University Health Centre - Research Institute, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>Fellowship Award</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>World J Urol</MedlineTA>
            <NlmUniqueID>8307716</NlmUniqueID>
            <ISSNLinking>0724-4983</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Body-mass index</Keyword>
            <Keyword MajorTopicYN="N">Exercise</Keyword>
            <Keyword MajorTopicYN="N">Prostatectomy</Keyword>
            <Keyword MajorTopicYN="N">Prostatic neoplasms</Keyword>
            <Keyword MajorTopicYN="N">Treatment failure</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30136199</ArticleId>
            <ArticleId IdType="doi">10.1007/s00345-018-2457-6</ArticleId>
            <ArticleId IdType="pii">10.1007/s00345-018-2457-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30136022</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-7339</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
                <ISOAbbreviation>Support Care Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unmet supportive care needs in Hispanic/Latino cancer survivors: prevalence and associations with patient-provider communication, satisfaction with cancer care, and symptom burden.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-018-4426-4</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to elucidate the prevalence of unmet supportive care needs in Hispanic/Latino cancer survivors and examine the association between unmet needs and patient-provider communication, satisfaction with cancer care, and cancer-specific symptom burden.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Hispanics/Latinos diagnosed with breast, prostate, or colorectal cancer within 15 months of treatment completion (n = 288) completed questionnaires as part of an NCI-funded project.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Hispanic/Latino cancer survivors reported greater unmet needs compared to previously published norms in primarily non-Hispanic/Latino white samples. Across the three cancer types, the two most common unmet needs were in the psychological domain: fear of metastasis (32.6%) and concern for close others (31.3%). However, unmet needs varied by cancer type. Factors associated with greater unmet needs included more recent cancer diagnosis (OR .98 [.96-.99]), younger age (OR .96-.97 [.93-.99]), female gender (OR 2.53-3.75 [1.53-7.36]), and being single (OR 1.82 [1.11-2.97]). Breast cancer survivors reported greater unmet needs than both prostate and colorectal cancer survivors (OR 2.33-5.86 [1.27-14.01]). Adjusting for sociodemographic and medical covariates, unmet needs were associated with lower patient-provider communication self-efficacy (B = - .18-- .22, p's &lt; .01) and satisfaction with cancer care (B = - 3.57-- 3.81, p's &lt; .05), and greater breast (B = - 4.18-- 8.30, p's &lt; .01) and prostate (B = - 6.01-- 8.13, p's &lt; .01) cancer-specific symptom burden.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Findings document unmet supportive care needs in Hispanic/Latino cancer survivors and suggest that reducing unmet needs in Hispanic/Latino cancer survivors may improve not only satisfaction with care, but also health-related quality of life.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moreno</LastName>
                    <ForeName>Patricia I</ForeName>
                    <Initials>PI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramirez</LastName>
                    <ForeName>Amelie G</ForeName>
                    <Initials>AG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>San Miguel-Majors</LastName>
                    <ForeName>Sandra L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Cancer Institute, Rockville, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castillo</LastName>
                    <ForeName>Leopoldo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fox</LastName>
                    <ForeName>Rina S</ForeName>
                    <Initials>RS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallion</LastName>
                    <ForeName>Kipling J</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Munoz</LastName>
                    <ForeName>Edgar</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Estabrook</LastName>
                    <ForeName>Ryne</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perez</LastName>
                    <ForeName>Arely</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lad</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Cook County Health and Hospital Systems, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hollowell</LastName>
                    <ForeName>Courtney</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urologic Surgery, Cook County Health and Hospital Systems, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Penedo</LastName>
                    <ForeName>Frank J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. frank.penedo@northwestern.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>U54CA153511</GrantID>
                    <Agency>National Cancer Institute</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>T32CA193193</GrantID>
                    <Agency>National Cancer Institute</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>P30CA060553</GrantID>
                    <Agency>National Cancer Institute</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>P30CA054174</GrantID>
                    <Agency>National Cancer Institute</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Support Care Cancer</MedlineTA>
            <NlmUniqueID>9302957</NlmUniqueID>
            <ISSNLinking>0941-4355</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hispanic</Keyword>
            <Keyword MajorTopicYN="N">Latino</Keyword>
            <Keyword MajorTopicYN="N">Patient-provider communication</Keyword>
            <Keyword MajorTopicYN="N">Satisfaction with care</Keyword>
            <Keyword MajorTopicYN="N">Supportive care</Keyword>
            <Keyword MajorTopicYN="N">Survivorship</Keyword>
            <Keyword MajorTopicYN="N">Unmet needs</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30136022</ArticleId>
            <ArticleId IdType="doi">10.1007/s00520-018-4426-4</ArticleId>
            <ArticleId IdType="pii">10.1007/s00520-018-4426-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30135606</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5489</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of impotence research</Title>
                <ISOAbbreviation>Int. J. Impot. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-018-0065-z</ELocationID>
            <Abstract>
                <AbstractText>We investigated the effect of testosterone replacement therapy (TRT) on glycemic control and sexual function among hypogonadal men with type 2 diabetes mellitus (T2DM). From the EARTH study, 86 patients (47 in the TRT and 39 in the non-TRT groups) with a diagnosis of T2DM were extracted. We collected data on waist circumference, body mass index, body fat volume, free testosterone, hemoglobin (Hb), fasting blood sugar, and hemoglobin A1c (HbA1c) at baseline and after 12 months. Aging Male Symptoms (AMS) score and International Prostate Symptom Score were obtained. Sexual function was assessed by questions 15 (sexual ability), 16 (morning erections), and 17 (sexual desire) of AMS subscores. The TRT group received intramuscular testosterone enanthate (250 mg) injections every 4 weeks for 12 months. Body fat percentage, Hb, and HbA1c were significantly improved in the TRT group. In addition, sexual ability and frequency, and sexual desire showed a significant improvement in the TRT group after 1 year TRT. On the other hand, any parameters including glycemic control and sexual functions were not significantly improved in non-TRT groups. One-year TRT can improve sexual function and glycemic control among hypogonadal men with T2DM.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shigehara</LastName>
                    <ForeName>Kazuyoshi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan. kshigehara0415@yahoo.co.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Konaka</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kanazawa Red Cross Hospital, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iijima</LastName>
                    <ForeName>Masashi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakashima</LastName>
                    <ForeName>Kazufumi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawaguchi</LastName>
                    <ForeName>Shohei</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nohara</LastName>
                    <ForeName>Takahiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Izumi</LastName>
                    <ForeName>Kouji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Namiki</LastName>
                    <ForeName>Mikio</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Hasegawa Hospital, Toyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizokami</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Int J Impot Res</MedlineTA>
            <NlmUniqueID>9007383</NlmUniqueID>
            <ISSNLinking>0955-9930</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30135606</ArticleId>
            <ArticleId IdType="doi">10.1038/s41443-018-0065-z</ArticleId>
            <ArticleId IdType="pii">10.1038/s41443-018-0065-z</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30135575</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1759-4782</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature reviews. Clinical oncology</Title>
                <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Alternative splicing in prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41571-018-0085-0</ELocationID>
            <Abstract>
                <AbstractText>Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair. AR-Vs, such as AR-V7, have been associated with unfavourable clinical outcomes in patients; however, attempts to specifically inhibit or prevent the formation of AR-Vs have, to date, been unsuccessful. Thus, novel therapeutic strategies are desperately needed to address the oncogenic effects of AR-Vs, which can drive lethal forms of prostate cancer. Disruption of alternative splicing through modulation of the spliceosome is one such potential therapeutic avenue; however, our understanding of the biology of the spliceosome and how it contributes to prostate cancer remains incomplete, as reflected in the dearth of spliceosome-targeted therapeutic agents. In this Review, the authors outline the current understanding of the role of the spliceosome in the progression of prostate cancer and explore the therapeutic utility of manipulating alternative splicing to improve patient care.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Paschalis</LastName>
                    <ForeName>Alec</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Institute for Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharp</LastName>
                    <ForeName>Adam</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Institute for Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Royal Marsden NHS Foundation Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Welti</LastName>
                    <ForeName>Jonathan C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Institute for Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neeb</LastName>
                    <ForeName>Antje</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Institute for Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raj</LastName>
                    <ForeName>Ganesh V</ForeName>
                    <Initials>GV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plymate</LastName>
                    <ForeName>Stephen R</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Bono</LastName>
                    <ForeName>Johann S</ForeName>
                    <Initials>JS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2034-595X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>The Institute for Cancer Research, London, UK. Johann.de-Bono@icr.ac.uk.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Royal Marsden NHS Foundation Trust, London, UK. Johann.de-Bono@icr.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
            <NlmUniqueID>101500077</NlmUniqueID>
            <ISSNLinking>1759-4774</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30135575</ArticleId>
            <ArticleId IdType="doi">10.1038/s41571-018-0085-0</ArticleId>
            <ArticleId IdType="pii">10.1038/s41571-018-0085-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30135193</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-7445</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer research</Title>
                <ISOAbbreviation>Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">canres.0941.2018</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-18-0941</ELocationID>
            <Abstract>
                <AbstractText>Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the disease invariably becomes non-responsive to these agents. Novel approaches are required to circumvent resistance pathways and extend survival, but the mechanisms underlying resistance remain poorly defined. Our group previously showed the histone lysine-N-methyltransferase EZH2 to be overexpressed in prostate cancer and quantitatively associated with progression and poor prognosis. In this study, we screened a library of epigenetic inhibitors for their ability to render CRPC cells sensitive to enzalutamide and found that EZH2 inhibitors specifically potentiated enzalutamide-mediated inhibition of proliferation. Moreover, we identified antisense oligonucleotides (ASO) as a novel drug strategy to ablate EZH2 and AR expression, which may have advantageous properties in certain settings. RNA-seq, ChIP-seq, and ATAC-seq demonstrated that EZH2 inhibition altered the AR cistrome to significantly upregulate AR signaling, suggesting an enhanced dependence of CRPC cells on this pathway following inhibition of EZH2. Combination treatment with ASO targeting EZH2 and AR transcripts inhibited prostate cancer cell growth in vitro and in vivo better than single agents. In sum, this study identifies EZH2 as a critical epigenetic regulator of ADT resistance and defines ASO-based co-targeting of EZH2 and AR as a promising strategy for treatment of CRPC.</AbstractText>
                <CopyrightInformation>Copyright ©2018, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Lanbo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Biology, Central South University, Xiangya School of Medicine, Cancer Research Institution.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tien</LastName>
                    <ForeName>Jean C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Michigan Center for Translational Pathology, University of Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vo</LastName>
                    <ForeName>Josh</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Mengyao</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parolia</LastName>
                    <ForeName>Abhijit</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yajia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan Medical School.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lisha</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiao</LastName>
                    <ForeName>Yuanyuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan Center for Translational Pathology, Department of Pathology, Comprehensive Cancer Center, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shukla</LastName>
                    <ForeName>Sudhanshu</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Dharwad.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xiaoju</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan Center for Translational Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Heng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Fengyun</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan Center for Translational Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jing</LastName>
                    <ForeName>Xiaojun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>DEPARTMENT OF PATHOLOGY,MICHIGAN CENTER FOR TRANSLATIONAL PATHOLOGY, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Esther</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delekta</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Juckette</LastName>
                    <ForeName>Kristin M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Alice</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Xuhong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan Center for Translational Pathology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alva</LastName>
                    <ForeName>Ajjai S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Internal Medicine, Division of Hematology/Oncology, University of Michigan-Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Youngsoo</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ionis Pharmaceuticals.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Macleod</LastName>
                    <ForeName>A Robert</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research, Ionis Pharmaceuticals.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chinnaiyan</LastName>
                    <ForeName>Arul M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University of Michigan-Ann Arbor Arul@med.umich.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Res</MedlineTA>
            <NlmUniqueID>2984705R</NlmUniqueID>
            <ISSNLinking>0008-5472</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30135193</ArticleId>
            <ArticleId IdType="pii">0008-5472.CAN-18-0941</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0941</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30134822</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-3658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular medicine (Cambridge, Mass.)</Title>
                <ISOAbbreviation>Mol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s10020-018-0035-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metastatic Prostate cancer (PCa) cells have gained survival and invasive advantages. Epidermal growth factor (EGF) receptor is a receptor tyrosine kinase, which may mediate signalling to promote progression and invasion of various cancers. In this study, we uncovered the molecular mechanisms underlying the interconnection among the androgen receptor (AR), matrix metalloproteinase-9 (MMP9) and EGFR in promoting PCa progression.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Immunohistochemical analysis of the tissue microarrays consisting of primary and metastatic PCa tissues was performed. The clinical importance of EGFR and its association with survivals were analyzed using three cohorts from MSKCC Prostate Oncogenome Project dataset (For primary tumors, n = 181; for metastatic tumors n = 37) and The Cancer Genome Atlas Prostate Adenocarcinoma Provisional dataset (n = 495). Targeted overexpression or inhibition of the proteins of interests was introduced into PCa cell lines. Treatment of PCa cell lines with the compounds was conducted. Immunoblot analysis was performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that AR, MMP-9 and EGFR are interconnect factors, which may cooperatively promote PCa progression. Altered EGFR expression was associated with poor disease-free survival in PCa patients. Induced overexpression of AR led to an increase in the expression of EGFR, p-GSK-3β and decrease in p27 expression in PCa cell lines in the presence of androgen stimulation. Overexpression of MMP9 significantly induced EGFR expression in PCa cells. Inhibition of PIP5K1α, a lipid kinase that acts upstream of PI3K/AKT greatly reduced expressions of AR, MMP-9 and EGFR.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings also suggest that PCa cells may utilize AR, EGFR and MMP-9 pathways in androgen-dependent as well as in castration-resistant conditions. Our data suggest a new therapeutic potential to block cancer metastasis by targeting AR, EGFR and MMP-9 pathways in subsets of PCa patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mandel</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Larsson</LastName>
                    <ForeName>Per</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarwar</LastName>
                    <ForeName>Martuza</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Experimental Cancer Research, Department of Translational Medicine, Clinical Research Centre, Lund University, Jan Waldenströms gatan 35, 205 02, Malmö, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Semenas</LastName>
                    <ForeName>Julius</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Syed Khaja</LastName>
                    <ForeName>Azharuddin Sajid</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Persson</LastName>
                    <ForeName>Jenny L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden. jenny_l.persson@med.lu.se.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Experimental Cancer Research, Department of Translational Medicine, Clinical Research Centre, Lund University, Jan Waldenströms gatan 35, 205 02, Malmö, Sweden. jenny_l.persson@med.lu.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Mol Med</MedlineTA>
            <NlmUniqueID>9501023</NlmUniqueID>
            <ISSNLinking>1076-1551</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2009 Apr;9(4):239-52</RefSource>
                <PMID Version="1">19279573</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1991 Jun 1;51(11):2780-5</RefSource>
                <PMID Version="1">2032218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2010 Jun 25;141(7):1117-34</RefSource>
                <PMID Version="1">20602996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Med Oncol. 2017 Apr;34(4):60</RefSource>
                <PMID Version="1">28315228</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2010 Jan 1;16(1):121-9</RefSource>
                <PMID Version="1">20028742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 2010 Sep 15;24(18):1967-2000</RefSource>
                <PMID Version="1">20844012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Feb 15;61(4):1320-6</RefSource>
                <PMID Version="1">11245428</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Oncol. 2012 May;40(5):1714-24</RefSource>
                <PMID Version="1">22200661</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Jan 1;26(1):139-40</RefSource>
                <PMID Version="1">19910308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2011 Mar 15;104(6):989-99</RefSource>
                <PMID Version="1">21326240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(11):e27720</RefSource>
                <PMID Version="1">22110740</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2001 May 17;411(6835):355-65</RefSource>
                <PMID Version="1">11357143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16392-7</RefSource>
                <PMID Version="1">21930937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2002 May 31;109(5):625-37</RefSource>
                <PMID Version="1">12062105</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Neurobiol. 2016 Apr;53(3):1648-1653</RefSource>
                <PMID Version="1">25682969</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2005 May 1;63(2):117-30</RefSource>
                <PMID Version="1">15486994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2016 Jun 10;7:11815</RefSource>
                <PMID Version="1">27283993</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2012 Jul 1;72(13):3228-37</RefSource>
                <PMID Version="1">22552284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2016 Mar 15;22(6):1307-12</RefSource>
                <PMID Version="1">26980062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2017 Nov 15;8(1):1508</RefSource>
                <PMID Version="1">29142193</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63</RefSource>
                <PMID Version="1">10318905</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tumour Biol. 2014 Jul;35(7):6673-8</RefSource>
                <PMID Version="1">24705809</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Oncol. 2015 Apr;9(4):906-19</RefSource>
                <PMID Version="1">25660577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Oncol. 2016 Dec;10(10):1628-1629</RefSource>
                <PMID Version="1">27838215</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2012 Jan 19;31(3):322-32</RefSource>
                <PMID Version="1">21685943</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2001 Oct;1(1):34-45</RefSource>
                <PMID Version="1">11900250</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2017 Jul 26;8(46):80568-80588</RefSource>
                <PMID Version="1">29113326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98</RefSource>
                <PMID Version="1">25071204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jul 12;487(7406):239-43</RefSource>
                <PMID Version="1">22722839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2004 Jul 15;22(14):2790-9</RefSource>
                <PMID Version="1">15254046</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1987 Oct;121(4):1461-7</RefSource>
                <PMID Version="1">3498628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36</RefSource>
                <PMID Version="1">18612129</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2006 Dec 15;12(24):7242-51</RefSource>
                <PMID Version="1">17189395</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2010 Jul 13;18(1):11-22</RefSource>
                <PMID Version="1">20579941</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Metastasis. 2009;26(5):485-96</RefSource>
                <PMID Version="1">19294521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Radiat Oncol. 2008 Apr;18(2):89-97</RefSource>
                <PMID Version="1">18314063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2012 May 24;12(6):387-400</RefSource>
                <PMID Version="1">22622641</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2017 Aug 1;400:9-17</RefSource>
                <PMID Version="1">28450158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2005 Feb;19(2):350-61</RefSource>
                <PMID Version="1">15514032</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Cancer. 2007 Apr 12;7:64</RefSource>
                <PMID Version="1">17430594</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2009 Apr 1;69(7):2941-9</RefSource>
                <PMID Version="1">19318561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine. 1999 Sep;11(9):722-7</RefSource>
                <PMID Version="1">10479409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Discov. 2015 Jul;5(7):713-22</RefSource>
                <PMID Version="1">25934077</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2010 Feb 2;102(3):457-61</RefSource>
                <PMID Version="1">20010942</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2002 May;2(5):389-96</RefSource>
                <PMID Version="1">12044015</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2013 Nov;19(11):1389-400</RefSource>
                <PMID Version="1">24202392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2005 Sep 22;24(42):6385-93</RefSource>
                <PMID Version="1">16007189</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 1999 Mar;5(3):280-5</RefSource>
                <PMID Version="1">10086382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2015 Oct 8;526(7572):263-7</RefSource>
                <PMID Version="1">26416732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2014 Jul 1;74(13):3408-17</RefSource>
                <PMID Version="1">24780757</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2013 Jan;31(1):82-6</RefSource>
                <PMID Version="1">21396844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 2006 Feb;147 Suppl 2:S144-52</RefSource>
                <PMID Version="1">16465179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2017 Jan 1;77(1):74-85</RefSource>
                <PMID Version="1">27793843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 1999 Jun;31(6):637-43</RefSource>
                <PMID Version="1">10404636</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 1999 Oct;155(4):1271-9</RefSource>
                <PMID Version="1">10514409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2002 Nov;8(11):3438-44</RefSource>
                <PMID Version="1">12429632</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2011 Oct 1;17(19):6218-28</RefSource>
                <PMID Version="1">21844010</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2015 Jun 15;75(12):2489-500</RefSource>
                <PMID Version="1">25870145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1991 Jul 15;51(14):3753-61</RefSource>
                <PMID Version="1">1712249</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian J Pharmacol. 2011 May;43(3):236-45</RefSource>
                <PMID Version="1">21713084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Cell Biol. 2000 Oct;2(10):737-44</RefSource>
                <PMID Version="1">11025665</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Oncol. 2010 Dec;33(6):609-13</RefSource>
                <PMID Version="1">20042973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2013 Jul;73(10):1082-9</RefSource>
                <PMID Version="1">23460133</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Drug Targets. 2012 Sep 1;13(10):1308-23</RefSource>
                <PMID Version="1">22746994</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Androgen receptor and androgen</Keyword>
            <Keyword MajorTopicYN="N">Cancer metastasis</Keyword>
            <Keyword MajorTopicYN="N">Epidermal growth factor receptor</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30134822</ArticleId>
            <ArticleId IdType="doi">10.1186/s10020-018-0035-4</ArticleId>
            <ArticleId IdType="pii">10.1186/s10020-018-0035-4</ArticleId>
            <ArticleId IdType="pmc">PMC6020326</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30134523</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">1996-1944</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Materials (Basel, Switzerland)</Title>
                <ISOAbbreviation>Materials (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nanoporous 3D-Printed Scaffolds for Local Doxorubicin Delivery in Bone Metastases Secondary to Prostate Cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E1485</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/ma11091485</ELocationID>
            <Abstract>
                <AbstractText>The spine is the most common site of bone metastasis, often originating from prostate, lung, and breast cancers. High systemic doses of chemotherapeutics such as doxorubicin (DOX), cisplatin, or paclitaxel often have severe side effects. Surgical removal of spine metastases also leaves large defects which cannot spontaneously heal and require bone grafting. To circumvent these issues, we designed an approach for local chemotherapeutic delivery within 3D-printed scaffolds which could also potentially serve as a bone substitute. Direct treatment of prostate cancer cell line LAPC4 and patient derived spine metastases cells with 0.01 µM DOX significantly reduced metabolic activity, proliferation, migration, and spheroid growth. We then assessed uptake and release of DOX in a series of porous 3D-printed scaffolds on LAPC4 cells as well as patient-derived spine metastases cells. Over seven days, 60⁻75% of DOX loaded onto scaffolds could be released, which significantly reduced metabolic activity and proliferation of both LAPC4 and patient derived cells, while unloaded scaffolds had no effect. Porous 3D-printed scaffolds may provide a novel and inexpensive approach to locally deliver chemotherapeutics in a patient-specific manner at tumor resection sites. With a composite design to enhance strength and promote sustained drug release, the scaffolds could reduce systemic negative effects, enhance bone repair, and improve patient outcomes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ahangar</LastName>
                    <ForeName>Pouyan</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. pouyan.ahangar@mail.mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akoury</LastName>
                    <ForeName>Elie</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. elie.akoury@mail.mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramirez Garcia Luna</LastName>
                    <ForeName>Ana Sofia</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. A.Ramirez@stud.uni-heidelberg.de.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Faculty Mannheim, Heidelberg University, D-68167 Heidelberg, Germany. A.Ramirez@stud.uni-heidelberg.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nour</LastName>
                    <ForeName>Antone</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. antone.nour@mail.mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. michael.weber@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Research Institute of the McGill University Health Centre, Montreal, QC H3H 2L9, Canada. michael.weber@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenzweig</LastName>
                    <ForeName>Derek H</ForeName>
                    <Initials>DH</Initials>
                    <Identifier Source="ORCID">0000-0002-6593-8177</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Orthopedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada. derek.rosenzweig@mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Research Institute of the McGill University Health Centre, Montreal, QC H3H 2L9, Canada. derek.rosenzweig@mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Montreal General Hospital C10.148.6, 1650 Cedar Ave, Montreal, QC H3G 1A4, Canada. derek.rosenzweig@mcgill.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Materials (Basel)</MedlineTA>
            <NlmUniqueID>101555929</NlmUniqueID>
            <ISSNLinking>1996-1944</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">bone metastases</Keyword>
            <Keyword MajorTopicYN="N">bone substitute</Keyword>
            <Keyword MajorTopicYN="N">doxorubicin</Keyword>
            <Keyword MajorTopicYN="N">local delivery</Keyword>
            <Keyword MajorTopicYN="N">low-cost 3D printing</Keyword>
            <Keyword MajorTopicYN="N">nanoporous filament</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30134523</ArticleId>
            <ArticleId IdType="pii">ma11091485</ArticleId>
            <ArticleId IdType="doi">10.3390/ma11091485</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30133757</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0045</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>78</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Prostate</Title>
                <ISOAbbreviation>Prostate</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1013-1023</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/pros.23659</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prostate cancer is recognized as a heterogeneous disease demanding appropriate preclinical models that reflect tumor complexity. Previously, we established the PSA-Cre;PtenLoxP/LoxP genetic engineered mouse model (GEMM) for prostate cancer reflecting the various stages of tumor development. Prostate tumors in this Pten KO model slowly develop, requiring more than 10 months. In order to enhance its practical utility, we established a syngeneic panel of cell lines derived from PSA-Cre targeted Pten KO tumors, designated the mouse prostate cancer (MuCap) model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Four different MuCaP epithelial cell lines were established from three independent primary Pten KO mouse prostate tumors. Tumorigenic capacity of the MuCaP cell lines was determined by subcutaneous inoculation of these cell lines in immunocompetent mice. Response to PI3K-targeted therapy was validated in ex vivo tissue slices of the established MuCaP tumors.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The MuCaP cell lines were all tumorigenic in immunocompetent mice after subcutaneous inoculation. Interestingly, these syngrafted tumors represented different tumor growth rates and morphologies. Treatment with the specific PI3K inhibitor GDC0941 resulted in responses very similar between syngeneic MuCaP and primary Pten KO prostate tumors. Finally, immunoprofiling of the different syngeneic MuCaP tumors demonstrated differential numbers of tumor infiltrating lymphocytes and distinct immune gene profiles with expression of CD8, INFy, and PD1 being inversely related to tumor aggressiveness.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Collectively, we present here a well-defined MuCaP platform of in vitro and in vivo mouse prostate cancer models that may support preclinical assessment of (immune)-therapies for prostate cancer.</AbstractText>
                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van Duijn</LastName>
                    <ForeName>Petra W</ForeName>
                    <Initials>PW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marques</LastName>
                    <ForeName>Rute B</ForeName>
                    <Initials>RB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ziel-van der Made</LastName>
                    <ForeName>Angelique C J</ForeName>
                    <Initials>ACJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Zoggel</LastName>
                    <ForeName>Hanneke J A A</ForeName>
                    <Initials>HJAA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aghai</LastName>
                    <ForeName>Ashraf</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berrevoets</LastName>
                    <ForeName>Cor</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Debets</LastName>
                    <ForeName>Reno</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jenster</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trapman</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Weerden</LastName>
                    <ForeName>Wytske M</ForeName>
                    <Initials>WM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0324-4804</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, JNI, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Prostate</MedlineTA>
            <NlmUniqueID>8101368</NlmUniqueID>
            <ISSNLinking>0270-4137</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MuCaP</Keyword>
            <Keyword MajorTopicYN="N">immunoprofile</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">syngeneic</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30133757</ArticleId>
            <ArticleId IdType="doi">10.1002/pros.23659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30133562</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1980-5322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>73</Volume>
                    <Issue>suppl 1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinics (Sao Paulo, Brazil)</Title>
                <ISOAbbreviation>Clinics (Sao Paulo)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Improving adenoviral vectors and strategies for prostate cancer gene therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e476s</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1807-59322018000200309</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.6061/clinics/2018/e476s</ELocationID>
            <Abstract>
                <AbstractText>Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Rodrigo Esaki</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Luna</LastName>
                    <ForeName>Igor Vieira</ForeName>
                    <Initials>IV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lana</LastName>
                    <ForeName>Marlous Gomes</ForeName>
                    <Initials>MG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strauss</LastName>
                    <ForeName>Bryan E</ForeName>
                    <Initials>BE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Clinics (Sao Paulo)</MedlineTA>
            <NlmUniqueID>101244734</NlmUniqueID>
            <ISSNLinking>1807-5932</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2015 Mar 1;136(5):E359-86</RefSource>
                <PMID Version="1">25220842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Oct 15;61(20):7464-72</RefSource>
                <PMID Version="1">11606381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 1999 May 1;10(7):1239-49</RefSource>
                <PMID Version="1">10340555</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2014 Nov 25;5:5548</RefSource>
                <PMID Version="1">25420520</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2007 Mar;15(3):636-42</RefSource>
                <PMID Version="1">17228316</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2014 Sep 15;135(6):1369-80</RefSource>
                <PMID Version="1">24523142</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2006 Apr 10;24(11):1689-99</RefSource>
                <PMID Version="1">16505415</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1985 Dec 15;34(24):4203-13</RefSource>
                <PMID Version="1">4074383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Otolaryngol. 2010 Mar-Apr;31(2):78-83</RefSource>
                <PMID Version="1">20015717</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Int Med Res. 2008 Nov-Dec;36(6):1273-8</RefSource>
                <PMID Version="1">19094436</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 1994 Mar;1(1):5-13</RefSource>
                <PMID Version="1">7621238</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Rep. 2016 Dec 15;6:39355</RefSource>
                <PMID Version="1">27976709</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Oct 7;351(15):1502-12</RefSource>
                <PMID Version="1">15470213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2008 Jan 1;14(1):291-9</RefSource>
                <PMID Version="1">18172281</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Chromosomes Cancer. 2008 Jul;47(7):565-72</RefSource>
                <PMID Version="1">18383208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2013 Nov;20(11):642-9</RefSource>
                <PMID Version="1">24052127</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Folia Biol (Praha). 2015;61(2):60-5</RefSource>
                <PMID Version="1">26333122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2016 Jan 22;11(1):e0147173</RefSource>
                <PMID Version="1">26799485</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1983 Sep 23;221(4617):1285-8</RefSource>
                <PMID Version="1">6137059</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76</RefSource>
                <PMID Version="1">26309896</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2002 Sep;6(3):415-21</RefSource>
                <PMID Version="1">12231179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 1994 Sep;5(9):1079-88</RefSource>
                <PMID Version="1">7833367</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2014 Aug;13(8):2092-103</RefSource>
                <PMID Version="1">24980947</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Urol. 2014 Apr;11(4):189-90</RefSource>
                <PMID Version="1">24595127</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 2001 Mar;7(3):683-94</RefSource>
                <PMID Version="1">11463392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2007 Dec;18(12):1225-32</RefSource>
                <PMID Version="1">18021019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2006 Sep-Oct;24(5):396-402</RefSource>
                <PMID Version="1">16962488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Oct 7;351(15):1488-90</RefSource>
                <PMID Version="1">15470210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2005 Feb;4(2):187-95</RefSource>
                <PMID Version="1">15713890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2017 Jan;67(1):7-30</RefSource>
                <PMID Version="1">28055103</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2013 Jan;41(Database issue):D962-9</RefSource>
                <PMID Version="1">23161690</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Cycle. 2012 Dec 15;11(24):4579-88</RefSource>
                <PMID Version="1">23187804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2000 Aug 31;157(1):105-12</RefSource>
                <PMID Version="1">10893449</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Biol Ther. 2016 Dec;17(12):1221-1230</RefSource>
                <PMID Version="1">27646031</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2002 Feb 15;20(4):957-65</RefSource>
                <PMID Version="1">11844817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Drugs. 2009 Aug;20(7):589-600</RefSource>
                <PMID Version="1">19491654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2007 Dec 20;357(25):2552-61</RefSource>
                <PMID Version="1">18094376</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 1997 Nov-Dec;4(6):383-90</RefSource>
                <PMID Version="1">9408609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 1996 Sep;2(9):985-91</RefSource>
                <PMID Version="1">8782455</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2000 Apr;7(4):537-44</RefSource>
                <PMID Version="1">10811471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Des Devel Ther. 2014 Oct 13;8:1851-67</RefSource>
                <PMID Version="1">25378905</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 1996 Sep 10;7(14):1683-91</RefSource>
                <PMID Version="1">8886839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2010 Oct 2;376(9747):1147-54</RefSource>
                <PMID Version="1">20888992</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Med. 2014 Jan 30;12:16</RefSource>
                <PMID Version="1">24479409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2009 Dec 1;15(23):7375-80</RefSource>
                <PMID Version="1">19920098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biomed Res Int. 2013;2013:624632</RefSource>
                <PMID Version="1">23484134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Des Devel Ther. 2011 Mar 10;5:117-24</RefSource>
                <PMID Version="1">21448449</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 1998 Sep 20;9(14):2075-82</RefSource>
                <PMID Version="1">9759934</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2001 Mar 15;19(6):1750-8</RefSource>
                <PMID Version="1">11251006</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2005 Sep;16(9):1016-27</RefSource>
                <PMID Version="1">16149900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Int Med Res. 2012;40(1):317-27</RefSource>
                <PMID Version="1">22429371</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2011 Nov 15;17(22):7174-82</RefSource>
                <PMID Version="1">21933889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2006 Jul;14(1):107-17</RefSource>
                <PMID Version="1">16690359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1998 Nov 20;282(5393):1497-501</RefSource>
                <PMID Version="1">9822382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Biol Cell. 1999 Apr;10(4):947-59</RefSource>
                <PMID Version="1">10198049</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Physiol. 2014 Jan;229(1):34-43</RefSource>
                <PMID Version="1">23868767</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5463-73</RefSource>
                <PMID Version="1">17875776</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Adv Med Oncol. 2012 Nov;4(6):329-40</RefSource>
                <PMID Version="1">23118808</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2007 May;15(5):1016-23</RefSource>
                <PMID Version="1">17375076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2002 Jan;167(1):339-46</RefSource>
                <PMID Version="1">11743353</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2007 Apr;15(4):834-40</RefSource>
                <PMID Version="1">17327829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virology. 2008 Feb 5;371(1):8-13</RefSource>
                <PMID Version="1">18076963</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2002 Jul;9(7):567-72</RefSource>
                <PMID Version="1">12082456</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2005 Dec;12(12):935-46</RefSource>
                <PMID Version="1">15905860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2002 Jul;9(7):553-66</RefSource>
                <PMID Version="1">12082455</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1996 Aug 15;56(16):3814-22</RefSource>
                <PMID Version="1">8706029</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 2005 Jul;68(1):40-7</RefSource>
                <PMID Version="1">15952985</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BioDrugs. 2003;17(3):216-22</RefSource>
                <PMID Version="1">12749760</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2006 Jan 1;13(1):13-20</RefSource>
                <PMID Version="1">16052227</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mod Pathol. 2008 Dec;21(12):1470-8</RefSource>
                <PMID Version="1">19020536</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2004 Apr 15;10(8):2587-93</RefSource>
                <PMID Version="1">15102659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian J Urol. 2016 Oct-Dec;32(4):262-270</RefSource>
                <PMID Version="1">27843207</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):4-9</RefSource>
                <PMID Version="1">12198632</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2011 Jun;18(6):444-9</RefSource>
                <PMID Version="1">21455255</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2007 Jun 1;67(8):829-39</RefSource>
                <PMID Version="1">17394196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2002 Jan 20;13(2):211-24</RefSource>
                <PMID Version="1">11812278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Mol Biol. 2001;175:495-520</RefSource>
                <PMID Version="1">11462854</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2013 Mar;73(4):418-27</RefSource>
                <PMID Version="1">22996738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a001222</RefSource>
                <PMID Version="1">20463003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Res. 2014 Aug;59(1-3):229-35</RefSource>
                <PMID Version="1">24847764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2006 Feb;13(2):169-81</RefSource>
                <PMID Version="1">16082381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2017 Aug;28(8):639-653</RefSource>
                <PMID Version="1">28181816</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncol Lett. 2017 May;13(5):3676-3680</RefSource>
                <PMID Version="1">28529585</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Med Chem Anticancer Agents. 2003 Jul;3(4):291-306</RefSource>
                <PMID Version="1">12769774</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1995 Oct 1;55(19):4210-3</RefSource>
                <PMID Version="1">7671222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transl Androl Urol. 2015 Jun;4(3):365-80</RefSource>
                <PMID Version="1">26814148</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2002 Sep 1;62(17):4968-76</RefSource>
                <PMID Version="1">12208748</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virology. 2004 Apr 10;321(2):165-72</RefSource>
                <PMID Version="1">15051377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1999 Mar 1;59(5):1021-8</RefSource>
                <PMID Version="1">10070958</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2010 Oct;21(10):1311-25</RefSource>
                <PMID Version="1">20497039</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2003 Nov 1;63(21):7497-506</RefSource>
                <PMID Version="1">14612551</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1995 Nov 15;55(22):5151-5</RefSource>
                <PMID Version="1">7585563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Gene Ther. 2009 May;16(5):405-14</RefSource>
                <PMID Version="1">19110543</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene Ther. 2014 Aug;21(8):723-31</RefSource>
                <PMID Version="1">24849040</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene Ther. 2001 Sep;8(18):1416-26</RefSource>
                <PMID Version="1">11571582</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2004 Dec 15;10(24):8147-51</RefSource>
                <PMID Version="1">15623588</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>ChemMedChem. 2007 Jul;2(7):920-42</RefSource>
                <PMID Version="1">17530726</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Chem Soc. 1971 May 5;93(9):2325-7</RefSource>
                <PMID Version="1">5553076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther Oncolytics. 2016;3:null</RefSource>
                <PMID Version="1">26900598</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2011 Jun;185(6):2376-81</RefSource>
                <PMID Version="1">21511293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 1997 May 2;71(3):377-82</RefSource>
                <PMID Version="1">9139872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Transl Sci. 2015 Dec;8(6):837-40</RefSource>
                <PMID Version="1">26621187</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2000 Jan 15;60(2):334-41</RefSource>
                <PMID Version="1">10667585</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Pharmacol Sin. 2016 Aug;37(8):1121-8</RefSource>
                <PMID Version="1">27345628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Drug Targets. 2013 Apr;14(4):460-71</RefSource>
                <PMID Version="1">23410128</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Zhejiang Univ Sci B. 2009 May;10(5):331-40</RefSource>
                <PMID Version="1">19434759</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Jan 15;61(2):517-25</RefSource>
                <PMID Version="1">11212244</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Laryngoscope. 2004 Nov;114(11):1871-9</RefSource>
                <PMID Version="1">15510008</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Interv Aging. 2010 Aug 09;5:187-97</RefSource>
                <PMID Version="1">20711438</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2001 Sep;7(9):2887-97</RefSource>
                <PMID Version="1">11555607</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1986 Sep;83(17):6302-6</RefSource>
                <PMID Version="1">3462696</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30133562</ArticleId>
            <ArticleId IdType="pii">S1807-59322018000200309</ArticleId>
            <ArticleId IdType="doi">10.6061/clinics/2018/e476s</ArticleId>
            <ArticleId IdType="pmc">PMC6097088</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30133148</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1757-7861</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Orthopaedic surgery</Title>
                <ISOAbbreviation>Orthop Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Is Ambulatory Status a Prognostic Factor of Survival in Patients with Spinal Metastases? An Exploratory Meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>173-180</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/os.12393</ELocationID>
            <Abstract>
                <AbstractText>This study was conducted to identify the influence of ambulatory status prior to treatment on survival of patients with spinal metastases. Two investigators independently retrieved relevant electronic literature in PubMed, Embase, and Cochrane Library databases, to identify eligible studies. Effect estimates for hazard risk (HR) were extracted and synthesized through fixed-effects or random-effects models as appropriate. A total of 17 eligible studies were identified, with an accumulated number of 3962 participants. HR from 14 studies regarding comparison between ambulatory versus non-ambulatory groups were pooled using a random-effects model, and statistical significance was presented for the pooled HR (HR = 1.96; 95% confidence interval [CI], 1.65-2.34). In subgroups of mixed primary tumor and lung cancer, ambulatory status was considered to be a significant prognostic factor (P &lt; 0.05), while in the subgroup of prostate cancer it was not (HR = 1.72; 95% CI, 0.79-3.74). HR from 4 studies related to comparison between Frankel E versus Frankel C-D were pooled using a fixed-effects model, which revealed statistical significance (HR = 1.73; 95% CI, 1.27-2.36). Ambulatory status is a significant prognostic factor in patients with spinal metastases. However, in patients with primary prostate cancer, the prognostic effect of ambulatory status has not yet been confirmed to be significant.</AbstractText>
                <CopyrightInformation>© 2018 Chinese Orthopaedic Association and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiong-Gang</ForeName>
                    <Initials>XG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Spine Surgery, Tianjin Hospital, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yong-Heng</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Yong-Cheng</ForeName>
                    <Initials>YC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bone Tumor, Tianjin Hospital, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lun</LastName>
                    <ForeName>Deng-Xing</ForeName>
                    <Initials>DX</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Spine Surgery, Weifang People's Hospital, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Jiang-Tao</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hua</LastName>
                    <ForeName>Kun-Chi</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Ming-You</ForeName>
                    <Initials>MY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Hao-Ran</ForeName>
                    <Initials>HR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>Orthop Surg</MedlineTA>
            <NlmUniqueID>101501666</NlmUniqueID>
            <ISSNLinking>1757-7853</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ambulatory status</Keyword>
            <Keyword MajorTopicYN="N">Overall survival</Keyword>
            <Keyword MajorTopicYN="N">Prognostic factor</Keyword>
            <Keyword MajorTopicYN="N">Spinal metastasis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30133148</ArticleId>
            <ArticleId IdType="doi">10.1111/os.12393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30131932</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2168-8184</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cureus</Title>
                <ISOAbbreviation>Cureus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Symptomatic Meckel's Cave Metastasis from Castration-resistant Prostate Cancer Treated with Gamma Knife Radiosurgery.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e2839</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.2839</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer commonly spreads to the axial and appendicular skeleton, but metastases to the brain parenchyma or skull base are uncommon. In the cases that this happens, the symptoms are usually associated with disease involving the orbit. Metastasis to the Meckel's cave causing trigeminal nerve palsy is an exceedingly rare entity. We are presenting a case of this in a man with metastatic castration-resistant prostate cancer. Metastatic prostate cancer to the Meckel's cave is extremely uncommon, and there is no standard of care. Radiation therapy, especially radiosurgery, is increasingly recognized as an excellent alternative to surgery for lesions in the Meckel's cave and intracranial/skull base prostate cancer metastases. Gamma Knife radiosurgery (Elekta, Stockholm, Sweden), in particular, has been reported to achieve local control close to 90% for calvarial and skull base metastases with few side effects and requires only one treatment. Our patient's 1.4 x 1.0 x 1.3 cm metastatic prostate cancer lesion in the Meckel's cave was treated with Gamma Knife to 22 Gy with good treatment response including rapid improvement in his symptoms and no side effects. We review the scarce literature documenting cases of prostate cancer metastatic to the brain or skull base and the only two other documented cases of prostate cancer metastasis the Meckel's cave neither of which was treated with radiotherapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reshko</LastName>
                    <ForeName>Leonid</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Education, Riverside Regional Medical Center, Newport News, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richardson</LastName>
                    <ForeName>Martin K</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Riverside Regional Medical Center, Newport News, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spencer</LastName>
                    <ForeName>Kelly</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiosurgery, Riverside Regional Medical Center, Newport News, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McAllister Iv</LastName>
                    <ForeName>William H</ForeName>
                    <Initials>WH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurosurgery, Riverside Regional Medical Center, Newport News, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kersh</LastName>
                    <ForeName>Charles R</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology, Riverside Regional Medical Center, Newport News, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cureus</MedlineTA>
            <NlmUniqueID>101596737</NlmUniqueID>
            <ISSNLinking>2168-8184</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Radiosurg SBRT. 2013;2(3):217-223</RefSource>
                <PMID Version="1">29296364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Neurol Neurosurg. 2010 Dec;112(10):927-32</RefSource>
                <PMID Version="1">20728984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Skull Base. 2009 Nov;19(6):425-30</RefSource>
                <PMID Version="1">20436844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosurg. 2014 Dec;121 Suppl:91-101</RefSource>
                <PMID Version="1">25434942</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Case Rep Otolaryngol. 2015;2015:250312</RefSource>
                <PMID Version="1">26294996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosurgery. 2018 Sep 1;83(3):529-539</RefSource>
                <PMID Version="1">29040711</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurooncol. 2005 Oct;75(1):63-9</RefSource>
                <PMID Version="1">16215817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncology (Williston Park). 2014 Dec;28(12):1115-6, 1124</RefSource>
                <PMID Version="1">25510811</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2003 Jul 15;98(2):363-8</RefSource>
                <PMID Version="1">12872358</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">gamma knife</Keyword>
            <Keyword MajorTopicYN="N">meckel’s cave</Keyword>
            <Keyword MajorTopicYN="N">metastatic prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">palliative care</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">radiosurgery</Keyword>
            <Keyword MajorTopicYN="N">skull base tumor</Keyword>
            <Keyword MajorTopicYN="N">srs</Keyword>
            <Keyword MajorTopicYN="N">stereotactic radiosurgery</Keyword>
            <Keyword MajorTopicYN="N">trigeminal nerve palsy</Keyword>
        </KeywordList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131932</ArticleId>
            <ArticleId IdType="doi">10.7759/cureus.2839</ArticleId>
            <ArticleId IdType="pmc">PMC6101457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30132975</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2648</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of advanced nursing</Title>
                <ISOAbbreviation>J Adv Nurs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate cancer-specific anxiety and the resulting health-related quality of life in couples.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jan.13828</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To explore health-related quality of life and its individual or mutual influences in patients with prostate cancer and their spouses.</AbstractText>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few studies have explored the influence of prostate cancer-specific anxiety of these patients and their spouses on their individual or mutual health-related quality of life.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Repeated-measures design.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data on 48 dyadic of patients and their spouses were collected from August 2015 to December 2016. Before the patients' treatment for prostate cancer, the first data collection occurred for the patients and their spouses. The second to fifth data collections were conducted 6, 10, 18 and 24 weeks after the initial measurement. The variables concerned health status, marital satisfaction, positive affect, negative affect, prostate cancer-specific anxiety and health-related quality of life. The Actor-Partner-Interdependence Model was adopted for data analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients who had better physical health-related quality of life were those with good self-reported health status, higher positive affect and lower prostate cancer-specific anxiety. Better physical HRQOL was observed in the spouses who had good self-reported health status and had lower prostate cancer-specific anxiety. The patients with localized cancer stages and lower negative affect had a better mental health-related quality of life. Better mental health-related quality of life was detected in spouses who had higher marital satisfaction, higher positive affect and lower negative affect.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nurses can improve the health-related quality of life of patients and their spouses by implementing activities that promote health and energy and reduce stress and by administering a mindfulness intervention. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chien</LastName>
                    <ForeName>Ching-Hui</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuang</LastName>
                    <ForeName>Cheng-Keng</ForeName>
                    <Initials>CK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Kuan-Lin</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Department of Surgery Chang, Gung Memorial Hospital at Linkou Tao-Yuan,, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>See-Tong</ForeName>
                    <Initials>ST</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Department of Surgery Chang, Gung Memorial Hospital at Linkou Tao-Yuan,, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Chun-Te</ForeName>
                    <Initials>CT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Ying-Hsu</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Adv Nurs</MedlineTA>
            <NlmUniqueID>7609811</NlmUniqueID>
            <ISSNLinking>0309-2402</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">couple</Keyword>
            <Keyword MajorTopicYN="N">marital satisfaction</Keyword>
            <Keyword MajorTopicYN="N">negative affect</Keyword>
            <Keyword MajorTopicYN="N">nurses</Keyword>
            <Keyword MajorTopicYN="N">positive affect</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer-specific anxiety</Keyword>
            <Keyword MajorTopicYN="N">prostate neoplasms</Keyword>
            <Keyword MajorTopicYN="N">quality of life</Keyword>
            <Keyword MajorTopicYN="N">self-reported health status</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30132975</ArticleId>
            <ArticleId IdType="doi">10.1111/jan.13828</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30131915</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2168-8184</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cureus</Title>
                <ISOAbbreviation>Cureus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Not Your Usual Suspect: Clear Cell Renal Cell Carcinoma Presenting as Ulcerative Esophagitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e2821</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.2821</ELocationID>
            <Abstract>
                <AbstractText>Renal cell carcinoma (RCC) has the propensity to hematogenously metastasize to the lung, bone, or liver, however, metastasis to the esophagus is exceedingly rare. We report a case of ulcerative esophagitis secondary to recurrent metastatic renal cell cancer status post remote nephrectomy. An 82-year-old Caucasian male presented with dark tarry stools for two days, progressive dysphagia to solid food for several weeks and unintentional weight loss. His past medical history was significant for hypertension, diverticulosis and right-sided renal cell cancer for which he underwent nephrectomy 13 years ago. Physical examination was unremarkable. Laboratory data showed hemoglobin of 12.5 g/dL, with normal platelet count and an international normalized ratio (INR). His stools were positive for occult blood. Esophagogastroduodenoscopy (EGD) revealed a fragile mid esophageal mass and antral erosive gastritis which were both biopsied. Colonoscopy showed diverticulosis without stigmata of active gastrointestinal (GI) bleed. CT scan (computed tomography) of the chest showed a solid esophageal mass in the lower esophagus as well as a right upper lobe lung mass for which CT-guided needle biopsy was obtained. The histopathology revealed metastatic renal cell cancer of clear cell subtype. The patient was started on palliative radiotherapy. On completion of radiotherapy two months later, his dysphagia had resolved. The patient is currently on chemotherapy with Sunitinib. Metastatic involvement of esophagus is relatively uncommon and is reported in 6% of patients with metastatic lung, breast and prostate cancer. Esophageal metastasis of clear cell RCC is very rare and so far only seven cases have been reported. Diagnosis is confirmed by endoscopy, imaging and histopathology. Treatment options include surgical or endoscopic resection for a solitary metastatic lesion. If the tumor is unresectable, multidisciplinary treatment including radiation and chemotherapy is indicated.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>Saeed</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Internal Medicine Residency, Florida Hospital, Orlando, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atiquzzaman</LastName>
                    <ForeName>Basher</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Florida Hospital Celebration Health, Celebration, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krall</LastName>
                    <ForeName>Konrad</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Interventional Endoscopy, Florida Hospital, Orlando, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Ranjeet</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Internal Medicine Residency, Florida Hospital, Orlando, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diagnostic Radiology, Florida Hospital, Orlando, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hebert-Magee</LastName>
                    <ForeName>Shantel</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, Florida Hospital, Orlando , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cureus</MedlineTA>
            <NlmUniqueID>101596737</NlmUniqueID>
            <ISSNLinking>2168-8184</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Jpn J Clin Oncol. 1997 Dec;27(6):410-4</RefSource>
                <PMID Version="1">9438004</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Drugs. 2015 Jan;26(1):112-6</RefSource>
                <PMID Version="1">25075797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Esophagus. 2015;12:91-94</RefSource>
                <PMID Version="1">25620904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Surg. 2009 Jun;96(6):579-92</RefSource>
                <PMID Version="1">19434703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 1975 Dec;114(6):836-8</RefSource>
                <PMID Version="1">1195458</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Urol Nephrol. 1995;27(1):1-8</RefSource>
                <PMID Version="1">7615361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 1998 Jun;16(6):2261-6</RefSource>
                <PMID Version="1">9626229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 1986 Oct;136(4):805-7</RefSource>
                <PMID Version="1">3761436</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nihon Hinyokika Gakkai Zasshi. 1987 Aug;78(8):1394-402</RefSource>
                <PMID Version="1">3325678</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">metastasis</Keyword>
            <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
            <Keyword MajorTopicYN="N">sunitinib</Keyword>
        </KeywordList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131915</ArticleId>
            <ArticleId IdType="doi">10.7759/cureus.2821</ArticleId>
            <ArticleId IdType="pmc">PMC6101459</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30131848</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>58</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jul</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>31200-31213</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25756</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Björk</LastName>
                    <ForeName>Johanna K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahonen</LastName>
                    <ForeName>Ilmari</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Mathematics and Statistics, University of Turku, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mirtti</LastName>
                    <ForeName>Tuomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erickson</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rannikko</LastName>
                    <ForeName>Antti</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bützow</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nordling</LastName>
                    <ForeName>Stig</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lundin</LastName>
                    <ForeName>Johan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lundin</LastName>
                    <ForeName>Mikael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sistonen</LastName>
                    <ForeName>Lea</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Nees</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Åkerfelt</LastName>
                    <ForeName>Malin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>ACS Chem Biol. 2016 Jan 15;11(1):200-10</RefSource>
                <PMID Version="1">26502114</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Surg Pathol. 2016 Feb;40(2):244-52</RefSource>
                <PMID Version="1">26492179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2015 Mar 1;136(5):E359-86</RefSource>
                <PMID Version="1">25220842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2007 Sep 21;130(6):1005-18</RefSource>
                <PMID Version="1">17889646</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 Aug 3;150(3):549-62</RefSource>
                <PMID Version="1">22863008</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 2010 Sep 15;24(18):1967-2000</RefSource>
                <PMID Version="1">20844012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2012 Oct 12;287(42):35646-57</RefSource>
                <PMID Version="1">22847003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Stress Chaperones. 2000 Jul;5(3):219-28</RefSource>
                <PMID Version="1">11005380</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2007 Sep 21;130(6):986-8</RefSource>
                <PMID Version="1">17889643</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Stat Softw. 2010;33(1):1-22</RefSource>
                <PMID Version="1">20808728</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2016 Apr 7;35(14):1770-84</RefSource>
                <PMID Version="1">26119944</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2007 Aug 2;26(35):5086-97</RefSource>
                <PMID Version="1">17310987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2016 Apr;22(4):369-78</RefSource>
                <PMID Version="1">26928463</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2012 Jul 19;31(29):3444-56</RefSource>
                <PMID Version="1">22120715</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2005 Aug 22;93(4):387-91</RefSource>
                <PMID Version="1">16106245</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2017 Aug;35(8):535</RefSource>
                <PMID Version="1">28623072</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2014 Jul 31;158(3):564-78</RefSource>
                <PMID Version="1">25083868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Ther Targets. 2009 Apr;13(4):469-78</RefSource>
                <PMID Version="1">19335068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Biol. 2008;9(9):R139</RefSource>
                <PMID Version="1">18803840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2000 Mar;156(3):857-64</RefSource>
                <PMID Version="1">10702402</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2015 Nov 5;163(4):1011-25</RefSource>
                <PMID Version="1">26544944</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2011 Feb;178(2):525-36</RefSource>
                <PMID Version="1">21281786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2012 Apr 1;118(7):1782-94</RefSource>
                <PMID Version="1">22009757</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Signal. 2013 Apr 02;6(269):pl1</RefSource>
                <PMID Version="1">23550210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 2011 Sep 13;30(19):3962-76</RefSource>
                <PMID Version="1">21915096</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jul 12;487(7406):239-43</RefSource>
                <PMID Version="1">22722839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Jul 19;367(3):203-13</RefSource>
                <PMID Version="1">22808955</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2011 Nov 15;117(22):5039-46</RefSource>
                <PMID Version="1">21647869</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2010 Jul 13;18(1):11-22</RefSource>
                <PMID Version="1">20579941</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Oncol (Dordr). 2016 Apr;39(2):97-106</RefSource>
                <PMID Version="1">26790878</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Transl Med. 2012 Oct 17;4(156):156ra139</RefSource>
                <PMID Version="1">23076356</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2006 Apr 7;281(14):9616-22</RefSource>
                <PMID Version="1">16469748</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Metab. 2011 Jul 6;14(1):91-103</RefSource>
                <PMID Version="1">21723507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 May 20;44(6):685-9</RefSource>
                <PMID Version="1">22610119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2016 Dec 20;7(51):84239-84245</RefSource>
                <PMID Version="1">27713164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Discov. 2012 May;2(5):401-4</RefSource>
                <PMID Version="1">22588877</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Pathol Lab Med. 2014 Dec;138(12):1564-77</RefSource>
                <PMID Version="1">25427038</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2009 Mar 6;136(5):823-37</RefSource>
                <PMID Version="1">19269363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2016 Mar;22(3):298-305</RefSource>
                <PMID Version="1">26855148</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2001 Nov;166(5):1692-7</RefSource>
                <PMID Version="1">11586204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2011 Jul 12;20(1):92-103</RefSource>
                <PMID Version="1">21741599</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2010 Aug;11(8):545-55</RefSource>
                <PMID Version="1">20628411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2013 Aug 1;19(15):4058-66</RefSource>
                <PMID Version="1">23704282</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2014 Jan 15;127(Pt 2):261-6</RefSource>
                <PMID Version="1">24421309</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):124-33</RefSource>
                <PMID Version="1">17525622</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 1999 Feb;53(2):372-7</RefSource>
                <PMID Version="1">9933057</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychol Methods. 2009 Dec;14(4):323-48</RefSource>
                <PMID Version="1">19968396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18378-83</RefSource>
                <PMID Version="1">22042860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2013 Jul 28;335(2):412-20</RefSource>
                <PMID Version="1">23499892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Stat Softw. 2011 Mar;39(5):1-13</RefSource>
                <PMID Version="1">27065756</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">heat shock factor</Keyword>
            <Keyword MajorTopicYN="N">predictive marker</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">tissue microarray (TMA)</Keyword>
        </KeywordList>
        <CoiStatement>CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131848</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.25756</ArticleId>
            <ArticleId IdType="pii">25756</ArticleId>
            <ArticleId IdType="pmc">PMC6101287</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131606</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5608</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Prostate cancer and prostatic diseases</Title>
                <ISOAbbreviation>Prostate Cancer Prostatic Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Estrogens and prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41391-018-0081-6</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hormonal influences such as androgens and estrogens are known contributors in the development and progression of prostate cancer (CaP). While much of the research to the hormonal nature of CaP has focused on androgens, estrogens also have critical roles in CaP development, physiology as well as a potential therapeutic intervention.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this review, we provide a critical literature review of the current basic science and clinical evidence for the interaction between estrogens and CaP.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Estrogenic influences in CaP include synthetic, endogenous, fungi and plant-derived compounds, and represent a family of sex hormones, which cross hydrophobic cell membranes and bind to membrane-associated receptors and estrogen receptors that localize to the nucleus triggering changes in gene expression in various organ systems.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Estrogens represent a under-recognized contributor in CaP development and progression. Further research in this topic may provide opportunities for identification of environmental influencers as well as providing novel therapeutic targets in the treatment of CaP.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dobbs</LastName>
                    <ForeName>Ryan W</ForeName>
                    <Initials>RW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malhotra</LastName>
                    <ForeName>Neha R</ForeName>
                    <Initials>NR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenwald</LastName>
                    <ForeName>David T</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Alice Y</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Vanderbilt University, Nashville, TN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prins</LastName>
                    <ForeName>Gail S</ForeName>
                    <Initials>GS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abern</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Illinois at Chicago, Chicago, IL, USA. Mabern1@uic.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Prostate Cancer Prostatic Dis</MedlineTA>
            <NlmUniqueID>9815755</NlmUniqueID>
            <ISSNLinking>1365-7852</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131606</ArticleId>
            <ArticleId IdType="doi">10.1038/s41391-018-0081-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41391-018-0081-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131605</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5608</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Prostate cancer and prostatic diseases</Title>
                <ISOAbbreviation>Prostate Cancer Prostatic Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCAness and prostate cancer: diagnostic and therapeutic considerations.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41391-018-0069-2</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent advances in genetic sequencing and recent studies focusing on the broader use of Poly ADP Ribose polymerase (PARP) inhibitors have led to an upsurge of interest in DNA repair mutations as they relate to prostate cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This review outlines ongoing studies and recent publications as they relate to the prevalence and detection of DNA repair mutations in metastatic prostate cancer. The detection of these mutations through multiple diagnostic approaches is discussed, including germline sequencing, somatic sequencing, cell-free DNA assays, and circulating tumor cell assays. The clinical course of patients with prostate cancer and DNA repair gene mutations is explored in addition to therapeutic strategies for this population.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In men with metastatic prostate cancer, it is reasonable to obtain germline genetic sequencing as well as somatic tumor genomic sequencing to help guide further treatment decisions that may include PARP inhibitors or carboplatin in the future. In the future, in men with metastatic castrate resistant prostate cancer with progression on PARP inhibitors, cell-free DNA sequencing may help elucidate mechanisms of resistance, which include reversion mutations.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dhawan</LastName>
                    <ForeName>Mallika</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryan</LastName>
                    <ForeName>Charles J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94115, USA. ryanc@umn.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Prostate Cancer Prostatic Dis</MedlineTA>
            <NlmUniqueID>9815755</NlmUniqueID>
            <ISSNLinking>1365-7852</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131605</ArticleId>
            <ArticleId IdType="doi">10.1038/s41391-018-0069-2</ArticleId>
            <ArticleId IdType="pii">10.1038/s41391-018-0069-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131604</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5608</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Prostate cancer and prostatic diseases</Title>
                <ISOAbbreviation>Prostate Cancer Prostatic Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41391-018-0079-0</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in therapy.</AbstractText>
                <AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T &lt; 50 ng/dL. Evidence shows that lowering T levels to &lt;20 ng/dL improves patient survival and delays disease progression. Routine monitoring of T in addition to prostate-specific antigen throughout treatment is important to ensure continuing efficacy of T suppression. New drugs that inhibit androgen signaling in combination with traditional ADT suppress T activity to near zero and have significantly improved patient survival. When personalizing ADT regimens physicians should consider a number of factors including initiation and duration of ADT, monitoring of T levels and PSA, the possibility of switching monotherapies if a patient does not achieve adequate T suppression, and consideration of intermittent vs. continuous ADT according to patients' lifestyles, comorbidities, risk factors and tolerance to treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Crawford</LastName>
                    <ForeName>E David</ForeName>
                    <Initials>ED</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Colorado School of Medicine, Denver, CO, USA. David.Crawford@UCDenver.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heidenreich</LastName>
                    <ForeName>Axel</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Cologne, Cologne, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Vienna, Vienna, Austria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawrentschuk</LastName>
                    <ForeName>Nathan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Melbourne, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tombal</LastName>
                    <ForeName>Bertrand</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cliniques Universitaires Saint-Luc, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pompeo</LastName>
                    <ForeName>Antonio C L</ForeName>
                    <Initials>ACL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculdade de Medicina do ABC, São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mendoza-Valdes</LastName>
                    <ForeName>Arturo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Médica Sur, Ciudad de México, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Kurt</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Debruyne</LastName>
                    <ForeName>Frans M J</ForeName>
                    <Initials>FMJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Andros Mannenkliniek, Arnhem, Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klotz</LastName>
                    <ForeName>Laurence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sunnybrook Health Sciences Centre, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Prostate Cancer Prostatic Dis</MedlineTA>
            <NlmUniqueID>9815755</NlmUniqueID>
            <ISSNLinking>1365-7852</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131604</ArticleId>
            <ArticleId IdType="doi">10.1038/s41391-018-0079-0</ArticleId>
            <ArticleId IdType="pii">10.1038/s41391-018-0079-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131546</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1827</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of cancer</Title>
                <ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41416-018-0123-9</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite most metastatic castration-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs. Long-term use of prednisone has been suggested as one of the mechanisms driving resistance, which may be reversed by switching to another steroid.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">SWITCH was a single-arm, open-label, single-stage phase II study. The primary objective was to evaluate the antitumour activity of abiraterone acetate plus dexamethasone 0.5 mg daily (AA + D) in mCRPC patients progressing to AA + P. Clinically stable mCRPC patients who had prostate-specific antigen (PSA) and/or limited radiographic progression after at least 12 weeks on AA + P, were eligible. The primary endpoint was measured as the proportion of patients achieving a PSA decline of  ≥ 30% (PSA30) from baseline after 6 weeks on AA + D. Secondary endpoints included: PSA50 response rate at 12 weeks, time to biochemical and radiological progression, overall survival, safety profile evaluation, benefit from subsequent treatment lines and the identification of biomarkers of response (AR copy number, TMPRSS2-ERG status and PTEN expression).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six patients were enrolled. PSA30 and PSA50 were 46.2% and 34.6%, respectively. Median time to biochemical and radiological progression were 5.3 and 11.8 months, respectively. Two radiological responses were observed. Median overall survival was 20.9 months. Patients with AR gain detected in plasma circulating tumour DNA did not respond to switch, whereas patients with AR normal status benefited the most. No significant toxicities were observed and PSA50 response rate to subsequent taxane was 50%.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In selected clinical stable mCRPC patients with limited disease progression on AA + P, a steroid switch from prednisone to dexamethasone can lead to PSA and radiological responses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romero-Laorden</LastName>
                    <ForeName>Nuria</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lozano</LastName>
                    <ForeName>Rebeca</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jayaram</LastName>
                    <ForeName>Anuradha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Pathology, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Academic Urology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>López-Campos</LastName>
                    <ForeName>Fernando</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saez</LastName>
                    <ForeName>Maria I</ForeName>
                    <Initials>MI</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montesa</LastName>
                    <ForeName>Alvaro</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gutierrez-Pecharoman</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Pathology Department, Hospital Universitario de Móstoles, Móstoles, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Villatoro</LastName>
                    <ForeName>Rosa</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Costa del Sol, Marbella, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herrera</LastName>
                    <ForeName>Bernardo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Urology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Correa</LastName>
                    <ForeName>Raquel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosero</LastName>
                    <ForeName>Adriana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pacheco</LastName>
                    <ForeName>María I</ForeName>
                    <Initials>MI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garcés</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cendón</LastName>
                    <ForeName>Ylenia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nombela</LastName>
                    <ForeName>Ma Paz</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van de Poll</LastName>
                    <ForeName>Floortje</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grau</LastName>
                    <ForeName>Gala</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivera</LastName>
                    <ForeName>Leticia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>López</LastName>
                    <ForeName>Pedro P</ForeName>
                    <Initials>PP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cruz</LastName>
                    <ForeName>Juan-Jesús</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lorente</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario La Fe, Valencia, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Attard</LastName>
                    <ForeName>Gerhardt</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Pathology, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Academic Urology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castro</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3691-6454</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ecastro@cnio.es.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospital Universitario Quirón, Madrid, Spain. ecastro@cnio.es.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olmos</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Department, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Cancer</MedlineTA>
            <NlmUniqueID>0370635</NlmUniqueID>
            <ISSNLinking>0007-0920</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131546</ArticleId>
            <ArticleId IdType="doi">10.1038/s41416-018-0123-9</ArticleId>
            <ArticleId IdType="pii">10.1038/s41416-018-0123-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131247</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(18)31611-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2018.07.110</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer (PCa) is a common malignancy in male urinary system. Cell division cycle-associated protein 1 (CDCA1) is expressed highly in many cancer cells. Yet, whether CDCA1 play an important role in PCa progression is uncertain. pH low insertion peptide (pHLIP), a PH-induced transmembrane structure, can pass through the cell membrane into intracellular in an acidic environment. In this study, we try to confirm the expression status of CDCA1 in the PCa patients' tissues and PCa cell line. In addition, to make the CDCA1-siRNA efficiently targeting the PCa cells, pHLIP and CDCA1-siRNA were combined with disulfide bond to become effector molecules. By the characteristics of the pHLIP allosteric occurring in cancer tissue acidic microenvironment, CDCA1-siRNA may be transported specificity into prostatic cancer cells and released in the cytoplasm. The interference effect of the effector molecules on the CDCA1 was detected in vitro and in vivo. The results showed that CDCA1 was highly expressed in PCa cell line and human PCa clinical samples. Knock down CDCA1 significantly inhibit the growth and promote the apoptosis of prostatic cancer cells. In the intracellular translocation experiment, CDCA1-siRNA could be delivered into cytoplasma at pH 6.2, but not at pH 7.4. In the in vivo test, the tumor size was reduced obviously in the NOD/SCID mice treated with pHLIP-CDCA1-siRNA compared to the CDCA1-siRNA and the bioluminescent signal of Cy5-pHLIP-CDCA1-siRNA was focused detected in the tumor site. Our findings indicated that CDCA1 might be a very key molecule regulating survival and proliferation of PCa. pHLIP-CDCA1-siRNA might be a promising targeting therapy for PCa.</AbstractText>
                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Zhining</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Xi'an, Shaanxi, 710038, China; Clinical Laboratory, 451 Hospital of Chinese People's Liberation Army, 269 Friendship East Road, Xi'an, Shaanxi, 710054, China. Electronic address: shirley_zzn@sina.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Changyu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hainan Cancer Hospital, No.6 West 4th Changbin Street, Haikou, HaiNan, 570100, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Xi'an, Shaanxi, 710038, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jinbo</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fourth Military Medical University, 169 Changle West Road, Xi'an, Shaanxi, 710032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Xiaoliang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Xi'an, Shaanxi, 710038, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Fan</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Xi'an, Shaanxi, 710038, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>He</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinsi Road, Xi'an, Shaanxi, 710038, China. Electronic address: whtangdu@sina.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, 169 Changle West Road, Xi'an, 710032, China. Electronic address: yb5870@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cell division cycle-associated protein 1</Keyword>
            <Keyword MajorTopicYN="N">Prostatic cancer</Keyword>
            <Keyword MajorTopicYN="N">Tumor acidic microenvironment</Keyword>
            <Keyword MajorTopicYN="N">pH-low insertion peptide</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131247</ArticleId>
            <ArticleId IdType="pii">S0006-291X(18)31611-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.07.110</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131183</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0887</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</Title>
                <ISOAbbreviation>Radiother Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0167-8140(18)33418-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.radonc.2018.07.019</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To describe toxicity, biochemical outcome and quality of life after MRI guided focal high dose rate brachytherapy (HDR-BT) in a single fraction of 19 Gy for localized prostate cancer.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Between May 2013 and April 2016, 30 patients were treated by MRI-guided focal HDR-BT. Patients with visible tumour on MRI were included. All patients were ≥65 years, T-stage &lt;T3, Gleason ≤7, PSA &lt;10 ng/mL and IPSS &lt;15. Focal irradiation was delivered in a single fraction of 19 Gy to the D95 of the clinical target volume. Toxicity was reported using the Common Terminology Criteria for Adverse Events version 4. Biochemical failure was defined according to the Phoenix criteria and quality of life was measured using validated questionnaires.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median follow up was 24 months. One patient developed a grade 2 and 3 GU toxicity after treatment. In the other 29 patients, no grade 2 or higher perioperative complications occurred. Five patients developed a biochemical recurrence. For all measured time points, there was no statistically significant deterioration in quality of life.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Focal MRI guided HDR-BT confers low toxicity rates and maintains quality of life. Biochemical recurrence is rather high, 5 patients developed a biochemical recurrence according to the Phoenix definition. Longer evaluation of these patients is necessary and caution is warranted before implementing focal HDR-BT in patients with localized prostate cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maenhout</LastName>
                    <ForeName>Metha</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiotherapy, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peters</LastName>
                    <ForeName>Max</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiotherapy, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moerland</LastName>
                    <ForeName>Marinus A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiotherapy, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meijer</LastName>
                    <ForeName>Richard P</ForeName>
                    <Initials>RP</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Urology, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van den Bosch</LastName>
                    <ForeName>Maurice A A J</ForeName>
                    <Initials>MAAJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiology, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frank</LastName>
                    <ForeName>Steven J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Department of Radiotherapy, Houston, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Paul L</ForeName>
                    <Initials>PL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana-Farber Cancer Institute, Department of Radiotherapy, Boston, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Vulpen</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiotherapy, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Voort van Zyp</LastName>
                    <ForeName>Jochem R N</ForeName>
                    <Initials>JRN</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Medical Center Utrecht, Department of Radiotherapy, the Netherlands. Electronic address: m.maenhout@erasmusmc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Radiother Oncol</MedlineTA>
            <NlmUniqueID>8407192</NlmUniqueID>
            <ISSNLinking>0167-8140</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Focal treatment</Keyword>
            <Keyword MajorTopicYN="N">HDR brachytherapy</Keyword>
            <Keyword MajorTopicYN="N">MRI guided</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131183</ArticleId>
            <ArticleId IdType="pii">S0167-8140(18)33418-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.radonc.2018.07.019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30131089</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1555-3906</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology research</Title>
                <ISOAbbreviation>Oncol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MicroRNA-152 acts as a tumor suppressor microRNA by inhibiting Krüppel-like factor 5 in human cervical cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.3727/096504018X15252202178408</ELocationID>
            <Abstract>
                <AbstractText>Aberrant expression of microRNA-152 (miR-152) is frequently observed in human cancers including ovarian cancer, breast cancer, prostate cancer, and gastric cancer. However, its expression and functional role in cervical cancer (CC) is poorly understood. Also, the association between miR-152 and Krüppel-like factor 5 (KLF5) expression in CC remains unclear. In this study, analyzing the expression of miR-152 by quantitative real-time PCR (qRT-PCR) revealed it was sharply reduced in CC tissues and cell lines. Meanwhile, the negative correlation of miR-152 expression and KLF5 expression was observed. The dual-luciferase reporter assay validated KLF5 was a target of miR-152. In vitro functional assays revealed that miR-152 could inhibit cell proliferation and cell cycle progression through regulating the expression of KLF5. Taken together, our study suggested miR-152 functions as a tumor suppressor in CC and the miR-152/KLF5 axis may provide novel therapeutic targets for CC treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Haiyan</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology, Affiliated Qilu Hospital of Shandong University, No. 127 West Cultural Road, Lixia District, Jinan, Shandong 250012, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology Ward-1, Linyi People's Hospital, No. 27 Jiefang Road, Hedong District, Linyi, Shandong 276003, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yanxia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology Ward-3, Linyi People's Hospital, Linyi, No. 27 Jiefang Road, Hedong District, Linyi, Shandong 276003, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Surong</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology Ward-3, Linyi People's Hospital, Linyi, No. 27 Jiefang Road, Hedong District, Linyi, Shandong 276003, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheng</LastName>
                    <ForeName>Xiugui</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology, Cancer Hospital Chinese Academy of Medical Sciences, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Shiqian</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology, Affiliated Qilu Hospital of Shandong University, No. 127 West Cultural Road, Lixia District, Jinan, Shandong 250012, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncol Res</MedlineTA>
            <NlmUniqueID>9208097</NlmUniqueID>
            <ISSNLinking>0965-0407</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30131089</ArticleId>
            <ArticleId IdType="doi">10.3727/096504018X15252202178408</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedBookArticle>
    <BookDocument>
        <PMID Version="18">26389500</PMID>
        <ArticleIdList>
            <ArticleId IdType="bookaccession">NBK83261</ArticleId>
        </ArticleIdList>
        <Book>
            <Publisher>
                <PublisherName>National Cancer Institute (US)</PublisherName>
                <PublisherLocation>Bethesda (MD)</PublisherLocation>
            </Publisher>
            <BookTitle book="pdqcis">PDQ Cancer Information Summaries</BookTitle>
            <PubDate>
                <Year>2002</Year>
            </PubDate>
            <BeginningDate>
                <Year>2002</Year>
            </BeginningDate>
            <Medium>Internet</Medium>
        </Book>
        <ArticleTitle book="pdqcis" part="CDR0000719335">Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version</ArticleTitle>
        <Language>eng</Language>
        <AuthorList Type="authors">
            <Author>
                <CollectiveName>PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</CollectiveName>
            </Author>
        </AuthorList>
        <PublicationType UI="D016454">Review</PublicationType>
        <Abstract>
            <AbstractText>This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of nutrition and dietary supplements for reducing the risk of developing prostate cancer or for treating prostate cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</AbstractText>
        </Abstract>
        <Sections>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__47">Introduction</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__426">Calcium</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__174">Green Tea</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__16">Lycopene</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__161">Modified Citrus Pectin</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__162">Pomegranate</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__283">Selenium</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__163">Soy</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__357">Vitamin D</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__328">Vitamin E</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__485">Multicomponent Therapies</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__387">Other Prostate Health Supplements</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__56">Changes to This Summary (08/16/2018)</SectionTitle>
            </Section>
            <Section>
                <SectionTitle book="pdqcis" part="CDR0000719335" sec="CDR0000719335__AboutThis_1">About This PDQ Summary</SectionTitle>
            </Section>
        </Sections>
        <KeywordList Owner="NOTNLM">
            <Keyword>CAM nutritional therapy</Keyword>
            <Keyword>prostate cancer</Keyword>
        </KeywordList>
        <ContributionDate>
            <Year>2018</Year>
            <Month>8</Month>
            <Day>16</Day>
        </ContributionDate>
    </BookDocument>
    <PubmedBookData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26389500</ArticleId>
        </ArticleIdList>
    </PubmedBookData>
</PubmedBookArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30130017</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1677-6119</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International braz j urol : official journal of the Brazilian Society of Urology</Title>
                <ISOAbbreviation>Int Braz J Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Robot - assisted laparoscopic local recurrence resection after radical prostatectomy.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1590/S1677-5538.IBJU.2017.0503</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION AND OBJECTIVE" NlmCategory="OBJECTIVE">Local prostate cancer recurrence is usually treated with salvage radiation (sRDT) with or with¬out adjuvant therapy. However, surgical resection could be an option. We aim to present the surgical technique for robot - assisted laparoscopic resection prostate cancer local recurrence after radical prostatectomy (RP) and sRDT in 2 cases.</AbstractText>
                <AbstractText Label="PATIENTS AND METHOD" NlmCategory="METHODS">First case depicts a 70 year - old man who underwent RP in 2001 and sRDT in 2004. Following ad¬juvant therapy, patient had biochemical recurrence. MRI showed a solid mass in the prostatic fossa close to vesicourethral anastomosis, measuring 2.1 cm and PET / CT revealed hyper caption significant uptake in the prostatic fossa. Second case is a 59 year - old man who underwent RP in 2010 and sRDT in 2011. Again, patient presented with biochemical recur¬rence. PET / CT showed hyper caption in the prostatic fossa. Biopsy conformed a prostate adenocarcinoma. Both patients underwent robot - assisted extended pelvic lymph nodes dissection and local recurrence resection. A standard 4 robotic arms port placement was utilized.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both procedures were uneventfully performed in less than 3 hours and there were no complications. Pathologi¬cal examination showed a prostate adenocarcinoma Gleason 7 and 8 in the first and second case, respectively; surgical margins and lymph nodes were negative. After 6 months of follow-up, continence was not affected and both patients presented with PSA &lt; 0.15 ng / mL.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Robot - assisted laparoscopic resection of prostate cancer local recurrence after RP and sRDT detected by PSMA PET / CT seems to be safe in experienced hands. It may postpone adjuvant therapy in selected cases.</AbstractText>
                <CopyrightInformation>Copyright® by the International Brazilian Journal of Urology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Torricelli</LastName>
                    <ForeName>Fabio C M</ForeName>
                    <Initials>FCM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Carvalho</LastName>
                    <ForeName>Paulo Afonso</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guglielmetti</LastName>
                    <ForeName>Giuliano B</ForeName>
                    <Initials>GB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahas</LastName>
                    <ForeName>William C</ForeName>
                    <Initials>WC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coelho</LastName>
                    <ForeName>Rafael F</ForeName>
                    <Initials>RF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Urologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D059040">Video-Audio Media</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Int Braz J Urol</MedlineTA>
            <NlmUniqueID>101158091</NlmUniqueID>
            <ISSNLinking>1677-5538</ISSNLinking>
        </MedlineJournalInfo>
        <CoiStatement>Conflict of interest: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30130017</ArticleId>
            <ArticleId IdType="doi">10.1590/S1677-5538.IBJU.2017.0503</ArticleId>
            <ArticleId IdType="pii">IBJU20170503</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30128924</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-2584</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International urology and nephrology</Title>
                <ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Can single positive core prostate cancer at biopsy be considered a low-risk disease?</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-018-1966-y</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Prostate cancer (PCa) may be a multifocal or bilateral disease. A single positive biopsy core is usually associated with indolent PCa, and doctors may choose to perform active surveillance or focal therapy. We investigated the correlation between finding a single positive biopsy core and the pathological outcome after radical prostatectomy (RP).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data from the Michinoku Japan Urological Cancer Study Group database including pre- and post-operative information, on 1928 consecutive patients with PCa treated with RP alone at four institutions was used. Among them, 503 patients with a single positive core PCa were followed up, and the clinical and pathological parameters influencing prognosis were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 503 patients, 258 (51.3%) had pathological findings ≥ pT2c and 160 (32%) had an undergraded Gleason Score (GS) based on their biopsy findings. A total of 112 patients (39.5%) with clinical T1c developed bilateral tumors (pT2c-T3). The rate of developing pT3 tumors in the single positive core group was significantly higher than that of the multiple positive core group. Moreover, there was no significant difference in the number of pT3b patients between the single and multiple positive core PCa groups.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on analysis of radical prostatectomy specimens, positive core PCa can lead to clinically significant disease, with considerable rates of pT3. For patients with PCa and a positive prostate biopsy core, definitive therapy such as RP should be considered.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Hayato</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4557-0619</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koie</LastName>
                    <ForeName>Takuya</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2980-127X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan. goodwin@hirosaki-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ookubo</LastName>
                    <ForeName>Teppei</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitsuzuka</LastName>
                    <ForeName>Koji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Narita</LastName>
                    <ForeName>Shintaro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inoue</LastName>
                    <ForeName>Takamitsu</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawamura</LastName>
                    <ForeName>Sadafumi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Miyagi Cancer Center, Natori, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Tomoyuki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tochigi</LastName>
                    <ForeName>Tatsuo</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Miyagi Cancer Center, Natori, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuchiya</LastName>
                    <ForeName>Norihiko</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Habuchi</LastName>
                    <ForeName>Tomonori</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arai</LastName>
                    <ForeName>Yoichi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohyama</LastName>
                    <ForeName>Chikara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int Urol Nephrol</MedlineTA>
            <NlmUniqueID>0262521</NlmUniqueID>
            <ISSNLinking>0301-1623</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gleason score</Keyword>
            <Keyword MajorTopicYN="N">Prostate biopsy</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Radical prostatectomy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30128924</ArticleId>
            <ArticleId IdType="doi">10.1007/s11255-018-1966-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s11255-018-1966-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30128923</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-2584</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International urology and nephrology</Title>
                <ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-018-1964-0</ELocationID>
            <Abstract>
                <AbstractText>Androgen deprivation therapy is an important therapy for prostate cancer (PCa) in aging men. Under the background of castration, it is inevitable that prostate cancer will develop into castration-resistant prostate cancer (CRPC), which has a high mortality rate, after 2-3 years. Androgen receptor (AR) plays a key role in PCa development and is essential to CRPC. More recent research studies have reported that the development of CRPC is largely due to altered mechanisms related to AR, so it is important for us to understand the roles of AR and detailed AR-related mechanisms in CRPC. The multiple AR-related mechanisms promoting the development of CRPC are as follows: (1) enhanced transformation and increased synthesis of intratumoral androgen; (2) AR overexpression, which enables CRPC to be hypersensitive to low levels of androgen; (3) AR cofactors, which enhanced AR transactivation; (4) AR-spliced variants, which mediated downstream gene expression without androgen; (5) the interaction between the AR pathway and classic tumor-related pathways; and» (6) AR mutations, which reduced AR specificity and enhanced AR transcription.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Zhonglin</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Weijie</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jianzhong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hongjun</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China. lihongjun@pumch.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int Urol Nephrol</MedlineTA>
            <NlmUniqueID>0262521</NlmUniqueID>
            <ISSNLinking>0301-1623</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Androgen deprivation therapy</Keyword>
            <Keyword MajorTopicYN="N">Androgen receptor</Keyword>
            <Keyword MajorTopicYN="N">Castration-resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Molecules</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30128923</ArticleId>
            <ArticleId IdType="doi">10.1007/s11255-018-1964-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s11255-018-1964-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30128005</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1792-1074</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology letters</Title>
                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3901-3906</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2018.9071</ELocationID>
            <Abstract>
                <AbstractText>Astragaloside (As) has been demonstrated extensively to serve roles in a variety of tumor types, including glioma, lung cancer, colorectal cancer, breast cancer and cervical cancer, and has therefore been widely used in Traditional Chinese Medicine. To the best of our knowledge, the present study was the first to investigate the efficacy of the Traditional Chinese Medicine astragaloside on tumor growth and the apoptosis of prostate cancer cells. In addition, further investigation into the underlying molecular mechanisms via the endoplasmic reticulum (ER) stress pathway was also performed. In the present study, the human prostate cancer DU-145 cell line was employed as an experimental model <i>in vitro</i> and cells were divided into five treatment groups: Dimethyl sulfoxide (DMSO) group (control), low-dose astragaloside group (L-As; 20 nmol/l), moderate-dose astragaloside group (M-As; 50 nmol/l), high-dose astragaloside group (H-As, 100 nmol/l) and ER stress suppressor group (tauroursodeoxycholic acid; TUDCA). The proliferative ability and apoptosis rate of the DU-145 cells were detected via Cell Counting kit-8 methods and flow cytometry, respectively. Furthermore, the ER stress factors [binding immunoglobulin protein (BiP), C/EBP homologous protein (CHOP) and caspase-12] were assessed through reverse transcription polymerase chain reaction. Additionally, the protein expression levels of inositol-requiring enzyme 1 (IRE1), phosphorylated protein kinase R-like ER kinase (p-PERK), iron-regulated transcriptional activator Aft (AFT)4 and AFT6 were measured detected by western blot analysis. Administration of As significantly reduced the cell viability and promoted apoptosis (P&lt;0.05) in a dose-dependent manner. Expression of ER-stressed genes BiP, CHOP and caspase-12 mRNA was increased by As administration, while TUDCA treatment led to a lower mRNA expression of these genes, compared with the control group. Results of western blot analysis indicated that the protein expression of IRE1, AFT4 and AFT6 was upregulated in the H-As group, and that the ratio of p-PERK/PERK was also higher than in the other groups. The administration of As demonstrated significant therapeutic effects on the proliferation of prostate cancer cells, as well as the expression of related proteins and genes. The results of the present study suggested future clinical potential of As for the treatment of prostate cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Renfeng</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jinhui</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Lett</MedlineTA>
            <NlmUniqueID>101531236</NlmUniqueID>
            <ISSNLinking>1792-1074</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Microbiol. 2014 Aug 05;5:388</RefSource>
                <PMID Version="1">25140166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2014 Mar;83(3):664-9</RefSource>
                <PMID Version="1">24411213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76</RefSource>
                <PMID Version="1">24837889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ethnopharmacol. 2015 Jul 1;169:210-8</RefSource>
                <PMID Version="1">25922268</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2005 Dec 15;65(24):11510-9</RefSource>
                <PMID Version="1">16357160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Cancer. 2013 Apr;4(2):61-9</RefSource>
                <PMID Version="1">23307762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>
                <PMID Version="1">11846609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ethnopharmacol. 2015 Jul 1;169:200-9</RefSource>
                <PMID Version="1">25917841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunobiology. 2014 Jul;219(7):565-71</RefSource>
                <PMID Version="1">24731407</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Cell Biol. 2011 Mar;13(3):184-90</RefSource>
                <PMID Version="1">21364565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a013169</RefSource>
                <PMID Version="1">23388626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102</RefSource>
                <PMID Version="1">22251901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Death Differ. 2011 May;18(5):769-82</RefSource>
                <PMID Version="1">21113145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32</RefSource>
                <PMID Version="1">26808342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2014 Jan;32(1):26.e25-31</RefSource>
                <PMID Version="1">23522840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antioxid Redox Signal. 2014 Jul 20;21(3):396-413</RefSource>
                <PMID Version="1">24702237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Nephrol. 2015 Mar 31;16:44</RefSource>
                <PMID Version="1">25886386</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Mol Life Sci. 2013 Jul;70(14):2425-41</RefSource>
                <PMID Version="1">23052213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71</RefSource>
                <PMID Version="1">24890451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2014 Dec 6;384(9959):2027-35</RefSource>
                <PMID Version="1">25108889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Physiol Biochem. 2014;33(6):1975-87</RefSource>
                <PMID Version="1">25012492</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2004 Jun 1;10(11):3919-26</RefSource>
                <PMID Version="1">15173101</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Diabetol. 2013 Nov 02;12:158</RefSource>
                <PMID Version="1">24180212</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2017 Sep 9;491(1):98-103</RefSource>
                <PMID Version="1">28709870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Immunopharmacol. 2014 Nov;23(1):304-13</RefSource>
                <PMID Version="1">25218161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2015 Mar 20;6(8):5860-76</RefSource>
                <PMID Version="1">25714022</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tumour Biol. 2017 Apr;39(4):1010428317697555</RefSource>
                <PMID Version="1">28443459</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Toxicol. 2014 Apr;29(4):428-39</RefSource>
                <PMID Version="1">22431435</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2015 Dec;75(16):1868-76</RefSource>
                <PMID Version="1">26310814</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">astragaloside</Keyword>
            <Keyword MajorTopicYN="N">endoplasmic reticulum stress pathway</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30128005</ArticleId>
            <ArticleId IdType="doi">10.3892/ol.2018.9071</ArticleId>
            <ArticleId IdType="pii">OL-0-0-9071</ArticleId>
            <ArticleId IdType="pmc">PMC6096132</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30127947</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1792-1074</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology letters</Title>
                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of genes that predict the biochemical recurrence of prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3447-3452</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2018.9106</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer (PCa) is one of the most prevalent cancer types in men. Biochemical recurrence continues to occur in a large proportion of patients after radical prostatectomy. Thus, prognostic biomarkers are required to determine which treatment is suitable. In the present study, RNA-sequencing gene expression data from The Cancer Genome Atlas was used in order to develop a risk-score staging system based on the expression of eight genes. Cox multivariate regression was used to predict the outcome of patients with PCa. The biomedical recurrence-free survival of patients with low-risk scores was significantly longer compared with patients with high-risk scores (P=5×10<sup>-7</sup>). This result was further validated using another dataset, GSE70769, from the National Center for Biotechnology Information. The prognostic values of other clinical information and risk scores were evaluated for 5-year biochemical recurrence. The prognostic value of the risk score was determined using an area under curve value of 0.819, predicting the 5-year biochemical recurrence of patients with PCa. The risk score was identified to be significantly associated with primary tumor stage (P&lt;0.01), Gleason score (P&lt;0.01), and lymph node invasion (P&lt;0.05), but was independent of age. Cox multivariate regression revealed that the risk score was an indicator for prediction of biochemical recurrence. Thus, the risk score is a valuable and robust indicator for predicting the biochemical recurrence of patients with PCa.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>Jianfeng</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ning</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gai</LastName>
                    <ForeName>Wentao</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Yantai Municipal Laiyang Central Hospital, Yantai, Shandong, 265200, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Lett</MedlineTA>
            <NlmUniqueID>101531236</NlmUniqueID>
            <ISSNLinking>1792-1074</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer. 2016 Aug 15;7(13):1842-1855</RefSource>
                <PMID Version="1">27698924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2014 Jan 30;5(2):451-61</RefSource>
                <PMID Version="1">24448395</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Clin Cancer Res. 2014 Apr 09;33:31</RefSource>
                <PMID Version="1">24716822</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2017 Nov 28;409:104-115</RefSource>
                <PMID Version="1">28923398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2008;11(2):112-20</RefSource>
                <PMID Version="1">17998918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Urol Nephrol. 2017 May;49(5):825-835</RefSource>
                <PMID Version="1">28188414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gynecol Oncol. 2015 Jun;137(3):529-37</RefSource>
                <PMID Version="1">25858696</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biostatistics. 2014 Oct;15(4):757-73</RefSource>
                <PMID Version="1">24728979</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2014 Sep;63(9):1457-67</RefSource>
                <PMID Version="1">24173294</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Stat Probab Lett. 2010 Jul 1;80(13-14):1056-1064</RefSource>
                <PMID Version="1">20582150</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):259-72</RefSource>
                <PMID Version="1">26109913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2016 Mar;69(3):428-35</RefSource>
                <PMID Version="1">26166626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Med Rep. 2015 Jul;12(1):1298-304</RefSource>
                <PMID Version="1">25760033</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biomed Res Int. 2014;2014:423174</RefSource>
                <PMID Version="1">24883311</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Metastasis Rev. 2017 Mar;36(1):159-177</RefSource>
                <PMID Version="1">27866303</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Analyst. 2016 Feb 7;141(3):740-55</RefSource>
                <PMID Version="1">26583164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2004 Feb 12;20(3):307-15</RefSource>
                <PMID Version="1">14960456</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Can Urol Assoc J. 2014 May;8(5-6):E333-41</RefSource>
                <PMID Version="1">24940460</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Onco Targets Ther. 2017 May 15;10:2553-2560</RefSource>
                <PMID Version="1">28546759</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Jan 1;29(1):17-24</RefSource>
                <PMID Version="1">21098318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2017 Oct;91(Pt A):53-59</RefSource>
                <PMID Version="1">28867541</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2015 Sep 1;31(17):2909-11</RefSource>
                <PMID Version="1">25913208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32</RefSource>
                <PMID Version="1">26808342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Rep. 2017 Mar 22;7(1):309</RefSource>
                <PMID Version="1">28331188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nutr J. 2010 Dec 22;9:69</RefSource>
                <PMID Version="1">21176210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71</RefSource>
                <PMID Version="1">24477410</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2016 May 19;7:11612</RefSource>
                <PMID Version="1">27194471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2002 Jan 1;30(1):207-10</RefSource>
                <PMID Version="1">11752295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Bioinformatics. 2011 Mar 17;12:77</RefSource>
                <PMID Version="1">21414208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Colorectal Dis. 2011 Aug;13(8):e220-6</RefSource>
                <PMID Version="1">21689314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EBioMedicine. 2015 Jul 29;2(9):1133-44</RefSource>
                <PMID Version="1">26501111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2012 Aug;3(8):824-32</RefSource>
                <PMID Version="1">22910040</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Bioinformatics. 2006 Oct 23;7:464</RefSource>
                <PMID Version="1">17059591</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2015 Jun;67(6):1160-1167</RefSource>
                <PMID Version="1">25301759</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Oncol. 2014 Dec;8(8):1653-66</RefSource>
                <PMID Version="1">25049118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2013 Dec 10;8(12):e81680</RefSource>
                <PMID Version="1">24339954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Bioinformatics. 2014 May 10;15:138</RefSource>
                <PMID Version="1">24886202</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer. 2017 Aug 3;8(13):2575-2586</RefSource>
                <PMID Version="1">28900495</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Proteomics. 2013 Jun;12(6):1589-601</RefSource>
                <PMID Version="1">23443136</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">biomedical recurrence</Keyword>
            <Keyword MajorTopicYN="N">gene expression</Keyword>
            <Keyword MajorTopicYN="N">model</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30127947</ArticleId>
            <ArticleId IdType="doi">10.3892/ol.2018.9106</ArticleId>
            <ArticleId IdType="pii">OL-0-0-9106</ArticleId>
            <ArticleId IdType="pmc">PMC6096182</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30127676</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1507-1367</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <MedlineDate>2018 Sep-Oct</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology</Title>
                <ISOAbbreviation>Rep Pract Oncol Radiother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association between EBRT dose volume histograms and quality of life in prostate cancer patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>360-368</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rpor.2018.07.009</ELocationID>
            <Abstract>
                <AbstractText Label="Aim" NlmCategory="UNASSIGNED">To evaluate the association between dose-volume histogram (DVH) values in organs at risk (OAR) and patient-reported HRQoL outcomes.</AbstractText>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Data on the association between DVHs and health-related quality of life (HRQoL) in prostate cancer (PCa) patients are limited.</AbstractText>
                <AbstractText Label="Materials and methods" NlmCategory="UNASSIGNED">Five-year follow-up study of 154 patients with organ-confined (stage T1/T2) PCa treated with EBRT between January 2003 and November 2005. HRQoL was evaluated with the Expanded Prostate Cancer Index (EPIC). DVH for OARs (penile bulb, rectum and bladder) were created for all patients for whom data were available (119/154; 77%). The functional data analysis (FDA) statistical method was used. HRQoL data was collected prospectively and data analysis was performed retrospectively.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Worsening of urinary incontinence and obstructive symptoms correlated with higher DVH dose distributions at 24 months. Increased rectal bleeding at months 24 and 60 correlated with higher DVH dose distributions in the 40-70 Gy range. Patients with deterioration in rectal incontinence presented a higher DVH distribution range than patients without rectal incontinence. Penile bulb DVH values and erectile dysfunction were not significantly associated.</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">DVH parameters and post-radiotherapy HRQoL appear to be closely correlated, underscoring the importance of assessing DVH values prior to initiating EBRT to determine the risk of developing HRQoL related adverse effects. Advanced treatment modalities may be appropriate in high risk cases to minimize treatment-related toxicity and to improve treatment outcomes and HRQoL. Future studies are needed to better elucidate the association between pre-treatment DVH parameters in organs at risk and subsequent HRQoL.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Boladeras</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrer</LastName>
                    <ForeName>Ferran</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Navarro</LastName>
                    <ForeName>Valentin</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Blas</LastName>
                    <ForeName>Rodolfo</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cunillera</LastName>
                    <ForeName>Oriol</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER en Epidemiología y Salud Pública, CIBERESP, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mateo</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gutierrez</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martinez</LastName>
                    <ForeName>Evelyn</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Villà</LastName>
                    <ForeName>Salvador</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia, Badalona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pera</LastName>
                    <ForeName>Joan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrer</LastName>
                    <ForeName>Montse</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER en Epidemiología y Salud Pública, CIBERESP, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guedea</LastName>
                    <ForeName>Ferran</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Català d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Rep Pract Oncol Radiother</MedlineTA>
            <NlmUniqueID>100885761</NlmUniqueID>
            <ISSNLinking>1507-1367</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1081-5</RefSource>
                <PMID Version="1">20207497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):654-63</RefSource>
                <PMID Version="1">25304951</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63</RefSource>
                <PMID Version="1">21147514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2014 Dec;84(6):1383-7</RefSource>
                <PMID Version="1">25440987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Health Qual Life Outcomes. 2004 Jun 29;2:32</RefSource>
                <PMID Version="1">15225377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2013 Aug;108(2):306-13</RefSource>
                <PMID Version="1">23849168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2012 Jun;103(3):347-52</RefSource>
                <PMID Version="1">22520267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Radiother. 2010 Oct;14(6-7):460-8</RefSource>
                <PMID Version="1">20797890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 2000 Dec 20;56(6):899-905</RefSource>
                <PMID Version="1">11113727</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Radiat Res. 2015 Jan;56(1):122-7</RefSource>
                <PMID Version="1">25212601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32</RefSource>
                <PMID Version="1">18325680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Conf Proc IEEE Eng Med Biol Soc. 2015;2015:5231-4</RefSource>
                <PMID Version="1">26737471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1357-63</RefSource>
                <PMID Version="1">15590165</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1310-7</RefSource>
                <PMID Version="1">20493642</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2014 Feb;110(2):291-7</RefSource>
                <PMID Version="1">24507766</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):19-25</RefSource>
                <PMID Version="1">20056354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1130-7</RefSource>
                <PMID Version="1">17881142</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Nov 1;28(31):4687-96</RefSource>
                <PMID Version="1">20921463</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1664-5; author reply 1666</RefSource>
                <PMID Version="1">15590205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2014 Feb;110(2):284-90</RefSource>
                <PMID Version="1">24411226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1351-6</RefSource>
                <PMID Version="1">15590164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2013 May 1;119(9):1729-35</RefSource>
                <PMID Version="1">23436283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2008 Mar 20;358(12):1250-61</RefSource>
                <PMID Version="1">18354103</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S130-4</RefSource>
                <PMID Version="1">20171507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2006 Sep;80(3):355-62</RefSource>
                <PMID Version="1">16949694</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2002 Jul;64(1):1-12</RefSource>
                <PMID Version="1">12208568</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Med Res Methodol. 2013 Mar 19;13:43</RefSource>
                <PMID Version="1">23510439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 2002 Aug;64(2):209-14</RefSource>
                <PMID Version="1">12242132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1998 Sep 16;280(11):969-74</RefSource>
                <PMID Version="1">9749478</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Organs at risk</Keyword>
            <Keyword MajorTopicYN="N">Prostatic neoplasms</Keyword>
            <Keyword MajorTopicYN="N">Quality of life</Keyword>
            <Keyword MajorTopicYN="N">Urinary bladder</Keyword>
            <Keyword MajorTopicYN="N">Urinary incontinence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30127676</ArticleId>
            <ArticleId IdType="doi">10.1016/j.rpor.2018.07.009</ArticleId>
            <ArticleId IdType="pii">S1507-1367(18)30085-3</ArticleId>
            <ArticleId IdType="pmc">PMC6097465</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30126765</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-0682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jul</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical genitourinary cancer</Title>
                <ISOAbbreviation>Clin Genitourin Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1558-7673(18)30397-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clgc.2018.07.008</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present study retrospectively evaluated the efficacy and safety of enzalutamide in different lines of metastatic castration-resistant prostate cancer (mCRPC) treatment in a real-world setting.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The clinical records of patients with mCRPC treated with enzalutamide between August 2015 and October 2017 were retrieved from all 7 public oncology centers in Hong Kong and reviewed. The primary endpoint was progression-free survival (PFS) in first (1L), second (2L), and third or fourth lines (3L or 4L) of CRPC treatment. Secondary endpoints included overall survival (OS), prostate-specific antigen (PSA) response, and tolerance.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among a total of 117 patients (median age of 73 years [range, 52-90 years]), 34 (29.1%), 57 (48.7%), and 26 (19.3%) patients had enzalutamide as their 1L (chemo-naive), 2L (post-docetaxel or -abiraterone), and 3L or above treatment options. The overall PSA response rates were 43.6%, and were 73.5%, 35.1%, and 19.2% for 1L, 2L, and 3L or 4L treatment, respectively. PFS and OS were significantly associated with the line of treatment in the univariate survival analysis (1L/2L/3L and 4L; PFS, 7.1/3.9/2.2 months; OS, not reached/15.8/7.4 months; both P = .0002) but not in the multivariate analysis. The observed incidence of any fatigue (grade 1 or 2, 54.7%; grade 3 or 4, 9.4%) was much higher than reported in the AFFIRM (A Study Evaluating the Efficacy and Safety of the Investigational Drug MDV3100 [ClinicalTrials.gov Identifier: NCT00974311]) (any grade, 34%) and PREVAIL (A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naïve Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy [ClinicalTrials.gov Identifier: NCT00974311]) (any grade, 36%) trials; as well, grade ≥ 2 fatigue was significantly associated with 3L or 4L treatment (P = .01 in both univariate and multivariate analyses).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the real-life setting, there was a higher incidence of enzalutamide-related fatigue than reported in the trials. Earlier lines of enzalutamide treatment were associated with longer PFS and OS, more frequent PSA response, and less fatigue.</AbstractText>
                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poon</LastName>
                    <ForeName>Darren M C</ForeName>
                    <Initials>DMC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong. Electronic address: mc_poon@clo.cuhk.edu.hk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Kenneth C W</ForeName>
                    <Initials>KCW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>T W</ForeName>
                    <Initials>TW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Law</LastName>
                    <ForeName>Kitty</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Princess Margaret Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Kuen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Eric K C</ForeName>
                    <Initials>EKC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Conrad</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, United Christian Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, Queen Mary Hospital, Hong Kong; Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Hong Kong Society of Uro-Oncology (HKSUO)</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00974311</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Genitourin Cancer</MedlineTA>
            <NlmUniqueID>101260955</NlmUniqueID>
            <ISSNLinking>1558-7673</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Abiraterone</Keyword>
            <Keyword MajorTopicYN="N">Chemo-naive</Keyword>
            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">Docetaxel</Keyword>
            <Keyword MajorTopicYN="N">Fatigue</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30126765</ArticleId>
            <ArticleId IdType="pii">S1558-7673(18)30397-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clgc.2018.07.008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30126434</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1748-717X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Radiation oncology (London, England)</Title>
                <ISOAbbreviation>Radiat Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of transperineal ultrasound imaging as a potential solution for target tracking during hypofractionated radiotherapy for prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>151</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13014-018-1097-8</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emerging hypofractionated prostate radiotherapy regimens require solutions for accurate target tracking during beam delivery. The goal of this study is to evaluate the performance of the Clarity ultrasound monitoring system for prostate motion tracking.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Five prostate patients underwent continuous perineum ultrasound imaging during their daily treatments. Initial absolute 3D positions of fiducials implanted in the prostate were estimated from the KV images. Fiducial positions in MV images acquired during beam delivery were compared with predicted positions based on Clarity 3D tracking. The uncertainty in the comparison results was evaluated in a phantom validation study.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Continuous real-time ultrasound motion tracking was recorded in 5 patients and 167 fractions for overall of 39.7 h. Phantom validation of the proposed procedure demonstrated that predicted and observed fiducial positions agree within 1.1 mm. In patients agreement between predicted and actual fiducial positions varied between 1.3 mm and 3.3 mm. On average ultrasound tracking reduced the maximum localization error in patients by 20% on average. With the motion corrected, the duration prostate beyond 1 mm from its initial treatment position can be reduced from 37 to 22% of the total treatment time.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Real-time ultrasound tracking reduces uncertainty in prostate position due to intra-fractional motion.</AbstractText>
                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">IRB Protocol #27372 . Date of registration of trial: 12/17/2013.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, 875 Blake Wilbur Drive, Room G203, Palo Alto, CA, 94304, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Najafi</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, 875 Blake Wilbur Drive, Room G203, Palo Alto, CA, 94304, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>David T</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Elekta Ltd, 2050 Bleury Suite 200, Montréal, QC, H3A 2J5, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lachaine</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Elekta Ltd, 2050 Bleury Suite 200, Montréal, QC, H3A 2J5, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>von Eyben</LastName>
                    <ForeName>Rie</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, 875 Blake Wilbur Drive, Room G203, Palo Alto, CA, 94304, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hancock</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, 875 Blake Wilbur Drive, Room G203, Palo Alto, CA, 94304, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hristov</LastName>
                    <ForeName>Dimitre</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, 875 Blake Wilbur Drive, Room G203, Palo Alto, CA, 94304, USA. dimitre.hristov@stanford.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Radiat Oncol</MedlineTA>
            <NlmUniqueID>101265111</NlmUniqueID>
            <ISSNLinking>1748-717X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Image-guidance</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Prostate motion</Keyword>
            <Keyword MajorTopicYN="N">Radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">Tracking</Keyword>
            <Keyword MajorTopicYN="N">Ultrasound</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30126434</ArticleId>
            <ArticleId IdType="doi">10.1186/s13014-018-1097-8</ArticleId>
            <ArticleId IdType="pii">10.1186/s13014-018-1097-8</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30125354</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0215</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of cancer</Title>
                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31818</ELocationID>
            <Abstract>
                <AbstractText>The androgen receptor (AR) plays a central role in the pathogenesis of prostate cancer (PCa). Most PCa cases develop eventually from an androgen-dependent stage to castration-resistant prostate cancer (CRPC) with AR-signaling still being active. Thus, inhibition of AR remains a well-established promising drug target in CRPC. However, in spite of the improvements of current treatment for CRPC by targeting the AR, the evolution of adaptive AR-signaling leads to therapy-resistant CRPC. Treatment failure is based mostly on the inability to keep AR under long-term restraint due to adaptive responses of AR-signaling. One underlying mechanism appears to be the increased AR protein stability. Therefore, the regulation of AR protein stability and its degradation is another interesting path that could enhance our knowledge of carcinogenesis and tumor evolution possibly leading to novel therapeutic targets. In this review, we discuss various molecular mechanisms and factors that stabilize AR protein levels directly or indirectly. We summarize novel approaches to interfere with AR stability including targeting the glucocorticoid receptor (GR), heat shock proteins, and co-chaperones as well as E3-ligases using small chimeric molecules. These novel approaches in combination with anti-androgen treatment inhibit PCa growth through the regulation of AR protein levels. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lakshmana</LastName>
                    <ForeName>Gopinath</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Human Genetics, Jena University Hospital, Jena, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baniahmad</LastName>
                    <ForeName>Aria</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1085-9161</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Institute of Human Genetics, Jena University Hospital, Jena, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Int J Cancer</MedlineTA>
            <NlmUniqueID>0042124</NlmUniqueID>
            <ISSNLinking>0020-7136</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Androgen Receptor</Keyword>
            <Keyword MajorTopicYN="N">Castration resistance</Keyword>
            <Keyword MajorTopicYN="N">Protein stability</Keyword>
            <Keyword MajorTopicYN="N">Receptor degradation</Keyword>
            <Keyword MajorTopicYN="N">Therapy resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30125354</ArticleId>
            <ArticleId IdType="doi">10.1002/ijc.31818</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30125258</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0025-7680</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>78</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Medicina</Title>
                <ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Prostate carcinoma and syndrome of inappropriate antidiuretic hormone secretion].</ArticleTitle>
            <Pagination>
                <MedlinePgn>290-293</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Prostate cancer is an extremely rare cause of syndrome of inappropriate antidiuretic hormone (SIADH) secretion. These tend to be aggressive tumors and SIADH can carry serious clinical consequences. A 64 years old patient was diagnosed with Gleason 4+3: 7 prostate adenocarcinoma in December 2014 and received hormonal blockade therapy. By March 2015 he was admitted for symptomatic hyponatremia and SIADH secretion was diagnosed, with no other probable cause than prostate cancer. He suffered a rapid progression of his oncologic disease, surprisingly with PSA in normal range, and died in the short term. There is great clinical and histopathological variability in the cases reported in the literature of association of prostate carcinoma and SIADH. However, they all agree on the aggressiveness of these tumors. This characteristic is present in tumors that have neuroendocrine features. They are frequently resistant to hormonal treatment and may present with paraneoplastic syndromes such as SIADH. The profile of its molecular alterations is under study for the development of target therapies. The association of prostate adenocarcinoma and SIADH is very uncommon and could involve neuroendocrine differentiation. For this reason, it is essential to perform a new biopsy of the tumor or its metastases at the progressive disease in order to conduct an appropriate treatment according to its morphological, immunohistochemical and, in the future, molecular characteristics.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Miretti</LastName>
                    <ForeName>Virginia S</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncología, Hospital Universitario Privado de Córdoba, Argentina. E-mail: virginiamiretti85@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ávila</LastName>
                    <ForeName>Rodolfo A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncología, Hospital Universitario Privado de Córdoba, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sierra</LastName>
                    <ForeName>Jeremías T</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncología, Hospital Universitario Privado de Córdoba, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>García</LastName>
                    <ForeName>Juan José</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncología, Hospital Universitario Privado de Córdoba, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laborié</LastName>
                    <ForeName>María Victoria</ForeName>
                    <Initials>MV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Anatomía Patológica, Hospital Universitario Privado de Córdoba, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Carcinoma de próstata y síndrome de secreción inadecuada de hormona antidiurética.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Argentina</Country>
            <MedlineTA>Medicina (B Aires)</MedlineTA>
            <NlmUniqueID>0204271</NlmUniqueID>
            <ISSNLinking>0025-7680</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">neuroendocrine carcinoma of the prostate</Keyword>
            <Keyword MajorTopicYN="N">prostate carcinoma</Keyword>
            <Keyword MajorTopicYN="N">syndrome of inappropriate antidiuretic hormone secretion (SIADH)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30125258</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30125150</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1553-4014</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>08</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annual review of pathology</Title>
                <ISOAbbreviation>Annu Rev Pathol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev-pathmechdis-012418-012818</ELocationID>
            <Abstract>
                <AbstractText>Evidence indicates that diet, nutrition, lifestyle, the environment, the microbiome, and other exogenous factors have pathogenic roles and also influence the genome, epigenome, transcriptome, proteome, and metabolome of tumor and nonneoplastic cells, including immune cells. With the need for big-data research, pathology must transform to integrate data science fields, including epidemiology, biostatistics, and bioinformatics. The research framework of molecular pathological epidemiology (MPE) demonstrates the strengths of such an interdisciplinary integration, having been used to study breast, lung, prostate, and colorectal cancers. The MPEresearch paradigm not only can provide novel insights into interactions among environment, tumor, and host but also opens new research frontiers. New developments-such as computational digital pathology, systems biology, artificial intelligence, and in vivo pathology technologies-will further transform pathology and MPE. Although it is necessary to address the rarity of transdisciplinary education and training programs, MPE provides an exemplary model of integrative scientific approaches and contributes to advancements in precision medicine, therapy, and prevention. Expected final online publication date for the Annual Review of Pathology: Mechanisms of Disease Volume 14 is January 24, 2019. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ogino</LastName>
                    <ForeName>Shuji</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02215, USA; email: shuji_ogino@dfci.harvard.edu , janowak@partners.org , reiko.nishihara@mail.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncologic Pathology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02215, USA; email: tsuyoshi_hamada@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nowak</LastName>
                    <ForeName>Jonathan A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02215, USA; email: shuji_ogino@dfci.harvard.edu , janowak@partners.org , reiko.nishihara@mail.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamada</LastName>
                    <ForeName>Tsuyoshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncologic Pathology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02215, USA; email: tsuyoshi_hamada@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milner</LastName>
                    <ForeName>Danny A</ForeName>
                    <Initials>DA</Initials>
                    <Suffix>Jr.</Suffix>
                    <AffiliationInfo>
                        <Affiliation>American Society for Clinical Pathology, Chicago, Illinois 60603, USA; email: dan.milner@ascp.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>These authors contributed equally to this article.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishihara</LastName>
                    <ForeName>Reiko</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02215, USA; email: shuji_ogino@dfci.harvard.edu , janowak@partners.org , reiko.nishihara@mail.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>These authors contributed equally to this article.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K07 CA190673</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R35 CA197735</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Annu Rev Pathol</MedlineTA>
            <NlmUniqueID>101275111</NlmUniqueID>
            <ISSNLinking>1553-4006</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30125150</ArticleId>
            <ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012818</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30124773</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1468-4357</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biostatistics (Oxford, England)</Title>
                <ISOAbbreviation>Biostatistics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Causal inference in continuous time: an example on prostate cancer therapy.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/biostatistics/kxy036</ELocationID>
            <Abstract>
                <AbstractText>In marginal structural models (MSMs), time is traditionally treated as a discrete parameter. In survival analysis on the other hand, we study processes that develop in continuous time. Therefore, Røysland (2011. A martingale approach to continuous-time marginal structural models. Bernoulli 17, 895-915) developed the continuous-time MSMs, along with continuous-time weights. The continuous-time weights are conceptually similar to the inverse probability weights that are used in discrete time MSMs. Here, we demonstrate that continuous-time MSMs may be used in practice. First, we briefly describe the causal model assumptions using counting process notation, and we suggest how causal effect estimates can be derived by calculating continuous-time weights. Then, we describe how additive hazard models can be used to find such effect estimates. Finally, we apply this strategy to compare medium to long-term differences between the two prostate cancer treatments radical prostatectomy and radiation therapy, using data from the Norwegian Cancer Registry. In contrast to the results of a naive analysis, we find that the marginal cumulative incidence of treatment failure is similar between the strategies, accounting for the competing risk of other death.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ryalen</LastName>
                    <ForeName>Pål Christie</ForeName>
                    <Initials>PC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Oslo, Domus Medica Gaustad, Sognsvannsveien 9, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stensrud</LastName>
                    <ForeName>Mats Julius</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Oslo, Domus Medica Gaustad, Sognsvannsveien 9, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Diakonhjemmet Hospital, Diakonveien 12, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fosså</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Nydalen, Oslo.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Clinical Medicine, Division of Cancer Medicine, Oslo University Hospital, Søsterhjemmet, Kirkeveien 166, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Registry of Norway, Ullernchausseen 64, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Røysland</LastName>
                    <ForeName>Kjetil</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Oslo, Domus Medica Gaustad, Sognsvannsveien 9, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Biostatistics</MedlineTA>
            <NlmUniqueID>100897327</NlmUniqueID>
            <ISSNLinking>1465-4644</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124773</ArticleId>
            <ArticleId IdType="pii">5075426</ArticleId>
            <ArticleId IdType="doi">10.1093/biostatistics/kxy036</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30124664</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1940-087X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>138</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>08</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of visualized experiments : JoVE</Title>
                <ISOAbbreviation>J Vis Exp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.3791/57996</ELocationID>
            <Abstract>
                <AbstractText>Phosphoproteomics involves the large-scale study of phosphorylated proteins. Protein phosphorylation is a critical step in many signal transduction pathways and is tightly regulated by kinases and phosphatases. Therefore, characterizing the phosphoproteome may provide insights into identifying novel targets and biomarkers for oncologic therapy. Mass spectrometry provides a way to globally detect and quantify thousands of unique phosphorylation events. However, phosphopeptides are much less abundant than non-phosphopeptides, making biochemical analysis more challenging. To overcome this limitation, methods to enrich phosphopeptides prior to the mass spectrometry analysis are required. We describe a procedure to extract and digest proteins from tissue to yield peptides, followed by an enrichment for phosphotyrosine (pY) and phosphoserine/threonine (pST) peptides using an antibody-based and/or titanium dioxide (TiO2)-based enrichment method. After the sample preparation and mass spectrometry, we subsequently identify and quantify phosphopeptides using liquid chromatography-mass spectrometry and analysis software.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Larry C</ForeName>
                    <Initials>LC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Program in Cellular and Molecular Pharmacology, School of Graduate Studies, Rutgers University, The State University of New Jersey; Graduate Program in Quantitative Biomedicine, School of Graduate Studies, Rutgers University, The State University of New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhen</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graeber</LastName>
                    <ForeName>Thomas G</ForeName>
                    <Initials>TG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, UCLA Metabolomics Center, and California NanoSystems Institute, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graham</LastName>
                    <ForeName>Nicholas A</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mork Family Department of Chemical Engineering and Materials Science, University of Southern California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drake</LastName>
                    <ForeName>Justin M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Program in Cellular and Molecular Pharmacology, School of Graduate Studies, Rutgers University, The State University of New Jersey; Graduate Program in Quantitative Biomedicine, School of Graduate Studies, Rutgers University, The State University of New Jersey; Department of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School; Pharmacology, Rutgers Robert Wood Johnson Medical School; Cancer Metabolism and Growth Program, Rutgers Cancer Institute of New Jersey; justin.drake@cinj.rutgers.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>T32 GM008339</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 CA092131</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 CA168585</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D059040">Video-Audio Media</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Vis Exp</MedlineTA>
            <NlmUniqueID>101313252</NlmUniqueID>
            <ISSNLinking>1940-087X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124664</ArticleId>
            <ArticleId IdType="doi">10.3791/57996</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30124601</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-5628</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nuclear medicine communications</Title>
                <ISOAbbreviation>Nucl Med Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MNM.0000000000000888</ELocationID>
            <Abstract>
                <AbstractText>Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sanli</LastName>
                    <ForeName>Yasemin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Division of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanli</LastName>
                    <ForeName>Oner</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Urology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Has Simsek</LastName>
                    <ForeName>Duygu</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramaniam</LastName>
                    <ForeName>Rathan M</ForeName>
                    <Initials>RM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Division of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nucl Med Commun</MedlineTA>
            <NlmUniqueID>8201017</NlmUniqueID>
            <ISSNLinking>0143-3636</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124601</ArticleId>
            <ArticleId IdType="doi">10.1097/MNM.0000000000000888</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30124599</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-5628</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nuclear medicine communications</Title>
                <ISOAbbreviation>Nucl Med Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MNM.0000000000000894</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the era of image-guided radiotherapy, PET has become an important tool for tumor delineation in several types of cancer. The aim of this study was to evaluate the effect of this imaging modality in treatment planning of a cohort of patients with prostate cancer eligible for radiotherapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">From September 2011 to January 2016, 135 consecutive patients (median age 69 years, range: 53-89) were referred to our department for radiation therapy with radical intent (n=28), for postoperative adjuvant (n=13) or salvage treatment (n=50), for re-irradiation (n=19), or for radiotherapy on oligometastases (n=25). Before planning the radiotherapy course, patients were submitted to carbon-11-choline PET (Cho-PET) to confirm the indication to radiotherapy and the irradiation volumes.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 135 patients subjected to Cho-PET, the indication to radiotherapy was modified in 66 (48.8%) cases based on the Cho-PET result. In particular, Cho-PET helped to better define the radiotherapy programme in 12 out of 28 (42.8%) patients who were candidates for primary radiation therapy, 33 (52.4%) of 63 patients undergoing adjuvant/salvage radiotherapy, and 21 out of 44 (47.7%) patients with relapsed/metastatic disease. Overall biochemical response is documented by mean and median prostate specific antigen values, which changed from 15.29 to 4.00 ng/ml, respectively, before to mean 4.74 ng/ml and median 0.81 ng/ml after therapy (P=0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In our series, Cho-PET had a significant effect on radiotherapy planning of patients affected by prostate cancer, determining a change in management in 48.8% of cases, considering all therapeutic indications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>D'Agostino</LastName>
                    <ForeName>Giuseppe R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopci</LastName>
                    <ForeName>Egesta</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuclear Medicine, Humanitas Clinical and Research Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Brina</LastName>
                    <ForeName>Lucia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franzese</LastName>
                    <ForeName>Ciro</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomatis</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castello</LastName>
                    <ForeName>Angelo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuclear Medicine, Humanitas Clinical and Research Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franceschini</LastName>
                    <ForeName>Davide</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Navarria</LastName>
                    <ForeName>Pierina</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiti</LastName>
                    <ForeName>Arturo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuclear Medicine, Humanitas Clinical and Research Hospital.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scorsetti</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Radiotherapy and Radiosurgery.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nucl Med Commun</MedlineTA>
            <NlmUniqueID>8201017</NlmUniqueID>
            <ISSNLinking>0143-3636</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124599</ArticleId>
            <ArticleId IdType="doi">10.1097/MNM.0000000000000894</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30124517</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-6586</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in urology</Title>
                <ISOAbbreviation>Curr Opin Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostate focal therapy: the rule or exception?</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOU.0000000000000540</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Prostate focal therapy has the potential to preserve urinary and sexual function while eliminating clinically significant cancer in a subset of men with low-volume, organ-confined prostate cancer. This systematic review aims to examine current evidence to determine the efficacy and safety of focal therapy for standard clinical application.</AbstractText>
                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Focal therapy reduces the rate of cancer progression and conversion to radical therapy in men on active surveillance for prostate cancer. As a strategy, success in focal therapy is heavily dependent on the use of imaging and targeted biopsies. Despite advances in these areas, there remains a small but significant risk of under-detecting clinically significant cancer. Similarly, under-estimation of tumor volume may contribute to infield recurrences and close attention must be paid to the ablation margin. Although long-term oncological outcomes remain lacking, focal therapy has a low complication rate, minimal impact on urinary continence and a moderate impact on erectile function.</AbstractText>
                <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">With the appropriate expertise in imaging, targeted biopsy and targeted ablation, focal therapy is a good option in men with low-intermediate risk cancer who are willing to maximize their urinary and sexual function. However, close posttreatment surveillance and the possibility of conversion to whole gland therapy must be accepted.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tay</LastName>
                    <ForeName>Kae Jack</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Singapore General Hospital, SingHealth Duke-NUS Academic Medical Center, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Opin Urol</MedlineTA>
            <NlmUniqueID>9200621</NlmUniqueID>
            <ISSNLinking>0963-0643</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124517</ArticleId>
            <ArticleId IdType="doi">10.1097/MOU.0000000000000540</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30124346</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7674</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on therapeutic patents</Title>
                <ISOAbbreviation>Expert Opin Ther Pat</ISOAbbreviation>
            </Journal>
            <ArticleTitle>5-HT1A receptor ligands and their therapeutic applications: review of new patents.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13543776.2018.1514011</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">5-HT<sub>1A</sub>R was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT<sub>1A</sub>R neurotransmission are linked to several psychiatric disorders, including anxiety, depression and movement disorders. Areas covered: The current review covers patent literature published between January 2012 and May 2018. Queries were performed on Espacenet, SciFinder, clinicaltrials.gov, pharmacodia.com and the websites of pharmaceutical companies. Expert opinion: Several novel therapeutic applications have been proposed for 5-HT<sub>1A</sub>R ligands, i.e., prostate cancer treatment, gastrointestinal and cardiopulmonary disorders, facilitation of urination and defecation and L-DOPA-induced dyskinesia. Interestingly, no patent application has been filed by Big Pharma companies, while numerous research is being conducted in smaller companies and academia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Staroń</LastName>
                    <ForeName>Jakub</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Institute of Pharmacology, Polish Academy of Sciences , Kraków , Poland .</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bugno</LastName>
                    <ForeName>Ryszard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Institute of Pharmacology, Polish Academy of Sciences , Kraków , Poland .</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hogendorf</LastName>
                    <ForeName>Adam S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Institute of Pharmacology, Polish Academy of Sciences , Kraków , Poland .</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bojarski</LastName>
                    <ForeName>Andrzej J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Institute of Pharmacology, Polish Academy of Sciences , Kraków , Poland .</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Ther Pat</MedlineTA>
            <NlmUniqueID>9516419</NlmUniqueID>
            <ISSNLinking>1354-3776</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-HT1A</Keyword>
            <Keyword MajorTopicYN="N">agonist</Keyword>
            <Keyword MajorTopicYN="N">antagonist</Keyword>
            <Keyword MajorTopicYN="N">serotonin modulator</Keyword>
            <Keyword MajorTopicYN="N">serotonin receptor</Keyword>
            <Keyword MajorTopicYN="N">therapeutic patent</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30124346</ArticleId>
            <ArticleId IdType="doi">10.1080/13543776.2018.1514011</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30123711</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2167-8359</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PeerJ</Title>
                <ISOAbbreviation>PeerJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e5386</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.5386</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Thiazolidinediones (TZDs), also called glitazones, are five-membered carbon ring molecules commonly used for the management of insulin resistance and type 2 diabetes. Recently, many prospective studies have also documented the impact of these compounds as anti-proliferative agents, though several negative side effects such as hepatotoxicity, water retention and cardiac issues have been reported. In this work, we synthesized twenty-six new TZD analogues where the thiazolidinone moiety is directly connected to an N-heterocyclic ring in order to lower their toxic effects.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">By adopting a widely applicable synthetic method, twenty-six TZD derivatives were synthesized and tested for their antiproliferative activity in MTT and Wound healing assays with PC3 (prostate cancer) and MCF-7 (breast cancer) cells.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Three compounds, out of twenty-six, significantly decreased cellular viability and migration, and these effects were even more pronounced when compared with rosiglitazone, a well-known member of the TZD class of antidiabetic agents. As revealed by Western blot analysis, part of this antiproliferative effect was supported by apoptosis studies evaluating BCL-xL and C-PARP protein expression.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Our data highlight the promising potential of these TZD derivatives as anti-proliferative agents for the treatment of prostate and breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Corigliano</LastName>
                    <ForeName>Domenica M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Syed</LastName>
                    <ForeName>Riyaz</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Messineo</LastName>
                    <ForeName>Sebastiano</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lupia</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Rahul</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food Science and Biotechnology, Dongguk University, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>Chittireddy Venkata Ramana</ForeName>
                    <Initials>CVR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dubey</LastName>
                    <ForeName>Pramod K</ForeName>
                    <Initials>PK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colica</LastName>
                    <ForeName>Carmela</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNR, IBFM UOS of Germaneto, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amato</LastName>
                    <ForeName>Rosario</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Sarro</LastName>
                    <ForeName>Giovambattista</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alcaro</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Indrasena</LastName>
                    <ForeName>Adisherla</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brunetti</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences, University &quot;Magna Græcia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PeerJ</MedlineTA>
            <NlmUniqueID>101603425</NlmUniqueID>
            <ISSNLinking>2167-8359</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Relat Cancer. 2014;21(6):R461-71</RefSource>
                <PMID Version="1">25273809</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuro Endocrinol Lett. 2005 Feb;26(1):51-4</RefSource>
                <PMID Version="1">15726020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1996 Jan 1;97(1):258-62</RefSource>
                <PMID Version="1">8550844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Immunother. 2013 Feb;62(2):225-36</RefSource>
                <PMID Version="1">22864396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Feb 25;280(8):6742-51</RefSource>
                <PMID Version="1">15569667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1993 Sep;92(3):1288-95</RefSource>
                <PMID Version="1">8376587</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PPAR Res. 2012;2012:929052</RefSource>
                <PMID Version="1">22448169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrine. 2018 Mar;59(3):622-632</RefSource>
                <PMID Version="1">28866834</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Relat Cancer. 2008 Mar;15(1):325-35</RefSource>
                <PMID Version="1">18310298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Drug Discov. 2015 Dec;10(12):1259-70</RefSource>
                <PMID Version="1">26479699</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2016 Mar 30;352:i1541</RefSource>
                <PMID Version="1">27029385</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2017 Jan 10;8(2):3042-3048</RefSource>
                <PMID Version="1">27936468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Care. 2011 Apr;34(4):916-22</RefSource>
                <PMID Version="1">21447663</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2012 Sep;26(9):1578-89</RefSource>
                <PMID Version="1">22745191</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS Lett. 2002 Oct 23;530(1-3):104-8</RefSource>
                <PMID Version="1">12387875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2009 Nov;41(11):2189-203</RefSource>
                <PMID Version="1">19389484</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):561-566</RefSource>
                <PMID Version="1">29295932</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2013 Oct 3;369(14):1285-7</RefSource>
                <PMID Version="1">23992603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2014 Oct 15;5(19):9039-48</RefSource>
                <PMID Version="1">25344863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Breast Cancer Res. 2011 Aug 12;13(4):215</RefSource>
                <PMID Version="1">21884641</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmazie. 2016 Mar;71(3):154-7</RefSource>
                <PMID Version="1">27183711</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2011 Nov;71(15):1668-79</RefSource>
                <PMID Version="1">21432867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Endocrinol (Lausanne). 2015 Jan 13;5:237</RefSource>
                <PMID Version="1">25628604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Physiol Biochem. 2016;39(5):1863-1876</RefSource>
                <PMID Version="1">27771704</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioorg Med Chem. 2002 Apr;10(4):1077-84</RefSource>
                <PMID Version="1">11836118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Endocrinol (Lausanne). 2018 Jul 03;9:357</RefSource>
                <PMID Version="1">30034366</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1998 Sep 10;395(6698):137-43</RefSource>
                <PMID Version="1">9744270</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2015 Nov 24;6(37):39398-407</RefSource>
                <PMID Version="1">26583576</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Ther. 2008;6(A):25-34</RefSource>
                <PMID Version="1">19079765</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Metab Syndr. 2015 Jan-Mar;9(1):46-50</RefSource>
                <PMID Version="1">25450819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Metab. 2014 Oct 7;20(4):573-91</RefSource>
                <PMID Version="1">25242225</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Care. 2011 Jun;34(6):1369-71</RefSource>
                <PMID Version="1">21515844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2007 Dec 12;298(22):2634-43</RefSource>
                <PMID Version="1">18073359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2013 Dec;154(12):4803-13</RefSource>
                <PMID Version="1">24064359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Metab Syndr Relat Disord. 2014 Feb;12(1):25-30</RefSource>
                <PMID Version="1">24148075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Metab Res Rev. 2018 Feb;34(2):</RefSource>
                <PMID Version="1">29125710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(12):e28157</RefSource>
                <PMID Version="1">22164237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2006 Feb;5(2):430-7</RefSource>
                <PMID Version="1">16505118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2014 Nov 15;5(21):10503-17</RefSource>
                <PMID Version="1">25361177</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Saf. 2013 Aug;36(8):643-9</RefSource>
                <PMID Version="1">23797604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioorg Chem. 2018 Apr;77:548-567</RefSource>
                <PMID Version="1">29475164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Cell Biol. 2008 Jun;20(3):294-302</RefSource>
                <PMID Version="1">18450439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Saudi J Gastroenterol. 2018 Mar-Apr;24(2):75-81</RefSource>
                <PMID Version="1">29637913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biomed Pharmacother. 2016 Oct;83:349-361</RefSource>
                <PMID Version="1">27416556</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2005 Aug 19;334(1):176-82</RefSource>
                <PMID Version="1">15993383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Diabetes Res. 2012;2012:789174</RefSource>
                <PMID Version="1">22701472</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Feb 15;61(4):1699-706</RefSource>
                <PMID Version="1">11245486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mediators Inflamm. 2014;2014:750860</RefSource>
                <PMID Version="1">24729662</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">BCL-xL</Keyword>
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Cell proliferation</Keyword>
            <Keyword MajorTopicYN="N">Cellular viability</Keyword>
            <Keyword MajorTopicYN="N">Thiazolidinediones</Keyword>
            <Keyword MajorTopicYN="N">Wound healing</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare there are no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30123711</ArticleId>
            <ArticleId IdType="doi">10.7717/peerj.5386</ArticleId>
            <ArticleId IdType="pii">5386</ArticleId>
            <ArticleId IdType="pmc">PMC6087425</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30123333</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1817-1737</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <MedlineDate>2018 Jul-Sep</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of thoracic medicine</Title>
                <ISOAbbreviation>Ann Thorac Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The pattern of bone involvement, management, and outcomes in patients with nonsmall cell lung cancer: A retrospective study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>150-155</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/atm.ATM_385_17</ELocationID>
            <Abstract>
                <AbstractText Label="CONTEXT AND AIM" NlmCategory="UNASSIGNED">The skeleton is a frequent site for metastasis in patients with breast, lung, and prostate cancer. Bone metastasis compromises skeletal integrity leading to skeletal-related events (SREs). This study aims at estimating the prevalence of bone metastasis in lung cancer and describing types of bone involvement, management, outcomes, and overall survival.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed the charts of 259 patients with nonsmall cell lung cancer who consulted the Department of Medical Oncology at our institution between January 2002 and December 2012. We documented their lung cancer characteristics, presence of skeletal metastases, management types, outcome parameters, and survival status.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 116 patients (58.6%) were diagnosed with bone metastasis. The most common site of metastasis was the spine. The most common SREs were bone pain (44%) and need for radiotherapy (25.9%). Patients with adenocarcinoma (<i>P</i> = 0.002) and concomitant liver metastasis (<i>P</i> = 0.013) tended to have more incidence of bone metastasis. Survival rates were (36%) at 1 year, and (3%) at 5 years. Metastasis to the bone did not impact patients' survival. Patients tended to have worse survival in the presence of concomitant bone and liver metastases (<i>P</i> = 0.012), older age (<i>P</i> = 0.024), lower limb metastasis (<i>P</i> = 0.014), hypercalcemia (<i>P</i> = 0.001), and not receiving calcium therapy (<i>P</i> = 0.011).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Metastatic bone disease is considered a huge burden on patients, clinicians, and the society. The majority of bone metastasis patients will experience SREs. Most SREs predict poor prognosis. Supportive therapy to overcome the reasons for poor prognosis may improve patients' survival and quality of life.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jazieh</LastName>
                    <ForeName>Abdulrahman M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>AlSumai</LastName>
                    <ForeName>Thuraya S</ForeName>
                    <Initials>TS</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>Yosra Z</ForeName>
                    <Initials>YZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheblaq</LastName>
                    <ForeName>Nagham R</ForeName>
                    <Initials>NR</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alkaiyat</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Ann Thorac Med</MedlineTA>
            <NlmUniqueID>101280721</NlmUniqueID>
            <ISSNLinking>1998-3557</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2002 Aug;2(8):584-93</RefSource>
                <PMID Version="1">12154351</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Thorac Oncol. 2014 Feb;9(2):231-8</RefSource>
                <PMID Version="1">24419421</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lung Cancer. 1997 Mar;16(2-3):133-43</RefSource>
                <PMID Version="1">9152945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Rep. 2015 Dec 22;5:18670</RefSource>
                <PMID Version="1">26690845</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Apr 15;350(16):1655-64</RefSource>
                <PMID Version="1">15084698</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108</RefSource>
                <PMID Version="1">15761078</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2007 Jun 1;109(11):2334-42</RefSource>
                <PMID Version="1">17450591</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Epidemiol. 2012;4:87-93</RefSource>
                <PMID Version="1">22570568</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Thorac Med. 2010 Jan;5(1):30-6</RefSource>
                <PMID Version="1">20351958</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncol Lett. 2015 Jun;9(6):2706-2712</RefSource>
                <PMID Version="1">26137132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lung Cancer. 2007 Aug;57(2):229-32</RefSource>
                <PMID Version="1">17451841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Cancer. 2014 Jun 10;14:416</RefSource>
                <PMID Version="1">24913188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Epidemiol. 1997 Feb;26(1):14-23</RefSource>
                <PMID Version="1">9126499</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adenocarcinoma</Keyword>
            <Keyword MajorTopicYN="N">bone metastasis</Keyword>
            <Keyword MajorTopicYN="N">nonsmall cell lung cancer</Keyword>
            <Keyword MajorTopicYN="N">skeletal-related events</Keyword>
        </KeywordList>
        <CoiStatement>There are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30123333</ArticleId>
            <ArticleId IdType="doi">10.4103/atm.ATM_385_17</ArticleId>
            <ArticleId IdType="pii">ATM-13-150</ArticleId>
            <ArticleId IdType="pmc">PMC6073785</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30122985</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1179-1322</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>10</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer management and research</Title>
                <ISOAbbreviation>Cancer Manag Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2357-2367</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CMAR.S164856</ELocationID>
            <Abstract>
                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">The purpose of this study was to provide evidence-based recommendations of intermittent androgen deprivation therapy (IADT) compared with continuous androgen deprivation therapy (CADT) for men with prostate cancer (PCA).</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We conducted a comprehensive search in MEDLINE, EMBASE, The Cochrane Library, CINAHL, and ECONLIT, from the database inception to December 2017. We adhered to the Grading of Recommendations, Assessment, Development and Evaluation framework to assess the quality of the evidence and to formulate recommendations.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">We included one systematic review with 15 trials as well as three additional studies that assessed IADT versus CADT, all of them focused on PCA patients in advanced stages. The findings did not show differences for critical and important outcomes, including adverse events. Trials reported the benefits of IADT in terms of selected domains of health-related quality of life, although with high heterogeneity. Evidence quality was considered moderate or low for most of the assessed outcomes. We identified a patient preference study reporting a high preference for IADT, due to issues related to quality of life, general well-being, and side effects, among others. We did not identify economic studies comparing these regimes. We formulate four recommendations: one no-recommendation, one conditional recommendation, and two good practice points.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">For men in early stages of PCA, it is not possible to make any recommendation about the preferable use of IADT or CADT due to the lack of available evidence. For men in advanced stages of the disease, an IADT should be considered as soon as clinically reasonable (weak recommendation and low certainty of the evidence). Clinicians should discuss the risks and benefits of IADT and CADT with their patients, taking into account their values and preferences.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bonfill</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER of Epidemiology and Public Health, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Iberoamerican Cochrane Centre, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arevalo-Rodriguez</LastName>
                    <ForeName>Ingrid</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación en Salud Pública y Epidemiología Clínica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador, inarev7@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Hospital Ramon y Cajal (IRYCIS), Clinical Biostatistics Unit, CIBER of Epidemiology and Public Health, Madrid, Spain, inarev7@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez García</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Iberoamerican Cochrane Centre, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quintana</LastName>
                    <ForeName>Maria Jesús</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER of Epidemiology and Public Health, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buitrago-Garcia</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación en Salud Pública y Epidemiología Clínica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador, inarev7@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lobos Urbina</LastName>
                    <ForeName>Diego</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pontificia Universidad Católica de Chile, Santiago, Chile.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cordero</LastName>
                    <ForeName>José Antonio</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Health Sciences Blanquerna - Ramon Llull University, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Cancer Manag Res</MedlineTA>
            <NlmUniqueID>101512700</NlmUniqueID>
            <ISSNLinking>1179-1322</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA Oncol. 2015 Dec;1(9):1261-9</RefSource>
                <PMID Version="1">26378418</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 2006 Feb 27;166(4):465-71</RefSource>
                <PMID Version="1">16505268</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Asian J Androl. 2012 Mar;14(2):187-92</RefSource>
                <PMID Version="1">22231300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Radiol. 2012 Apr;22(4):746-57</RefSource>
                <PMID Version="1">22322308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1990 Apr 15;50(8):2275-82</RefSource>
                <PMID Version="1">2317815</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Oncol. 2014 Jun;21(3):e457-65</RefSource>
                <PMID Version="1">24940106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Med Res Methodol. 2007 Feb 15;7:10</RefSource>
                <PMID Version="1">17302989</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Med Res Methodol. 2015 Jul 31;15:57</RefSource>
                <PMID Version="1">26227021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2014 Apr;65(4):704-9</RefSource>
                <PMID Version="1">23433805</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol Focus. 2016 Dec;2(5):514-521</RefSource>
                <PMID Version="1">28723517</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Urol. 2005;7 Suppl 5:S37-43</RefSource>
                <PMID Version="1">16985883</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2013 Apr;14(4):306-16</RefSource>
                <PMID Version="1">23465742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CMAJ. 2014 Nov 4;186(16):1211-9</RefSource>
                <PMID Version="1">25200758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2016 Apr;69(4):720-727</RefSource>
                <PMID Version="1">26520703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Support Care Cancer. 2013 Oct;21(10):2899-911</RefSource>
                <PMID Version="1">23852408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>ESMO Open. 2016 Mar 18;1(2):e000040</RefSource>
                <PMID Version="1">27843596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2016 May;34(5):233.e17-25</RefSource>
                <PMID Version="1">26705101</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2013 Jan 15;108(1):9-13</RefSource>
                <PMID Version="1">23321508</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Epidemiol. 2011 Apr;64(4):383-94</RefSource>
                <PMID Version="1">21195583</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2013 May 28;108(10):2194</RefSource>
                <PMID Version="1">23632481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2012 Jan;61(1):11-25</RefSource>
                <PMID Version="1">21871711</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Transl Oncol. 2017 Mar;19(3):373-378</RefSource>
                <PMID Version="1">27770397</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61</RefSource>
                <PMID Version="1">26656522</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2013 May;24(5):1141-62</RefSource>
                <PMID Version="1">23303340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2012 Sep;15(3):296-302</RefSource>
                <PMID Version="1">22733160</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GRADE approach</Keyword>
            <Keyword MajorTopicYN="N">evidence-based medicine</Keyword>
            <Keyword MajorTopicYN="N">hormone deprivation therapy</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">prostate neoplasm</Keyword>
        </KeywordList>
        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30122985</ArticleId>
            <ArticleId IdType="doi">10.2147/CMAR.S164856</ArticleId>
            <ArticleId IdType="pii">cmar-10-2357</ArticleId>
            <ArticleId IdType="pmc">PMC6080876</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30122947</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1178-6930</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>OncoTargets and therapy</Title>
                <ISOAbbreviation>Onco Targets Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4551-4558</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/OTT.S151314</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">This study investigated the prognostic value of inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy with or without neoadjuvant androgen deprivation therapy (ADT).</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Inflammation-based scores included the neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and plasma fibrinogen. A total of 440 patients (380 patients treated without neoadjuvant ADT and 60 patients treated with neoadjuvant ADT) were retrospectively evaluated in our medical center. Receiver operating characteristic (ROC) curves and Kaplan-Meier analyses were performed to compare the prognostic value of these scores. Univariate and multivariate Cox regression analyses were also performed.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">For all patients, dNLR and PNI were predictive of biochemical recurrence (.=0.041 and &lt;0.001, respectively). Subgroup analysis of neoadjuvant strategies was also performed. For patients treated with neoadjuvant ADT, no selected inflammation-based scores were significantly correlated with biochemical recurrence (.&gt;0.05). In contrast, for patients treated without neoadjuvant ADT, NLR (area under the ROC curve [AUC] =0.576, <i>P</i>=0.033), dNLR (.=0.585 and 0.017), PLR (AUC =0.582, <i>P</i>=0.024), and PNI (AUC =0.622, <i>P</i>&lt;0.001) were predictive of biochemical recurrence. Kaplan-Meier analyses showed that dNLR (.=0.044), PLR (.=0.028), and PNI (.=0.004) were significantly associated with biochemical recurrence. Based on multivariable models, PNI was an independent predictor of biochemical recurrence (hazard ratio: 0.56, 95% confidence interval: 0.35-0.90, <i>P</i>=0.016).</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">High dNLR, high PLR, and low PNI were associated with poor biochemical recurrence-free survival in patients undergoing radical prostatectomy for high-risk localized prostate cancer not treated with neoadjuvant ADT. In particular, PNI was an independent prognostic factor for biochemical recurrence.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shu</LastName>
                    <ForeName>Kunpeng</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institute of Urology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Surgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Junru</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Institute of Urology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wenbin</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, liwenbinchn@foxmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Ke</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thyroid and Parathyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China, jkhx2015@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Onco Targets Ther</MedlineTA>
            <NlmUniqueID>101514322</NlmUniqueID>
            <ISSNLinking>1178-6930</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Asian Pac J Cancer Prev. 2015;16(5):1813-6</RefSource>
                <PMID Version="1">25773829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2018 May 20;36(15):1498-1504</RefSource>
                <PMID Version="1">29624463</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Braz J Urol. 2013 Sep-Oct;39(5):639-46; discussion 647-8</RefSource>
                <PMID Version="1">24267107</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Urol. 2008 May;18(3):315-9</RefSource>
                <PMID Version="1">18382242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Urol. 2016 Jun;34(6):821-7</RefSource>
                <PMID Version="1">26449784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2018 Jan;68(1):7-30</RefSource>
                <PMID Version="1">29313949</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Clin Nutr Metab Care. 2005 May;8(3):265-9</RefSource>
                <PMID Version="1">15809528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Surg. 1980 Jan;139(1):160-7</RefSource>
                <PMID Version="1">7350839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2011 Apr 1;71(7):2411-6</RefSource>
                <PMID Version="1">21427354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Gastroenterol. 2015 Nov 21;21(43):12410-20</RefSource>
                <PMID Version="1">26604648</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2014 Nov 1;120(21):3346-52</RefSource>
                <PMID Version="1">24995769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2006 Mar 13;94(5):637-41</RefSource>
                <PMID Version="1">16479253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Dec 19-26;420(6917):860-7</RefSource>
                <PMID Version="1">12490959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1996 Apr 5;272(5258):60-6</RefSource>
                <PMID Version="1">8600538</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Jpn J Clin Oncol. 2011 May;41(5):656-62</RefSource>
                <PMID Version="1">21430020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2017 Sep;77(12):1233-1241</RefSource>
                <PMID Version="1">28752926</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Immunother. 2009 Dec;58(12):1919-33</RefSource>
                <PMID Version="1">19221747</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2013 Jul 1;:null</RefSource>
                <PMID Version="1">23863628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2015 Apr;26(4):743-9</RefSource>
                <PMID Version="1">25515657</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncologist. 2012;17(12):1508-14</RefSource>
                <PMID Version="1">22971522</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32</RefSource>
                <PMID Version="1">26808342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Inflamm (Lond). 2016 Nov 25;13:35</RefSource>
                <PMID Version="1">27924136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg. 2009 May;249(5):788-93</RefSource>
                <PMID Version="1">19387324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2011 Aug 4;118(5):1359-69</RefSource>
                <PMID Version="1">21680800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2016 Sep;19(3):298-304</RefSource>
                <PMID Version="1">27349499</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJU Int. 2014 Dec;114(6b):E11-E17</RefSource>
                <PMID Version="1">24529213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>
                <PMID Version="1">19097774</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2015 May;33(5):201.e9-16</RefSource>
                <PMID Version="1">25769845</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2016 Jun;19(2):209-15</RefSource>
                <PMID Version="1">26951714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2001 Feb 17;357(9255):539-45</RefSource>
                <PMID Version="1">11229684</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genitourin Cancer. 2014 Oct;12(5):317-24</RefSource>
                <PMID Version="1">24806399</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2014 May 29;106(6):dju124</RefSource>
                <PMID Version="1">24875653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Cancer. 2016 May 24;16:329</RefSource>
                <PMID Version="1">27222030</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1001-5</RefSource>
                <PMID Version="1">6438478</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Mol Sci. 2017 Feb 11;18(2):</RefSource>
                <PMID Version="1">28208664</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2011 Feb;11(2):123-34</RefSource>
                <PMID Version="1">21258396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Urol. 2015 Oct;33(10):1467-73</RefSource>
                <PMID Version="1">25475065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1962 Nov 17;196:651-5</RefSource>
                <PMID Version="1">13949634</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1974 Nov 11;230(6):858-60</RefSource>
                <PMID Version="1">4213823</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1973 Apr 1;137(4):932-42</RefSource>
                <PMID Version="1">4632629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer Res Clin Oncol. 2014 Sep;140(9):1537-49</RefSource>
                <PMID Version="1">24878931</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2009 Jan 1;457(7225):36-7</RefSource>
                <PMID Version="1">19122629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82</RefSource>
                <PMID Version="1">17329145</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">biochemical recurrence</Keyword>
            <Keyword MajorTopicYN="N">derived neutrophil-to-lymphocyte ratio</Keyword>
            <Keyword MajorTopicYN="N">platelet-to-lymphocyte ratio</Keyword>
            <Keyword MajorTopicYN="N">prognostic nutritional index</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30122947</ArticleId>
            <ArticleId IdType="doi">10.2147/OTT.S151314</ArticleId>
            <ArticleId IdType="pii">ott-11-4551</ArticleId>
            <ArticleId IdType="pmc">PMC6082347</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30122344</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2496</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Urologic oncology</Title>
                <ISOAbbreviation>Urol. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1078-1439(18)30252-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.urolonc.2018.07.004</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this study was to investigate the utility of pre-treatment multiparametric magnetic resonance imaging (mpMRI) in a modern cohort of intermediate and high-risk prostate cancer patients treated with primary radiotherapy.</AbstractText>
                <AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">One hundred twenty three men with National Comprehensive Cancer Network (NCCN) intermediate or high-risk prostate cancer were treated with primary EBRT and/or brachytherapy and had evaluable pre-treatment mpMRI with endorectal coil. Images were assessed for the presence of radiographic extraprostatic extension (rEPE), seminal vesicle invasion (rSVI), lymph node involvement (LNI), sextant involvement, and largest axial tumor diameter. Imaging characteristics were analyzed along with clinical risk factors against freedom from biochemical failure (FFBF). Median follow-up time was 50 months.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen (11%) men developed biochemical failure. The 5-year FFBF was 94% in intermediate-risk patients and 82% in high-risk patients (p &lt; 0.01). mpMRI findings including rEPE (29% vs. 66%, p &lt; 0.01), rSVI (6% vs. 25%, p &lt; 0.01), LNI (1% vs. 30%, p &lt; 0.01), and largest axial tumor size&gt; 15 mm (27% vs. 48%, p = 0.02) were identified in men with intermediate vs. high risk prostate cancer, respectively. mpMRI features associated with 5-y FFBF biochemical failure on univariate analysis included rEPE (80% vs 98%), rSVI (55% vs. 96%), LNI (65% vs. 93%), and largest axial tumor size &gt;15 mm (81% vs. 94%, all p &lt; 0.01). Men without any high risk MRI finding had a 5-y FFBF of 100% vs. 81% (p &lt; 0.01). Adverse imaging features (HR 8.9, p &lt; 0.01) were independently associated with biochemical failure in a bivariate model analyzed alongside clinical risk category (HR 3.2, p = 0.04).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pre-treatment mpMRI findings are strongly associated with biochemical outcomes in a modern cohort of intermediate and high-risk patients treated with primary radiotherapy. mpMRI may aid risk stratification beyond clinical risk factors in men treated with radiation therapy; further study is warranted to better understand how mpMRI can be used to individualize therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kauffmann</LastName>
                    <ForeName>Greg</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arif</LastName>
                    <ForeName>Fauzia</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Pritesh</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University of Chicago, Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oto</LastName>
                    <ForeName>Aytek</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University of Chicago, Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liauw</LastName>
                    <ForeName>Stanley L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. Electronic address: sliauw@radonc.uchicago.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Oncol</MedlineTA>
            <NlmUniqueID>9805460</NlmUniqueID>
            <ISSNLinking>1078-1439</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Multiparametric magnetic resonance imaging</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Radiation therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30122344</ArticleId>
            <ArticleId IdType="pii">S1078-1439(18)30252-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.urolonc.2018.07.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30121970</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2092-7193</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Epidemiology and health</Title>
                <ISOAbbreviation>Epidemiol Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the US veterans with prostate cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.4178/epih.e2018040</ELocationID>
            <Abstract>
                <AbstractText Label="Objectives" NlmCategory="UNASSIGNED">We investigated whether androgen deprivation therapy use in prostate cancer patients is associated with decreased risks for second primary lung cancer in the US veterans.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Prostate cancer diagnoses among the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as two diagnoses made within 1 year were excluded from the analysis. Cancer free survival was estimated with Kaplan-Meier method and hazard ratios were estimated with Cox proportional hazard model.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among the 63,141 patients with prostate cancer identified, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and median follow-up period was 28 months. ADT use was associated with longer lung cancer free survival in prostate cancer patients (logrank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15%, 21%, and 24% after 1, 2, and 3 years, respectively.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Androgen deprivation therapy in prostate cancer patients is potentially associated with decreased second primary lung cancer risk among the US veterans.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Kyungsuk</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Fox Chase Cancer Center, Philadelphia, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jong Chul</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Hyunseok</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brandes</LastName>
                    <ForeName>Johann</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Atlanta Veterans Affairs Medical Center, Atlanta, United States.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Medical Oncology, Emory University, Atlanta, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Epidemiol Health</MedlineTA>
            <NlmUniqueID>101519472</NlmUniqueID>
            <ISSNLinking>2092-7193</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">US veterans</Keyword>
            <Keyword MajorTopicYN="N">androgen deprivation therapy</Keyword>
            <Keyword MajorTopicYN="N">hormonal therapy</Keyword>
            <Keyword MajorTopicYN="N">lung cancer</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30121970</ArticleId>
            <ArticleId IdType="pii">epih.e2018040</ArticleId>
            <ArticleId IdType="doi">10.4178/epih.e2018040</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30121624</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-6821</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrine-related cancer</Title>
                <ISOAbbreviation>Endocr. Relat. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">ERC-18-0310</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1530/ERC-18-0310</ELocationID>
            <Abstract>
                <AbstractText>Patients with thyroid cancers refractory to radioiodine (RAI) treatment show a limited response to various therapeutic options and a low survival rate. The recent use of multikinase inhibitors has also met limited success. An alternative approach relies on drugs that induce cell differentiation, as the ensuing increased expression of the cotransporter for sodium and iodine (NIS) may partially restore sensitivity to radioiodine. The inhibition of the ERK1/2 pathway has shown some efficacy in this context. Aggressive thyroid tumors overexpress the isoform A of the insulin receptor (IR-A) and its ligand IGF-2; this IGF-2/IR-A loop is associated with de-differentiation and stem-like phenotype, resembling RAI refractory tumors. Importantly, IR-A has been shown to be positively modulated by the non-integrin collagen receptor DDR1 in human breast cancer. Using undifferentiated human thyroid cancer cells, we now evaluated the effects of DDR1 on IGF-2/IR-A loop and on markers of cell differentiation and stemness. DDR1 silencing or downregulation caused significant reduction of IR-A and IGF-2 expression, and concomitant increased levels of differentiation markers (NIS, Tg, TSH, TPO). Conversely, markers of epithelial-to-mesenchymal transition (Vimentin, Snail-2, Zeb1, Zeb2, and N-Cadherin) and stemness (OCT-4, SOX-2, ABCG2, and Nanog) decreased. These effects were collagen-independent. In contrast, overexpression of either DDR1 or its kinase inactive variant K618A DDR1 induced changes suggestive of less differentiated and stem-like phenotype. Collagen stimulation was uneffective. In conclusion, in poorly differentiated thyroid cancer, DDR1 silencing or downregulation blocks the IGF-2/IR-A autocrine loop and induces cellular differentiation. These results may open novel therapeutic approaches for thyroid cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vella</LastName>
                    <ForeName>Veronica</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>V Vella, Human and Social Sciences, University of Enna, Enna, 94100, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nicolosi</LastName>
                    <ForeName>Maria Luisa</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>M Nicolosi, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cantafio</LastName>
                    <ForeName>Patrizia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>P Cantafio, Department of Health Sciences, Universita degli Studi Magna Graecia di Catanzaro, Catanzaro, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Massimino</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>M Massimino, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lappano</LastName>
                    <ForeName>Rosamaria</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>R Lappano, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vigneri</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>P Vigneri, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciuni</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>R Ciuni, Unit of Thyroid and Neck Surgery, Vittorio Emanuele II, Hospital &quot;Policlinico Vittorio Emanuele&quot;, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gangemi</LastName>
                    <ForeName>Pietro</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>P Gangemi, Unit of Pathology, Vittorio Emanuele II, University Hospital &quot;Policlinico Vittorio Emanuele&quot;, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morrione</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>A Morrione, Department of Urology and Biology of Prostate Cancer Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Philadelphia, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malaguarnera</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>R Malaguarnera, Clinical and Experimental Medicine, University of Catanzaro, Catanzaro, Italy malaguarnera@unicz.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belfiore</LastName>
                    <ForeName>Antonino</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>A Belfiore, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Endocr Relat Cancer</MedlineTA>
            <NlmUniqueID>9436481</NlmUniqueID>
            <ISSNLinking>1351-0088</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30121624</ArticleId>
            <ArticleId IdType="pii">ERC-18-0310</ArticleId>
            <ArticleId IdType="doi">10.1530/ERC-18-0310</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30121492</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1967</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>70</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer treatment reviews</Title>
                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>De novo metastatic castration sensitive prostate cancer: State of art and future perspectives.</ArticleTitle>
            <Pagination>
                <MedlinePgn>67-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(18)30140-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2018.08.005</ELocationID>
            <Abstract>
                <AbstractText>De novo metastatic castration sensitive prostate cancer (mCSPC) accounts for about 4% of all prostate tumors in Western Countries. This condition has a heterogeneous biological e clinical behavior, ranging from indolent to aggressive and rapidly fatal forms. Recently, the therapeutic landscape for mCSPC has been broadly enriched; indeed robust evidence supports the addiction of chemotherapy (docetaxel) or abiraterone acetate to androgen deprivation therapy (ADT), the latter considered for long the unique standard of care. However, the prognostic stratification and the definition of the ideal therapeutic approach for the subpopulation of de novo mCSPC - albeit largely represented in pivotal clinical trials enrolling mCSPC patients - have yet to be prospectively outlined. The aim of this review was to describe the current state of art about clinical presentation, prognostic classification, and different therapeutic options available for de novo mCSPC patients. Furthermore, we shed light on ongoing clinical trials and future perspectives for this disease setting.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mosillo</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; Department of Radiological, Oncological, and Pathological Sciences, University &quot;Sapienza&quot; of Rome, Roma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iacovelli</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: roberto.iacovelli@alice.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciccarese</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fantinel</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bimbatti</LastName>
                    <ForeName>Davide</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brunelli</LastName>
                    <ForeName>Matteo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostics and Public Health, University of Verona, Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bisogno</LastName>
                    <ForeName>Iolanda</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kinspergher</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buttigliero</LastName>
                    <ForeName>Consuelo</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tucci</LastName>
                    <ForeName>Marcello</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caffo</LastName>
                    <ForeName>Orazio</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tortora</LastName>
                    <ForeName>Giampaolo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cancer Treat Rev</MedlineTA>
            <NlmUniqueID>7502030</NlmUniqueID>
            <ISSNLinking>0305-7372</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Abiraterone</Keyword>
            <Keyword MajorTopicYN="N">De novo metastatic castration sensitive prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Docetaxel</Keyword>
            <Keyword MajorTopicYN="N">Prognostic</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">mCSPC</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30121492</ArticleId>
            <ArticleId IdType="pii">S0305-7372(18)30140-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ctrv.2018.08.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30121008</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5586</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neoplasia (New York, N.Y.)</Title>
                <ISOAbbreviation>Neoplasia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>917-929</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1476-5586(18)30285-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neo.2018.07.003</ELocationID>
            <Abstract>
                <AbstractText>Current treatment strategies provide minimal results for patients with castration-resistant prostate cancer (CRPC). Attempts to target the androgen receptor have shown promise, but resistance ultimately develops, often due to androgen receptor reactivation. Understanding mechanisms of resistance, including androgen receptor reactivation, is crucial for development of more efficacious CRPC therapies. Here, we report that the RON receptor tyrosine kinase is highly expressed in the majority of human hormone-refractory prostate cancers. Further, we show that exogenous expression of RON in human and murine prostate cancer cells circumvents sensitivity to androgen deprivation and promotes prostate cancer cell growth in both in vivo and in vitro settings. Conversely, RON loss induces sensitivity of CRPC cells to androgen deprivation. Mechanistically, we demonstrate that RON overexpression leads to activation of multiple oncogenic transcription factors (namely, β-catenin and NF-κB), which are sufficient to drive androgen receptor nuclear localization and activation of AR responsive genes under conditions of androgen deprivation and support castration-resistant growth. In total, this study demonstrates the functional significance of RON during prostate cancer progression and provides a strong rationale for targeting RON signaling in prostate cancer as a means to limit resistance to androgen deprivation therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Nicholas E</ForeName>
                    <Initials>NE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paluch</LastName>
                    <ForeName>Andrew M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nashu</LastName>
                    <ForeName>Madison A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komurov</LastName>
                    <ForeName>Kakajan</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waltz</LastName>
                    <ForeName>Susan E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; Research Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45267, USA. Electronic address: susan.waltz@uc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>F31 CA165767</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F31 CA200390</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA125379</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 CA117846</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Neoplasia</MedlineTA>
            <NlmUniqueID>100886622</NlmUniqueID>
            <ISSNLinking>1476-5586</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2010 Jun 15;70(9):934-51</RefSource>
                <PMID Version="1">20209642</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prog Clin Biol Res. 1980;37:115-32</RefSource>
                <PMID Version="1">7384082</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2014 May 15;74(10):2763-72</RefSource>
                <PMID Version="1">24686169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2005 Nov;8(5):393-406</RefSource>
                <PMID Version="1">16286247</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6</RefSource>
                <PMID Version="1">14711987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2016 Sep 1;34(25):3005-13</RefSource>
                <PMID Version="1">27400947</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Ther Targets. 2012 Sep;16(9):921-31</RefSource>
                <PMID Version="1">22834780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2005 Mar 15;11(6):2222-8</RefSource>
                <PMID Version="1">15788670</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2011 May;53(5):1618-28</RefSource>
                <PMID Version="1">21520175</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2016 Mar 22;7(12):14048-63</RefSource>
                <PMID Version="1">26872377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2010 Feb 2;102(3):570-6</RefSource>
                <PMID Version="1">20068566</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2015 Apr 2;34(14):1745-57</RefSource>
                <PMID Version="1">24837363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Mens Health. 2013 Apr;31(1):36-46</RefSource>
                <PMID Version="1">23658864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2017 Jul 22;8(35):58918-58933</RefSource>
                <PMID Version="1">28938607</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 Jun 1;67(11):5117-25</RefSource>
                <PMID Version="1">17545589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1985 Mar;51(3):419-23</RefSource>
                <PMID Version="1">3970818</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2011 Aug 25;30(34):3694-704</RefSource>
                <PMID Version="1">21423209</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Sep 27;367(13):1187-97</RefSource>
                <PMID Version="1">22894553</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate. 2012 May 1;72(6):587-91</RefSource>
                <PMID Version="1">21796655</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2005 Dec 15;65(24):11565-71</RefSource>
                <PMID Version="1">16357166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 2009 Mar 12;52(5):1251-4</RefSource>
                <PMID Version="1">19260711</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2012 Jan 1;314(1):92-101</RefSource>
                <PMID Version="1">22004727</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Innate Immun. 2011 Dec;17(6):499-507</RefSource>
                <PMID Version="1">21088048</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Cell. 2016 Jan;29(1):22-9</RefSource>
                <PMID Version="1">26250899</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Chromosomes Cancer. 2009 Apr;48(4):366-80</RefSource>
                <PMID Version="1">19156837</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jul 12;487(7406):239-43</RefSource>
                <PMID Version="1">22722839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Shock. 2010 Feb;33(2):197-204</RefSource>
                <PMID Version="1">19487969</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Mar 23;276(12):8865-74</RefSource>
                <PMID Version="1">11116146</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34</RefSource>
                <PMID Version="1">16203770</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2014 Feb;65(2):467-79</RefSource>
                <PMID Version="1">24321502</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Mar 11;464(7286):302-5</RefSource>
                <PMID Version="1">20220849</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Mar 29;277(13):11336-44</RefSource>
                <PMID Version="1">11792709</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2014 Jul 30;5(14):5547-58</RefSource>
                <PMID Version="1">24980820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1994 May 15;54(10):2577-81</RefSource>
                <PMID Version="1">8168083</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2011 May 26;364(21):1995-2005</RefSource>
                <PMID Version="1">21612468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2009 Aug;175(2):489-99</RefSource>
                <PMID Version="1">19628766</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Cancer. 2007 Apr 12;7:64</RefSource>
                <PMID Version="1">17430594</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2010 Jan 14;29(2):214-26</RefSource>
                <PMID Version="1">19838218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2014 Jul;66(1):32-9</RefSource>
                <PMID Version="1">24054872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2000 Sep 1;60(17):4709-13</RefSource>
                <PMID Version="1">10987273</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2005 Feb 15;65(4):1285-93</RefSource>
                <PMID Version="1">15735014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1997 Aug 22;272(34):21096-103</RefSource>
                <PMID Version="1">9261113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2005 Oct 28;310(5748):644-8</RefSource>
                <PMID Version="1">16254181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1995 Nov 1;86(9):3394-403</RefSource>
                <PMID Version="1">7579443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2013 Mar 15;73(6):1752-63</RefSource>
                <PMID Version="1">23328584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatobiliary Pancreat Dis Int. 2014 Jun;13(3):281-92</RefSource>
                <PMID Version="1">24919612</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2011 Dec 15;30(50):4990-8</RefSource>
                <PMID Version="1">21625214</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharm Res. 2006 Aug;23(8):1641-58</RefSource>
                <PMID Version="1">16841196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Aug 15;61(16):5974-8</RefSource>
                <PMID Version="1">11507037</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Breast Cancer Res Treat. 2010 Oct;123(3):725-31</RefSource>
                <PMID Version="1">20020197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Aug 1;61(15):5692-6</RefSource>
                <PMID Version="1">11479199</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30121008</ArticleId>
            <ArticleId IdType="pii">S1476-5586(18)30285-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neo.2018.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC6098205</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30120817</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-7634</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer medicine</Title>
                <ISOAbbreviation>Cancer Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1655</ELocationID>
            <Abstract>
                <AbstractText>Prostate cancer (PCa) is one of the most common malignancies associated with bone metastases, and palliative radiation therapy (RT) is an effective treatment option. A total of 2641 patients were identified with PCa and bone metastases at diagnosis from 2010 to 2014 in the NCDB. Fractionation scheme was designated as short course ([SC-RT]: 8 Gy in 1 fraction and 20 Gy in 5 fractions) vs long course ([LC-RT]: 30 Gy in 10 fractions and 37.5 Gy in 15 fractions). Patient characteristics were correlated with fractionation scheme using logistic regression. Overall survival was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards models, and propensity score-matched analyses. A total of 2255 (85.4%) patients were included in the LC-RT group and 386 (14.6%) patients in the SC-RT group. SC-RT was more common in patients over 75 years age (odds ratio [OR]: 1.70, 95% confidence interval [CI] 1.32-2.20), treatment at an academic center (OR: 1.76, 1.20-2.57), living greater than 15 miles distance to treatment facility (OR: 1.38, 1.05-1.83), treatment to the rib (OR: 2.99, 1.36-6.60), and in 2014 (OR: 1.73, 1.19-2.51). RT to the spine was more commonly long course (P &lt; .0001). In the propensity-matched cohort, LC-RT was associated with improved OS (P &lt; .0001), but no OS difference was observed between 37.5 Gy and either 8 Gy in one fraction or 20 Gy in 5 fractions (P &gt; .5). LC-RT remains the most common treatment fractionation scheme for palliative bone metastases in PCa patients. Use of palliative SC-RT is increasing, particularly in more recent years, for older patients, treatment at academic centers, and with increasing distance from a treatment center.</AbstractText>
                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fischer-Valuck</LastName>
                    <ForeName>Benjamin W</ForeName>
                    <Initials>BW</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2348-9710</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baumann</LastName>
                    <ForeName>Brian C</ForeName>
                    <Initials>BC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Apicelli</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rao</LastName>
                    <ForeName>Yuan James</ForeName>
                    <Initials>YJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roach</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daly</LastName>
                    <ForeName>Mackenzie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dans</LastName>
                    <ForeName>Maria C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hospice &amp; Palliative Medicine, Department of Hospital Medicine, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>White</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hospice &amp; Palliative Medicine, Department of Hospital Medicine, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Contreras</LastName>
                    <ForeName>Jessika</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henke</LastName>
                    <ForeName>Lauren</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gay</LastName>
                    <ForeName>Hiram</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michalski</LastName>
                    <ForeName>Jeff M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abraham</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Med</MedlineTA>
            <NlmUniqueID>101595310</NlmUniqueID>
            <ISSNLinking>2045-7634</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">National Cancer Database</Keyword>
            <Keyword MajorTopicYN="N">metastatic prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">palliative radiation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30120817</ArticleId>
            <ArticleId IdType="doi">10.1002/cam4.1655</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30120678</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-2584</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International urology and nephrology</Title>
                <ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-018-1963-1</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of the study was to define clinical factors for successful treatment response and re-exposure to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">An mCRPC database of patients receiving first-line docetaxel and rechallenge courses was established. Several clinical factors were evaluated for prediction of treatment response. Multivariate cox-regression analysis was used to define pre-treatment and treatment factors for survival.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2005 and 2013, 94 patients with mCRPC were treated with docetaxel. Full data set and follow-up were available for 62 patients. Median follow-up was 84 m [interquartile range (IQR) 64-104 m]. Median biochemical progression-free survival (bPFS) and overall survival under docetaxel were 9 m (IQR 5-16 m) and 20 m (IQR 16-26 m), respectively. Partial PSA-response at first docetaxel-sequence (n = 62), rechallenge (n = 32), and third-sequence (n = 22) docetaxel was 48.4%, 31.6%, and 34.8%, respectively. Time from start of primary androgen deprivation to CRPC &gt; 47 m was the only independent pre-treatment parameter to predict improved overall survival (Hazard Ratio 0.48, p = 0.015). Interestingly, there was a strong trend for improved overall survival in patients with high Gleason Score (Hazard Ratio 0.58; p = 0.08). Partial PSA-response at docetaxel-rechallenge (Hazard Ratio 0.31; p = 0.008) and treatment-free interval &gt; 3 m (Hazard Ratio 3.49; p = 0.014) were the only independent predictive factors under taxane treatment for overall survival.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite novel hormonal drugs, docetaxel still plays an important role in the treatment of mCRPC. Patients with partial-PSA-response at rechallenge or a treatment-free interval &gt; 3 m benefit most from docetaxel re-exposure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thomas</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6511-965X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. thomasch@uni-mainz.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brandt</LastName>
                    <ForeName>Maximilian P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baldauf</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsaur</LastName>
                    <ForeName>Igor</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frees</LastName>
                    <ForeName>Sebastian</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borgmann</LastName>
                    <ForeName>Hendrik</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jäger</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartsch</LastName>
                    <ForeName>Georg</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>Meike</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dotzauer</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neisius</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haferkamp</LastName>
                    <ForeName>Axel</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int Urol Nephrol</MedlineTA>
            <NlmUniqueID>0262521</NlmUniqueID>
            <ISSNLinking>0301-1623</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Docetaxel</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Rechallenge</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30120678</ArticleId>
            <ArticleId IdType="doi">10.1007/s11255-018-1963-1</ArticleId>
            <ArticleId IdType="pii">10.1007/s11255-018-1963-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30120592</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1534-6269</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current oncology reports</Title>
                <ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.</ArticleTitle>
            <Pagination>
                <MedlinePgn>75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-018-0712-z</ELocationID>
            <Abstract>
                <AbstractText>Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although Sipuleucel-T represented the first successful vaccine for the treatment of established cancer, other immunotherapeutic approaches for prostate cancer such as checkpoint inhibitors have been relatively disappointing to date. However, significant promise is on the horizon as there is a wide array trials evaluating immunotherapy in prostate cancer patients. These include both immune checkpoint inhibitors and antigen-specific approaches including vaccines, antibody-drug conjugates, and antitumor antibodies. Furthermore, a better understanding of the key mechanisms that promote the immunosuppressive microenvironment of prostate cancer is emerging. These insights may eventually make it possible to determine which patients will benefit from immunotherapy. This review will discuss the successes and failures of immunotherapy in prostate cancer. We will also present key lessons learned from completed trials and highlight important ongoing studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Comiskey</LastName>
                    <ForeName>Michael C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, 161 Fort Washington Avenue, Mezzanine, New York, NY, 10032, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dallos</LastName>
                    <ForeName>Matthew C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drake</LastName>
                    <ForeName>Charles G</ForeName>
                    <Initials>CG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA. Cgd2139@cumc.columbia.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA. Cgd2139@cumc.columbia.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Oncol Rep</MedlineTA>
            <NlmUniqueID>100888967</NlmUniqueID>
            <ISSNLinking>1523-3790</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2013 Jul 11;369(2):122-33</RefSource>
                <PMID Version="1">23724867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2015 Apr 20;33(12):1325-33</RefSource>
                <PMID Version="1">25584002</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Nov 8;367(19):1783-91</RefSource>
                <PMID Version="1">23020162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7</RefSource>
                <PMID Version="1">15365184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Immunother. 2012 Dec;61(12):2227-38</RefSource>
                <PMID Version="1">22644735</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2013 Jul;24(7):1813-21</RefSource>
                <PMID Version="1">23535954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Oct 7;351(15):1502-12</RefSource>
                <PMID Version="1">15470213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Immunol. 2009 Apr;21(2):215-23</RefSource>
                <PMID Version="1">19327974</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2012 May;13(5):509-17</RefSource>
                <PMID Version="1">22326922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Oncol. 2012 Jun;39(3):311-22</RefSource>
                <PMID Version="1">22595054</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2012 Dec;11(12):2664-73</RefSource>
                <PMID Version="1">23041545</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2016 Aug 16;7(33):52810-52817</RefSource>
                <PMID Version="1">27429197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2017 May 15;23(10):2451-2459</RefSource>
                <PMID Version="1">27836866</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Jun 28;366(26):2443-54</RefSource>
                <PMID Version="1">22658127</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1991 Mar 8;64(5):891-901</RefSource>
                <PMID Version="1">1705867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8</RefSource>
                <PMID Version="1">2513569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2017 Jan;67(1):7-30</RefSource>
                <PMID Version="1">28055103</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2007 Dec 27;357(26):2696-705</RefSource>
                <PMID Version="1">18160689</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncotarget. 2015 Jan 1;6(1):234-42</RefSource>
                <PMID Version="1">25428917</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9</RefSource>
                <PMID Version="1">14610416</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Oct 7;351(15):1513-20</RefSource>
                <PMID Version="1">15470214</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2000 Dec 1;18(23):3894-903</RefSource>
                <PMID Version="1">11099318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2017 Jul 28;357(6349):409-413</RefSource>
                <PMID Version="1">28596308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1999 Jul 1;59(13):3192-8</RefSource>
                <PMID Version="1">10397265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urol Oncol. 2006 Sep-Oct;24(5):419-24</RefSource>
                <PMID Version="1">16962494</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2017 Jan;35(1):124-125</RefSource>
                <PMID Version="1">27646950</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32</RefSource>
                <PMID Version="1">26260996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2011 Apr 28;117(17):4542-51</RefSource>
                <PMID Version="1">21300981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2017 Jan;35(1):40-47</RefSource>
                <PMID Version="1">28034081</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Cell Biol. 2015 Mar;93(3):290-6</RefSource>
                <PMID Version="1">25367186</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2017 Mar 2;376(9):836-847</RefSource>
                <PMID Version="1">28249141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer J. 2018 Jan/Feb;24(1):20-30</RefSource>
                <PMID Version="1">29360724</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Immunol. 2014 May 06;5:191</RefSource>
                <PMID Version="1">24834066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Res. 2017 Nov;5(11):992-1004</RefSource>
                <PMID Version="1">28970196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunother. 2011 Oct;34(8):597-605</RefSource>
                <PMID Version="1">21904216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Mol Ther. 2005 Oct;7(5):454-60</RefSource>
                <PMID Version="1">16248280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63</RefSource>
                <PMID Version="1">18042703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Oncol. 2011 Jun;18(3):e150-7</RefSource>
                <PMID Version="1">21655153</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Urol. 2010 Winter;12(1):25-34</RefSource>
                <PMID Version="1">20428291</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2014 Apr 24;123(17):2625-35</RefSource>
                <PMID Version="1">24578504</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2018 Jan 15;200(2):375-383</RefSource>
                <PMID Version="1">29311378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2013 Sep 15;19(18):5182-91</RefSource>
                <PMID Version="1">23714732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2017 Dec 28;377(26):2545-2554</RefSource>
                <PMID Version="1">29226764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biosci Rep. 2015 Jun 12;35(4):null</RefSource>
                <PMID Version="1">26182432</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Immunother. 2008 Sep;57(9):1301-13</RefSource>
                <PMID Version="1">18273616</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2014 Sep 25;5:4988</RefSource>
                <PMID Version="1">25255306</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Adv Hematol Oncol. 2013 Jan;11(1):14-23</RefSource>
                <PMID Version="1">23416859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2014 Jun;15(7):700-12</RefSource>
                <PMID Version="1">24831977</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infect Immun. 2000 Feb;68(2):999-1003</RefSource>
                <PMID Version="1">10639481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2015 Jun 25;372(26):2509-20</RefSource>
                <PMID Version="1">26028255</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004</RefSource>
                <PMID Version="1">25717386</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2010 Jul 29;363(5):411-22</RefSource>
                <PMID Version="1">20818862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Clin Oncol. 2014 Jan;11(1):24-37</RefSource>
                <PMID Version="1">24247168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2017 Dec 28;377(26):2531-2544</RefSource>
                <PMID Version="1">29226797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2011 Nov 15;17(22):6958-62</RefSource>
                <PMID Version="1">21900389</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ADX031-142</Keyword>
            <Keyword MajorTopicYN="N">Antibody-drug conjugates</Keyword>
            <Keyword MajorTopicYN="N">B7-H3</Keyword>
            <Keyword MajorTopicYN="N">Bi-specific antibodies</Keyword>
            <Keyword MajorTopicYN="N">CAR T</Keyword>
            <Keyword MajorTopicYN="N">CD8</Keyword>
            <Keyword MajorTopicYN="N">CTLA-4</Keyword>
            <Keyword MajorTopicYN="N">Cancer vaccine</Keyword>
            <Keyword MajorTopicYN="N">Checkpoint inhibitors</Keyword>
            <Keyword MajorTopicYN="N">GVAX</Keyword>
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Ipilimumab</Keyword>
            <Keyword MajorTopicYN="N">J591</Keyword>
            <Keyword MajorTopicYN="N">Nivolumab</Keyword>
            <Keyword MajorTopicYN="N">PD-1</Keyword>
            <Keyword MajorTopicYN="N">PD-L1</Keyword>
            <Keyword MajorTopicYN="N">PROSTVAC-VF</Keyword>
            <Keyword MajorTopicYN="N">PSMA ADC</Keyword>
            <Keyword MajorTopicYN="N">Pembrolizumab</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Sipuleucel-T</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30120592</ArticleId>
            <ArticleId IdType="doi">10.1007/s11912-018-0712-z</ArticleId>
            <ArticleId IdType="pii">10.1007/s11912-018-0712-z</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30120411</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5594</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncogene</Title>
                <ISOAbbreviation>Oncogene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41388-018-0450-6</ELocationID>
            <Abstract>
                <AbstractText>Expression levels of retinoic acid receptor gamma (NR1B3/RARG, encodes RARγ) are commonly reduced in prostate cancer (PCa). Therefore, we sought to establish the cellular and gene regulatory consequences of reduced RARγ expression, and determine RARγ regulatory mechanisms. RARG shRNA approaches in non-malignant (RWPE-1 and HPr1-AR) and malignant (LNCaP) prostate models revealed that reducing RARγ levels, rather than adding exogenous retinoid ligand, had the greatest impact on prostate cell viability and gene expression. ChIP-Seq defined the RARγ cistrome, which was significantly enriched at active enhancers associated with AR binding sites. Reflecting a significant genomic role for RARγ to regulate androgen signaling, RARγ knockdown in HPr1-AR cells significantly regulated the magnitude of the AR transcriptome. RARγ downregulation was explained by increased miR-96 in PCa cell and mouse models, and TCGA PCa cohorts. Biochemical approaches confirmed that miR-96 directly regulated RARγ expression and function. Capture of the miR-96 targetome by biotin-miR-96 identified that RARγ and a number of RARγ interacting co-factors including TACC1 were all targeted by miR-96, and expression of these genes were prominently altered, positively and negatively, in the TCGA-PRAD cohort. Differential gene expression analyses between tumors in the TCGA-PRAD cohort with lower quartile expression levels of RARG and TACC1 and upper quartile miR-96, compared to the reverse, identified a gene network including several RARγ target genes (e.g., SOX15) that significantly associated with worse disease-free survival (hazard ratio 2.23, 95% CI 1.58 to 2.88, p = 0.015). In summary, miR-96 targets a RARγ network to govern AR signaling, PCa progression and disease outcome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Long</LastName>
                    <ForeName>Mark D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Prashant K</ForeName>
                    <Initials>PK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Russell</LastName>
                    <ForeName>James R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Llimos</LastName>
                    <ForeName>Gerard</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosario</LastName>
                    <ForeName>Spencer</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rizvi</LastName>
                    <ForeName>Abbas</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van den Berg</LastName>
                    <ForeName>Patrick R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Leiden institute of Physics, Leiden University, 2300 RA, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirk</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sucheston-Campbell</LastName>
                    <ForeName>Lara E</ForeName>
                    <Initials>LE</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Veterinary Medicine, The Ohio State University, Columbus, OH, 43210, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smiraglia</LastName>
                    <ForeName>Dominic J</ForeName>
                    <Initials>DJ</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8852-1510</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campbell</LastName>
                    <ForeName>Moray J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, 536 Parks Hall, Columbus, OH, 43210, USA. campbell.1933@osu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016056</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Oncogene</MedlineTA>
            <NlmUniqueID>8711562</NlmUniqueID>
            <ISSNLinking>0950-9232</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30120411</ArticleId>
            <ArticleId IdType="doi">10.1038/s41388-018-0450-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41388-018-0450-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30119985</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-7560</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European urology</Title>
                <ISOAbbreviation>Eur. Urol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Managing Nonmetastatic Castration-resistant Prostate Cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0302-2838(18)30557-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2018.07.035</ELocationID>
            <Abstract>
                <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients.</AbstractText>
                <AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">A literature search up to July 2018 was conducted, including clinical trials and clinical practice guidelines (National Comprehensive Cancer Network, European Society for Medical Oncology, European Association of Urology, Prostate Cancer Clinical Trials Working Group, Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence). Keywords included prostate cancer, nonmetastatic, castration resistance, rising PSA, and biochemical relapse.</AbstractText>
                <AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">Recommendations regarding indications for, and frequency of, imaging and PSA testing, as well as for initiating systemic therapy in nmCRPC are based on PSA rise kinetics and symptoms. Both enzalutamide and apalutamide have been shown to significantly increase metastasis-free survival in phase III placebo-controlled randomised trials in nmCRPC patients with PSA doubling time (DT) ≤10 mo. The expected impact of new imaging techniques in the assessment of nmCRPC is also reviewed.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">nmCRPC is a heterogeneous disease; while observation may be an option for some patients, enzalutamide and apalutamide may be appropriate to treat nmCRPC patients with PSA-DT ≤10 mo. The emergence of more accurate imaging modalities as well as circulating tumour biomarker assays will likely redefine the assessment of nmCRPC in the near future.</AbstractText>
                <AbstractText Label="PATIENT SUMMARY" NlmCategory="UNASSIGNED">Herein, we review key literature and clinical practice guidelines to summarise the optimal management of patients with prostate cancer and rising prostate-specific antigen despite castrate testosterone levels, but with no evidence of distant metastasis on traditional imaging. New drugs are being developed for this disease setting; novel imaging and tumour biomarker blood tests are likely to define this disease state more accurately.</AbstractText>
                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mateo</LastName>
                    <ForeName>Joaquin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fizazi</LastName>
                    <ForeName>Karim</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Gustave Roussy and University of Paris Sud, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gillessen</LastName>
                    <ForeName>Silke</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hematology, Kantonsspital St. Gallen, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heidenreich</LastName>
                    <ForeName>Axel</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Hospital Aachen, Cologne, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perez-Lopez</LastName>
                    <ForeName>Raquel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oyen</LastName>
                    <ForeName>Wim J G</ForeName>
                    <Initials>WJG</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Royal Marsden Hospital and The Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shore</LastName>
                    <ForeName>Neal</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Carolina Urologic Research Center and Atlantic Urology Clinics, Myrtle Beach, SC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sweeney</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tombal</LastName>
                    <ForeName>Bertrand</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cliniques Universitaires Saint Luc, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomlins</LastName>
                    <ForeName>Scott A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan Center for Translational Pathology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Bono</LastName>
                    <ForeName>Johann S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address: johann.de-bono@icr.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Eur Urol</MedlineTA>
            <NlmUniqueID>7512719</NlmUniqueID>
            <ISSNLinking>0302-2838</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apalutamide</Keyword>
            <Keyword MajorTopicYN="N">Castration-resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Enzalutamide</Keyword>
            <Keyword MajorTopicYN="N">Imaging biomarkers</Keyword>
            <Keyword MajorTopicYN="N">Metastasis-free survival</Keyword>
            <Keyword MajorTopicYN="N">Nonmetastatic castration-resistant prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Prostate-specific antigen doubling time</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30119985</ArticleId>
            <ArticleId IdType="pii">S0302-2838(18)30557-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.eururo.2018.07.035</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30119969</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1699-7980</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Actas urologicas espanolas</Title>
                <ISOAbbreviation>Actas Urol Esp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Incidence of second tumours in high risk prostate cancer patients according to the primary treatment applied.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0210-4806(18)30187-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuro.2018.07.002</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">The onset of second primary tumours should be considered in high-risk prostate cancer patients in the natural course of the disease. Our aim was to evaluate the influence of primary treatment with curative intent for these patients on the development of second primary tumours.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A retrospective study of 286 patients diagnosed between 1996 and 2008, treated by radical prostatectomy (n=145) or radiotherapy and androgen blockade (n=141). The homogeneity of both series was analysed using the Chi-squared test for the qualitative variables, and the Student's t-test for the quantitative variables. A multivariate Cox regression analysis was performed to assess whether the type of primary treatment influenced the development of second tumours.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age was 66 years, and the median follow-up was 117.5 months. At the end of follow-up, 60 patients (21%) had developed a second primary tumour. In the prostatectomy group it was located in the pelvis in 13 (9%) cases, and those treated with radiotherapy and hormonotherapy in 8 (5.7%) cases (P=.29). The most common organ sites were: colo-rectal in 17 (28.3%) patients, the lung in 11 (18.3%), and the bladder in 6 (10%) patients. In the multivariable analysis, the risk of a second tumour doubled for those treated with radiotherapy and hormonotherapy (HR=2.41, 95%CI: 1.31-4.34, P=.005) compared to the patients treated by prostatectomy. Age and rescue radiotherapy did not behave as independent predictive factors.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The onset of a second primary tumour was related with the primary treatment given; thus the risk for those treated with radiotherapy and androgen deprivation therapy more than doubled.</AbstractText>
                <CopyrightInformation>Copyright © 2018 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Caño-Velasco</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: jorcavel@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herranz-Amo</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbas-Bernardos</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Polanco-Pujol</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lledó-García</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernández-Fernández</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Incidencia de segundos tumores en pacientes con cáncer de próstata de alto riesgo según el tratamiento primario aplicado.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Spain</Country>
            <MedlineTA>Actas Urol Esp</MedlineTA>
            <NlmUniqueID>7704993</NlmUniqueID>
            <ISSNLinking>0210-4806</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cáncer de próstata</Keyword>
            <Keyword MajorTopicYN="N">External radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">Prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">Prostatectomy</Keyword>
            <Keyword MajorTopicYN="N">Prostatectomía</Keyword>
            <Keyword MajorTopicYN="N">Radioterapia externa</Keyword>
            <Keyword MajorTopicYN="N">Second tumour</Keyword>
            <Keyword MajorTopicYN="N">Segundo tumor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30119969</ArticleId>
            <ArticleId IdType="pii">S0210-4806(18)30187-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.acuro.2018.07.002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30119882</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4022</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medical dosimetry : official journal of the American Association of Medical Dosimetrists</Title>
                <ISOAbbreviation>Med Dosim</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Avoidance sectors to reduce dosimetric impact of an irreproducible pannus on setup uncertainty in prostate SBRT VMAT: A case study.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0958-3947(18)30074-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.meddos.2018.05.003</ELocationID>
            <Abstract>
                <AbstractText>This work investigates whether the use of an avoidance sector in a two-arc volumetric modulated arc therapy (VMAT) prostate stereotactic body radiotherapy (SBRT) plan reduces dosimetric variations due to an irreproducible pannus. A morbidly obese patient with favorable-risk prostate cancer elected treatment with SBRT. The patient was treated with the avoidance arcs across the pannus to eliminate reproducibility issues created by daily pannus variability in set up. For post-treatment assessment, the case was planned using Varian Eclipse™ treatment planning system (TPS) with two VMAT arcs with and without 100° avoidance sectors across the pannus. The dose was re-calculated using the external body contour from four daily treatment cone-beam computer tomography scans, and on two virtual body contours created by expanding the pannus region of the external contour by 5 and 10 mm. Dose differences between planned and re-calculated rectal wall mean dose and the V<sub>24Gy</sub> were numerically larger in the absence of the avoidance sector for all fractions and for both simulated pannus variations, with maximum changes of 2.6% and 1.3%. Maximum point dose variations in the PTV, CTV, rectum, bladder, and femoral heads were 105 cGy or less for all cases, with and without the avoidance sector. The use of an avoidance sector across this large, asymmetrical pannus did not inhibit achieving dose constraints and provided a reduction in dose variability which was nominal in this case for 10 mm variations. Avoidance sectors can be safely implemented in cases with obvious reproducibility concerns in the setting of prostate VMAT SBRT.</AbstractText>
                <CopyrightInformation>Copyright © 2018 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hubley</LastName>
                    <ForeName>Emily</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107, USA. Electronic address: emilyhubley1@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shukla</LastName>
                    <ForeName>Gaurav</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vakhnenko</LastName>
                    <ForeName>Yelena</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Den</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrison</LastName>
                    <ForeName>Amy S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Dosim</MedlineTA>
            <NlmUniqueID>8908862</NlmUniqueID>
            <ISSNLinking>1873-4022</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Avoidance sector</Keyword>
            <Keyword MajorTopicYN="N">Pannus</Keyword>
            <Keyword MajorTopicYN="N">Prostate</Keyword>
            <Keyword MajorTopicYN="N">SBRT</Keyword>
            <Keyword MajorTopicYN="N">Treatment planning</Keyword>
            <Keyword MajorTopicYN="N">VMAT</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30119882</ArticleId>
            <ArticleId IdType="pii">S0958-3947(18)30074-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.meddos.2018.05.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30118330</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on investigational drugs</Title>
                <ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2018.1513490</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Despite the heterogeneity of prostate cancer (PCa), androgen stimulation is fundamental to its development, growth and lethality. Therefore, the blockade of androgen receptor (AR) signaling is critical to controlling the disease, even after progression with castrate levels of androgens. Areas covered: We review the current understanding of new ways to block the AR, using novel antiandrogen inhibitors, which act on different parts of the AR signaling pathway in PCa. We also review new approaches, such as the use of poly (ADP-ribose) polymerase (PARP) inhibitors, targeting both the AR and the DNA repair pathway, potentially adding synergy and improving efficacy and the combination of AR inhibitors and immunotherapy. Bipolar androgen therapy (BAT), an innovative strategy to target the AR, has shown early evidence of efficacy in PCa is also discussed in detail. We highlight some of the key ongoing studies of greatest relevance to this topic. Expert commentary: Clinical trials investigating new AR targeted therapies should be encouraged in patients with PCa. While it is unlikely that one AR inhibitor will produce long-lasting responses in a substantial proportion of patients, there is evidence that some strategies, such as the BAT could resensitize the AR to antiandrogens, alternating therapies and delaying time to progression, maximizing benefit to patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Isaacsson Velho</LastName>
                    <ForeName>Pedro</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore , MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carducci</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore , MD.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>b Brady Urological Institute , Johns Hopkins University , Baltimore , MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Investig Drugs</MedlineTA>
            <NlmUniqueID>9434197</NlmUniqueID>
            <ISSNLinking>1354-3784</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">androgen</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">hormone</Keyword>
            <Keyword MajorTopicYN="N">prostate</Keyword>
            <Keyword MajorTopicYN="N">receptor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30118330</ArticleId>
            <ArticleId IdType="doi">10.1080/13543784.2018.1513490</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
